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Abstract 
Nonnatural amino acid incorporation has been one of the most important protein 
engineering techniques. Particularly site-specific incorporation of nonnatural amino acids 
would allow design of artificial proteins containing a nonnatural amino acid with minimal 
perturbation of their native properties. Site-specific incorporation of phenylalanine (Phe) 
analogs and tryptophan (Trp) analogs, such as p-bromophenylalanine (pBrF), p-
iodophenylalanine, p-azidophenylalanine, 6-chlorotrytophan, 6-bromotryptophan, 5-
bromotrytophan, and benzothienylalanine, into proteins in Escherichia coli has been 
realized by E. coli strains outfitted with a mutant yeast phenylalanyl-tRNA suppressor 
(ytRNAPheCUA) and a mutant yeast phenylalanyl-tRNA synthetase (yPheRS (T415G)) with 
a point mutation in the active site of the enzyme. In order to reduce Trp and lysine (Lys) 
misincorporation at an amber codon, the ytRNAPheCUA_UG containing the optimized 
sequence and the yPheRS (T415A) showing higher specificity toward pBrF were 
developed. Combining ytRNAPheCUA_UG and yPheRS (T415A) allowed incorporation of 
pBrF into murine dihydrofolate reductase in response to an amber codon with at least 98% 
fidelity.  
Re-assignment of degenerate sense codons offers the prospect of a substantially 
expanded genetic code and a correspondingly enriched set of building blocks for natural 
and artificial proteins. Here we describe the use of a mutant yeast phenylalanine transfer 
RNA (ytRNAPheAAA) containing a modified anticodon to break the degeneracy of the 
genetic code in E. coli. By using an E. coli strain co-transformed with ytRNAPheAAA and a 
mutant yPheRS (T415G), we demonstrated efficient replacement of Phe by L-3-(2-
naphthyl)alanine (2Nal) at UUU, but not at UUC codons.  
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However, this method had two limitations. First, the yPheRS (T415G) also 
activated Trp, which led to Trp misincorporation.  Second, 2Nal was misincorporated at 
UUC Phe codons, due to the relaxed codon recognition of AAA anticodon in the 
ytRNAPheAAA. High-throughput screening of a yPheRS library led to a more selective 
yPheRS variant (yPheRS_naph). The rationally designed ytRNAPheCAA, which has the CAA 
anticodon recognizing only a UUG (Leu) codon, allowed incorporation of 2Nal only at 
UUG codon. Combined use of yPheRS_naph and ytRNAPheCAA achieved multiple-site-
specific incorporation of 2Nal into proteins. These results illustrate a general method for 
increasing the number of distinct, genetically-encoded amino acids available for protein 
engineering. 
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Abstract 
Nonnatural amino acid incorporation has been one of the most important protein 
engineering platforms. In particular, site-specific incorporation of nonnatural amino acids 
allows design of proteins containing a nonnatural amino acid with minimal perturbation of 
native properties. Until now more than 30 nonnatural amino acids have been introduced 
into proteins in E. coli hosts outfitted with orthogonal pairs of cognate tRNAs and 
aminoacyl-tRNA synthetases (aaRS). Substrate specificity of aaRS has been altered to 
recognize various nonnatural amino acids through either rational design of the active site of 
aaRS or high-throughput screening of aaRS library. In this approach, site-specificity has 
been achieved by assigning a nonnatural amino acid to a stop codon, a degenerate codon, or 
a frameshift codon for efficient discrimination of the programmed sites from unwanted 
sites.     
 
Introduction 
Genetically encoded nonnatural amino acids have been used to endow recombinant 
proteins with novel chemical, physical, or biological properties. Several distinct methods 
have been developed to introduce nonnatural amino acids into recombinant proteins at 
programmed sites in vivo. Residue-specific incorporation involves the global replacement 
of a particular natural amino acid with a nonnatural amino acid in a target protein using 
auxotrophic hosts.1-14 The strength of this technique lies in efficient protein translation and 
multi-site incorporation of a nonnatural amino acid, because sense codons are reassigned 
for a nonnatural amino acid. Residue-specific incorporation of 5’,5’,5’-trifluoroleucine 
(TFL) into a leucine-zipper protein enhanced its thermal stability.15 A reactive 
3 
phenylalanine analog, para-ethynylphenylalanine, has been used for selective dye-labeling 
of newly synthesized protein in E. coli.16  Newly synthesized proteins in mammalin cells 
have been selectively indentified using bioorthogonal noncanonical amino acid tagging.17 
Trp analogs containing selenophene and thienyl functional groups have been used in the X-
ray crystallography of proteins.18,19 Aminotryptophan was used to design protein-based pH 
sensors3 and greatly changed the spectral properties of fluorescent proteins.1 Regardless of 
many successful applications of residue-specific incorporation, its further application to the 
design of biologically-active macromolecules could be restricted by two limitations. First, 
reassignment of sense codons for a nonnatural amino acid usually leads to exclusion of one 
natural amino acid, which is encoded by the sense codons, in protein translation. Second, 
native properties of a target protein may be impaired by incorporation of a nonnatural 
amino acid at non-permissive sites of a target protein,20,21 though the Tirrell laboratory 
recently showed that the impaired properties may be rescued through directed evolution of 
the target protein.21    
Site-Specific Incorporation 
Site-specific incorporation involves introduction of a nonnatural amino acid into a 
target protein at any position selected. Access to all 20 natural amino acids and site-
specificity of the method may allow design of proteins containing a nonnatural amino acid 
with minimal perturbation of native properties. Site-specific incorporation requires 
outfitting the cell with an “orthogonal pair” comprising a suppressor tRNA and a cognate 
aminoacyl-tRNA synthetase (aaRS) that operate independently of the endogenous 
synthetase-tRNA pairs in E. coli. The site-specific incorporation of a nonnatural amino acid 
into recombinant proteins via this strategy was reported by Furter in 199822 and the Schultz 
4 
laboratory has developed powerful selection methods to identify heterologous synthetases 
and tRNAs.23-26 A general strategy for site-specific incorporation consists of four steps and 
each step will be discussed in more detail in the following sections.   
 
Choice of a Nonnatural Amino Acid 
First of all, it is necessary to choose a nonnatural amino acid suitable for goals. 
Until now more than 30 nonnatural amino acids have been successfully introduced to 
proteins in a site-specific manner27,28 (Figure 1) including reactive nonnatural amino acids, 
such as para-acetylphenylalanine 1, meta-acetylphenylalanine 2, para-(3-oxobutanoyl)-L-
phenylalanine 3, para-(2-amino-3-hydroxylenthynyl)phenylalanine 4, para-
ehthynylthiocarbonyl-phenylalanine 5, para-propargyloxyphenylalanine 6, para-
azidophenylalanine 7,  para-ethynylphenylalanine 32, para-iodophenylalanine 20, and 
para-bromophenylalanine 31.  These reactive nonnatural amino acids can be used to 
modify proteins through bio-orthogonal chemical transformations.  For example, the keto 
and β-diketo functional groups (1-3) can selectively react with both hydrazides and 
alkoxyamines.29-31 Azide functional groups (7) can be ligated to alkynes through copper-
catalyzed [3+2] cycloaddition.16,32,33 Aryl halides (20 and 31) can be conjugated to terminal 
alkynes or alkenes via palladium-catalyzed coupling reactions.34-39 Nonnatural amino acids 
containing photoactive side chains including para-azidophenylalanine 7,40,41 para-
benzoylphenylalanine 9,42,43 O-(2-nitrobenzyl)tyrosine 12,44 and S-(2-nitrobenzyl)cysteine 
1045 have been inserted into proteins.   
Genetically-encoded nonnatural amino acids can be used as probes of various kinds. 
First, nonnatural amino acids containing heavy atoms (I and Se) have been used for X-ray 
5 
crystallographic studies of protein structure.18,46 Second, fluorinated phenylalanine and 15N-
labelled methoxy phenylalanine have been used to label proteins for NMR study.22,47 Third, 
para-L-cyanophenylalanine 22 containing nitrile group has been introduced to proteins as 
an infrared probe to investigate changes in local environment.48 Fourth, introduction of a 
fluorophore into proteins at defined sites can greatly facilitate study of protein function and 
structure. For example, the two fluorescent amino acids, 2-amino-3-(5-
(dimethylamino)naphthalene-1-sulfonamide)propanoic acid (dansylalanine) 18 and L-(7-
hydroxycoumarin-4-yl)ethylglycine 17, have been introduced to proteins to monitor 
unfolding of proteins.49,50  
 
Orthogonal Pairs 
Activation of an amino acid followed by charging the activated amino acid into a 
cognate tRNA by a cognate aminoacyl-tRNA synthetase (aaRS) is a key step to ensure high 
fidelity in a protein translation process. One orthogonal pair of aaRS/tRNA is assigned to 
each natural amino acid. Therefore, a new orthogonal aaRS/tRNA pair is necessary for a 
nonnatural amino acid to be utilized in protein translation machinery. Therefore, the 
development of orthogonal pairs to each living organism is one of the key steps in 
achieving site-specific incorporation of a nonnatural amino acid into proteins in vivo.  
 
Modification of Endogenous Orthogonal Pairs.  Initially Schultz and colleagues tried to 
modify an E. coli endogenous RNA/aaRS pair to obtain a new orthogonal pair. Three sites 
in tRNAGln2 sequence, which are critical for binding with E. coli glutamyl-tRNA synthetase 
(eGlnRS), were mutated to reduce affinity to eGlnRS. Then eGlnRS was evolved to 
6 
recognize the mutant tRNAGln2 and retain its orthogonality with the endogenous tRNAs in 
E. coli. However, the approach was unsuccessful due to poor discrimination of the mutant 
tRNAGln2 against wild-type tRNAGln2 by even the best eGlnRS mutant.51   
 
Orthogonal Pairs Derived from Yeast. A second approach to generate an orthogonal pair 
was the use of a heterologous tRNA/aaRS pair obtained from another organism in E. coli. 
The yeast phenylalanyl-tRNA/yeast phenylalanyl-tRNA synthetase pair was known to be 
orthogonal to the E. coli endogenous system. In vitro aminoacylation studies indicated that 
there was little cross-talk between E. coli and yeast phenylalanyl-tRNA/synthetase 
pairs.52,53 Aminoacylation activity of yeast tRNAPhe by E. coli PheRS is 10-fold lower than 
that of E. coli tRNAPhe.22 Aminoacylation activity of E. coli tRNAPhe by yeast PheRS is 24- 
or 34-fold lower than that of yeast tRNAPhe,54,55 because U20 in E. coli tRNAPhe replaces 
G20, one of the identity elements of yeast tRNAPhe recognized by yPheRS (Figure 2).54 A 
yeast amber suppressor derived from tRNAPheGAA (ytRNAPheCUA_wt) has been widely used 
to study suppression of amber codons, though E. coli lysyl-tRNA synthetase (eLysRS) 
shows a weak activity to aminoacylate ytRNAPheCUA_wt with Lys.22 A wild-type tRNA 
sequence can be engineered to eliminate the cross-reactivity with E.coli synthetase but 
preserve efficient recognition by the cognate aaRS. When ytRNAPheCUA_wt was co-
expressed with wild-type yPheRS in an E. coli host, 60% of the amber codon was occupied 
by Lys.22 The mischarging by Lys was likely due to the presence of U36 and A73 in the 
ytRNAPheCUA_wt, which are the main identity elements for eLysRS.56 However, when G37 
was replaced by A37 and ytRNAPheCUA was co-expressed with wild-type yPheRS, only 5% 
of the amber codon was occupied by Lys. The remaining 5% of Lys misincorporation was 
7 
eliminated by rational design of ytRNA sequence. Disruption of a Watson-Crick base pair 
between nucleotides 30 and 40 in ytRNAPheCUA reduced mischarging by the eLysRS. As an 
alternative orthogonal tRNA/synthetase pair, an amber suppressor derived from yeast 
tyrosyl-tRNA (ytRNATyr) and yeast tyrosyl-tRNA synthetase (yTyrRS) pair was 
examined.57,58 RajBhandary and colleagues generated yTyrRS variants using error-prone 
PCR to enhance discrimination of the suppressor tRNA over E. coli proline tRNA by 
factors of 2.2- to 6.8-fold. Nishikawa and colleagues optimized the sequence of yeast 
amber suppressor tRNATyr to minimize Lys charging by eLysRS.59 This optimized yeast 
tRNATyr, together with yeast TyrRS, could be used as an orthogonal pair for incorporation 
of nonnatural amino acids into proteins.  Schultz and colleagues developed two orthogonal 
pairs derived from yeast. An amber suppressor derived from yeast glutamyl-tRNAs 
(ytRNAGln2_CUA) is not a substrate for any E. coli endogenous synthetase. In turn, yeast 
glutamyl-tRNA synthetase (yGlnRS) aminoacylated ytRNAGln2 in E. coli but did not 
charge E. coli tRNAGln.60 An amber suppressor derived from yeast aspartidyl-tRNA 
(ytRNAAspCUA) is not recognized by E. coli synthetases. Introduction of E188K mutation in 
yeast aspartidyl-tRNA synthetase (yAspRS) led to reduction in aminoacylation activity 
with E. coli tRNAAsp.61 Therefore, both ytRNAGln2_CUA/yGlnRS pair and 
ytRNAAspCUA/yAspRS (E188K) form orthogonal pairs in E. coli suitable for the 
incorporation of nonnatural amino acids into proteins in vivo.  
 
Orthogonal Pairs Derived from Archaebacteria. Schultz and colleagues developed an 
orthogonal tyrosyl-tRNA/synthetase pair obtained from archaea, since archeal aminoacyl-
tRNA synthetases are more similar to eukaryotic than prokaryotic counterparts. The amber 
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suppressor tyrosyl-tRNA (MjtRNATyr)/synthetase (MjTyrRS) pair derived from 
Methanococcus jannaschii was selected and evolved to be orthogonal to the E. coli 
endogenous system.25,62 The amber suppressor MjtRNATyrCUA was efficiently 
aminoacylated by MjTyrRS in E. coli. However, E. coli endogenous synthetases showed 
weak activity towards MjtRNATyrCUA. Therefore, a selection method to obtain orthogonal 
tRNAs in E. coli has been developed to enhance orthogonality with respect to E. coli 
endogenous synthetases and retain recognition by the cognate synthetase and the protein 
translational machinery (Figure 3).25 This method includes positive and negative selection 
of a mutant tRNA library. In the negative selection, amber codons were introduced into a 
toxic barnase protein at permissive sites that allow replacement of amino acids. Eleven 
nucleotides of MjtRNATyrCUA that do not bind to MjTyrRS were saturated with all four 
bases to generate a tRNA library. When the tRNA library was expressed in minimal 
medium without MjTyrRS, cells containing tRNA variants aminoacylated by E. coli 
endogenous synthetases resulted in cell death. The plasmids were isolated from the cells 
survived, and co-transformed with a plasmid harboring both a MjTyrRS gene and a β-
lactamase gene containing an amber codon at a permissive site into E. coli hosts. When 
cells were cultured in liquid medium in the presence of ampicillin, cells harboring tRNA 
variants aminoacylated by MjTyrRS survived. After the negative and positive screening of 
tRNA library, the tRNAs were orthogonal to the E. coli endogenous synthetases and 
retained their affinity to the cognate synthetase. Schultz and colleagues developed another 
orthogonal pair obtained from Archea. An amber suppressor leucyl-tRNA and a leucyl-
tRNA synthetase were derived from Halobacterium sp. NRS-1 and Methanobacterium 
thermoautotrophicum, respectively. Aminoacylation activity of the suppressor leucyl-
9 
tRNA by the leucyl-tRNA synthetase and its orthogonality with E. coli synthetases were 
significantly enhanced by extensive mutations in the anticodon loop and acceptor stem.23         
 
Substrate Specificity Change 
Another issue to achieve incorporation of a nonnatural amino acid into protein in 
vivo is alteration of substrate specificity of an aminoacyl-tRNA synthetase toward the 
nonnatural amino acid. Aminoacyl-tRNA synthetases ensure the high fidelity of 
transforming genetic code sequences into biologically functional proteins through a two-
step aminoacylation reaction.63-67  In the first step, the cognate amino acid is activated by 
aaRS in the presence of ATP to form the amino acid adenylate. Subsequently aaRS 
catalyzes the esterification reaction to join the amino acid to the 2’- or 3’-OH of the 
terminal ribonucleotide of its cognate tRNA. Manipulation of such reactions could 
potentially alter the genetic code to allow incorporation of novel amino acid into proteins in 
vivo.68 Some nonnatural amino acids including TFL, azidohomoalanine, and para-
fluorophenylalanine, are recognized by wild-type cognate aminoacyl-tRNA 
synthetases.5,15,22 However, the majority of nonnatural amino acids are very poor substrates 
for natural aminoacyl-tRNA synthetases. Engineering the new synthetase activity is almost 
inevitable when one wants to incorporate an amino acid that is not recognized by wild-type 
enzymes.  
 
Rational Design of the Active Sites of Aminoacyl-tRNA Synthetases. Alteration of 
substrate specificity of aminoacyl-tRNA synthetases has been achieved in several labs by 
the rational design of the binding pocket to accommodate nonnatural amino acid. Tirrell 
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and colleagues have been interested in exploring the possibility of incorporating substituted 
phenylalanines, such as p-bromophenylalanine, p-iodophenylalanine, and p-
azidophenylalanine. On the basis of the crystal structure of the PheRS (tPheRS) from 
Thermus thermophilus (Figure 4a and b), Safro and colleagues proposed that Val 261 and 
Ala 314 in the amino acid binding pocket of α-subunit of the tPheRS are critical in the 
discrimination of Phe from its amino acid competitors.  Sequence alignment indicates that 
Ala 314 in α-subunit of the tPheRS corresponds to Ala 294 in α-subunit of the ePheRS 
(Figure 4c), and the Hennecke group showed that the substrate specificity of the ePheRS 
can be relaxed by a mutation at Ala 294. The A294G mutant was shown to enable 
incorporation of para-chlorophenylalanine into recombinant proteins.69 A subsequent 
computational simulation, consistent with the Safro prediction, identified two cavity-
forming mutations (T251G and A294G) in ePheRS binding pocket. These two mutations 
led to relaxed substrate specificity and efficient in vivo replacement of Phe by para-
acetylphenylalanine (pAcF).4  Sequence alignment showed that Thr 415 in yPheRS is 
equivalent to Thr 251 in ePheRS. Therefore, a T415G mutation was introduced into the 
yPheRS to enlarge the active site. The yPheRS (T415G) variant showed activity for p-
bromophenylalanine, p-iodophenylalanine, and p-azidophenylalanine in ATP-PPi exchange 
assays in vitro (see Chapters 2 and 4). There was an interesting finding that the yPheRS 
(T415G) efficiently activated Trp and 2-naphthylalanine as well as Phe analogs. 
Considering the spectrum of nonnatural amino acids recognized by yPheRS (T415G), 
Tirrell and colleagues explored whether the yPheRS (T415G) can activate even Trp 
analogs. In vitro activation studies showed that the yPheRS (T415G) efficiently activated 
four Trp analogs, 6-chlorotryptophan (6ClW), 6-bromotryptophan (6BrW), and 5-
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bromotrytophan (5BrW), which were not utilized by the endogenous E. coli translational 
system (see Chapter 3). A phenylalanine auxotrophic E. coli strain transformed with this 
yPheRS (T415G) and cognate suppressor tRNA enabled the assignment of an amber 
nonsense codon to Phe analogs and Trp analogs in vivo (see Chapters 2-4).  The cavity 
formed due to the T415G mutation in the binding pocket of yPheRS led to the activation of 
Trp as well as nonnatural amino acids, which resulted in misincorporation of Trp at the 
programmed sites. Therefore, the binding site of yPheRS was re-designed to enhance 
specificity for pBrF. Specifically, Tirrell and colleagues used the T415A variant, which 
exhibits 5-fold higher activity towards pBrF as compared to Trp in ATP-PPi exchange 
assays. Use of the yPheRS (T415A) eliminated misincorporation of Trp at programmed 
sites in proteins.70  
Nishikawa and colleagues have changed substrate specificity of yeast tyrosyl-tRNA 
synthetase (yTyrRS) to accommodate tyrosine analogs.71 Based on the crystal structure of 
TyrRS obtained from Bacillus stearothermophilus TyrRS and sequence alignment of two 
homologous TyrRSs, active site residues in yTyrRS have been mutated to generate a series 
of yTyrRS variants.  Among the yTyrRS variants, one containing the Tyr43Gly mutation 
(yTyrRS (Y43G)) was found to show activity for several 3-substituted tyrosine analogs in 
aminoacylation assays in vitro. yTyrRS (Y43G) efficiently charged ytRNATyr with 3-iodo-
tyrosine, which was not utilized by wild-type yTyrRS. The yTyrRS (Y43G) showed 400-
fold lower activity towards tyrosine than wild-type yTyrRS.  Similarly, Yokoyama and 
colleagues72 screened E. coli TyrRS variants recognizing 3-iodotyrosine via in vitro 
biochemical assays. The E. coli TyrRS variant that has two mutations (Y37V and Q195C) 
in the active site activated 3-iodotyrosine 10-fold more efficiently than tyrosine.72 
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Combined use of E. coli TyrRS (V37C195) and a suppressor tRNA derived from Bacillus 
stearothermophilus allowed incorporation of 3-iodotyrosine into proteins in mammalian 
cells.73  
 
Directed Evolution of Aminoacyl-tRNA Synthetase Substrate Specificity. Aminoacyl-
tRNA synthetases are known to be readily evolvable. Schultz and colleagues have 
developed powerful selection methods to change the substrate specificity of tyrosyl-tRNA 
synthetase (MjTyrRS) derived from Methanococcus jannaschii toward nonnatural amino 
acids.23,24,26,74  The selection method consists of a series of positive and negative 
selections.68 Based on the crystal structure of the homologous TyrRS from Bacillus 
stearothermophilus, five residues in the active site of MjTyrRS were selected and 
randomized to generate a MjTyrRS mutant library. In the positive selection, an amber 
codon was inserted at permissive sites in a chloramphenicol acetyltransferase (CAT) gene. 
The library was cultured in medium containing chloramphenicol in the presence of a 
nonnatural amino acid. Only the cells containing MjTyrRS variants allowing suppression of 
an amber codon in CAT gene survived. Surviving cells were subjected to the negative 
selection. In the negative selection, the cells were regrown in medium containing 
chloramphenicol in the absence of the nonnatural amino acid. Those cells that could not 
survive were isolated from the replica plates containing the nonnatural amino acid. Using 
this method, substrate specificity of MjTyrRS was changed to selectively recognize O-
methyl-L-tyrosine.68  
Alternative selection methods for evolving substrate specificity of MjTyrRS 
towards nonnatural amino acids have been developed. One of them involves a positive 
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selection similar to the previous one, but a different negative selection.60 The negative 
selection is based on suppression of amber codons inserted at permissive sites in the 
barnase gene that is lethal to E. coli. When the cells survived from the positive selection 
were cultured in the absence of nonnatural amino acids, the cells containing MjTyrRS 
variants recognizing natural amino acids resulted in cell death due to expression of the 
barnase protein.  Another method for evolving MjTyrRS specificity to nonnatural amino 
acids involves an amplifiable fluorescent reporter, a green fluorescent protein.24 Amber 
codons were introduced at various sites in a T7 RNA polymerase gene that controlled 
expression of a green fluorescent protein. In the positive screening, the MjTyrRS library 
cells were cultured in the presence of a nonnatural amino acid. The cells containing 
MjTyrRS variants that recognized the nonnatural amino acid and suppressed the amber 
codons in T7 RNA polymerase gene became fluorescent and were collected with a 
fluorescence-activated cell sorter (FACS). In the negative screening, the cells collected 
from the positive screening were cultured in the absence of the nonnatural amino acid; the 
cells containing MjTyrRS variants that did not recognize any natural amino acid were not 
fluorescent and collected with a FACS. Therefore, the cells collected from the positive and 
negative screenings contained the MjTyrRS variants that can selectively charge the 
nonnatural amino acid into the cognate tRNA.  One advantage of the latter method is that 
both reporter genes are encoded in a single plasmid, which eliminates the need for DNA 
isolation after each selection step. However, the method requires a FACS for high-
throughput screening.         
Most attempts to evolve aminoacyl-tRNA synthetase substrate specificity have 
been limited to prokaryotic or archaeal aminoacyl-tRNA synthetases. Recently, Tirrell and 
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colleagues have evolved a eukaryotic aminoacyl-tRNA synthetase, yPheRS, to change its 
substrate specificity towards a hydrophobic phenylalanine analog, 2-naphthylalanine (see 
Chapter 6). The yPheRS library was constructed by randomizing four residues (N412, 
T415, S418, and S437) that contact the Phe substrate inside the binding pocket (Figure 5a). 
The screening consisted of a series of positive and negative screenings (Figure 5b), and 
involved expression of a GFP reporting folding status. The active synthetases would allow 
incorporation of either 2Nal or other natural amino acids at non-permissive sites of a GFP, 
which resulted in poorly-folded GFP showing weak fluorescence. Therefore, in the positive 
screening, the library cells were cultured in the presence of 2Nal and then the cells 
containing active synthetases were collected by high-throughput screening with a FACS. 
The yPheRS variants with very low activity toward natural amino acids will not 
misincorporate any natural amino acid at Phe sites in GFP and so GFP would retain full 
intensity of fluorescence. In the negative screening, the cells obtained from the positive 
screening were cultured in the absence of 2Nal and then the cells containing selective 
synthetases were collected with a FACS.  
 
New Codon-Anticodon Interactions 
Among the sixty-four codons, sixty-one (sense codons) are assigned to one of the 
twenty natural amino acids. The other three codons (nonsense codons) are stop codons that 
terminate protein translation. In order to incorporate a nonnatural amino acid into proteins 
in vivo, we need to either re-assign an existing codon or generate a new codon for the 
nonnatural amino acid. Until now three distinct approaches have been explored, re-
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assignment of a stop codon, reassignment of a degenerate codon, and assignment of a 
frameshift codon.  
 
Nonsense Suppression. In 1989 incorporation of a nonnatural amino acid into proteins in 
vitro was demonstrated by two independent groups, the Chamberlin group75 and the 
Schultz group.76 Nonsense suppression means that one of the stop codons (nonsense 
codons) can be read by a suppressor charged with an amino acid. Otherwise protein 
translation will be terminated at the stop codon. Three stop codons, amber 
(UAG),46,68,70,74,77 ochre (UAA),23,78,79 and opal (UGA) stop codons,23,78 have been 
reassigned for nonnatural amino acids. The amber codon has been used most 
widely,22,40,42,43,48,70,74,76,80-83 because it is the least common stop codon in E. coli, and 
because several naturally occurring suppressor tRNAs recognize it efficiently.84,85 Use of 
the amber codon to encode nonnatural amino acids requires outfitting the cell with an 
“orthogonal pair” comprising a suppressor tRNA and a cognate aminoacyl-tRNA 
synthetase (aaRS) that operate independently of the endogenous synthetase-tRNA pairs in 
E. coli as described in previous sections. To date, more than thirty nonnatural amino acids 
have been incorporated into proteins in response to the amber stop codon with high 
fidelity.27,28,70   
 
Breaking the Degeneracy of the Genetic Code.  Suppression of the amber stop codon has 
worked well for single-site insertion of novel amino acids. However, the utility of this 
approach is limited by moderate suppression efficiency. Competition between elongation 
and termination produces mixtures of full-length and truncated chains, and protein yields 
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are reduced accordingly. Efficient multi-site incorporation has been accomplished by 
replacement of natural amino acids in auxotrophic E. coli strains,1,6,9-11,86,87 and by using 
aminoacyl-tRNA synthetases with relaxed substrate specificity4 or attenuated editing 
activity.11  Although this method provides efficient incorporation of analogs at multiple 
sites, it suffers from the limitation that one of the natural amino acids must be excluded 
from the engineered protein. Efficient multiple-site-specific incorporation can be achieved 
by re-assignment of a sense codon, if the sense codon can be efficiently distinguished from 
other sense codons. Tirrell and colleagues investigated re-assignment of a degenerate 
codon for a nonnatural amino acid. As a test case for establishing the feasibility of breaking 
the degeneracy of the code, phenylalanine codons were investigated (see Chapter 5).   
Although 2Nal incorporaton was biased to UUU codons in the first study, 
misincorporation of 2Nal at unwanted sites (UUC codons) could not be avoided due to 
ambiguity in codon recognition by the AAA anticodon of ytRNAPheAAA. Misincorporation 
of a nonnatural amino acid at unwanted sites might cause perturbation or loss of function of 
a target protein.20,21 Based on experimental findings88-95 and stereo-chemical modeling96-99 
of codon-anticodon interactions, an expanded wobble rule was proposed by Lim and 
Curran.90 The expanded wobble rule indicates that A in the first position of the anticodon 
can recognize all four bases in the third position of the codon, although its affinity to C is 
lower than that to U. The observed incomplete discrimination of UUU from UUC codons 
by the AAA anticodon of ytRNAPhe motivated us to explore a different set of degenerate 
codons. Several considerations recommend the UUG codon. First, Leu is encoded by six 
codons: UUA, UUG, CUA, CUG, CUU, and CUC. Discrimination of UUG from CUN (N 
= A/U/G/C) codons might be highly efficient due to discrimination at the first position in 
17 
the codon.  Second, our existing yeast orthogonal pair should be readily adapted to the 
incorporation of Phe analogs in response to UUG codons. Third, according to the expanded 
wobble rules, C in the first position of the anticodon can recognize only G in the third 
position of the codon (see Chapter 6). 
 
Frameshift Suppression. The utility of stop or degenerate codons might be restricted by 
limited number of codons. In order to overcome this limitation, extended codons have been 
investigated. Although three-base codons are universal for most living organisms, 
frameshift suppression of a four-base codon occurs is a regulatory mechanism in viruses 
and bacteria, and is mediated either by slipping of normal tRNAs at the ribosome or by 
natural frameshift suppressor tRNAs with four-base anticodons. Sisido and colleagues have 
pioneered frameshift suppression for incorporation of nonnatural amino acids into proteins 
in E. coli.100-103 In this approach, four-base codons were inserted into a target protein at 
programmed sites. When the four-base codons are read by a modified tRNA that is charged 
with nonnatural amino acid and contains the corresponding anticodon, the full length target 
protein can be synthesized. If the four-base codons are read as three-base codons, truncated 
proteins will be formed due to early termination of protein translation. Four-base codons 
were usually derived from rarely used codons to minimize reading as three-base codons by 
the endogenous tRNAs. The translation efficiencies of some four-base codons were higher 
than those of three-base stop codons. In particular, a GGGU codon showed 86% translation 
efficiency,104 while the suppression efficiencies of an amber codon were ca. 20-60%.75,105 
A number of four-base codons; CGGG, GGGU, CGGU, AGGU, CCCU, and CUCU have 
been generated.101-103,106-108 The four-base codon strategy has also been applied to 
18 
incorporate two different nonnatural amino acids into two programmed sites in a protein, 
which showed orthogonality of each four-base codon to other four-base codons as well as 
three-base codons.103,104,109 The frameshift suppression method has been extended to five-
base codon to incorporate nonnatural amino acids.110 Recently, Sisido and colleagues have 
demonstrated frameshift suppression of a four-base codon (UAGN) in mammalian cells 
using tRNA containing NCUA anticodon.108   
Schultz and colleagues developed a combinatorial approach to select efficient 
suppressors of four-base codons; AGGA, UAGA, CCCU, and CUAG.23,111  This approach 
has been extended to five- and six-base codons with tRNAs containing 6-10 nucleotides in 
the anticodon loops.112 They identified suppressors of several five-base codons, such as 
AGGAU, CUACU, and CUAGU. However, translation efficiency of five-base codons was 
ca. 10%, which was lower than that of four-base codons. Suppression of six-base codons 
was too weak to be detected.112 Recently, Schultz and colleagues have shown that a four-
base codon can be used to incorporate a nonnatural amino acid into proteins in E. coli 
outfitted with a heterologous tRNA/synthetase orthogonal pair.  In particular, L-
homoglutamine was charged into archeal tRNALys by the evolved archeal lysyl-tRNA 
synthetase, and then was inserted into proteins in response to an AGGA codon in E. coli.113      
 
Conclusions 
In 1989 the concept of site-specific incorporation in vitro was independently 
demonstrated by the Chamberlin group and the Schultz group. Recently, several groups 
achieved site-specific incorporation of nonnatural amino acids into proteins in vivo using 
E. coli hosts outfitted with a twenty-first orthogonal pair of tRNA/aaRS. Schultz and 
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colleagues altered the substrate specificity of TyrRS, which was derived from M. 
jannaschii, to various nonnatural amino acids via high-throughput screening of a MjTyrRS 
library. Tirrell and colleagues altered yPheRS substrate specificity toward Phe analogs, 
which led to site-specific incorporation of Phe analogs in E. coli.  The moderate 
suppression efficiency of amber codons has motivated exploration of alternative codons 
that encode nonnatural amino acids. Breaking the degeneracy of the genetic code or 
frameshift suppression greatly expands the theoretical number of codons that can be 
assigned to nonnatural amino acids.  
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Figure 1: Nonnatural amino acids that have been genetically incorporated into proteins in 
bacteria, yeast or mammalian cells. This figure is reprinted, with permission, from the 
Annual Review of Biophysics and Biomolecular Structure, Volume 35, Wang, L.; Xie, J.; 
Schultz, P. G., Expanding the genetic code, 225,27 Copyright (2006) by Annual Reviews 
www.annualreviews.org.   
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Figure 2: Structures of yeast tRNAPhe (left) and E. coli tRNAPhe (right). This figure is 
reprinted from Dudock, B. S.; Diperi, C.; Michael, M. S. J. Biol. Chem. 1970, 245, 2465-
2468,114 Copyright 1970 with permission from the American Society for Biochemistry and 
Molecular Biology. 
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Figure 3: (a) Anticodon-loop tRNA library (left) and all-loop tRNA library (right) derived 
from M. jannaschii tRNATyrCUA (N means all four nucleotides (A/U/G/C)). (b) A general 
selection scheme for suppressor tRNAs that are orthogonal to the E. coli endogenous 
systems and charged efficiently by a cognate synthetase. These figures are reprinted from 
from Chem. Biol., 8, Wang, L.; Schultz, P.G., A general strategy for orthogonal tRNA, 
883,25 Copyright (2001) with permission from Elsevier.  
(a) 
(b) 
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Figure 4: (a) Crystal structure of the T. thermophilus PheRS (tPheRS, pdb 1B70) in ribbon 
model.  Only (αβ) monomeric portion of structure is shown.   (b) Active sites of tPheRS.  
Only residues within 6 Å of substrate Phe are shown.  Substrate is shown as space-filling 
model, while residues surrounding the substrate are shown in stick model.  (c) Sequence 
alignment of PheRS from 21 different organisms. Only residues flanking equivalent 
residues of V261 and A314 in T. thermophilus are represented.  The shaded residues are the 
conserved residues equivalent to V261 and A314 from T. thermophilus.  Sequences 
adjacent to V261 and A314 are also highly conserved.  The sequences are obtained from 
aminoacyl-tRNA synthetase database (http://rose.man.poznan.pl/aars/). These figures were 
adapted from Wang’s thesis (2003).41  
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Figure 5: (A) Phe substrate (red) and four residues (blue) within 7 Å of the para-position 
of the phenyl ring of the substrate inside the binding pocket of a homology model of 
yPheRS. (B) A screening scheme for yPheRS library. GFP6 in yPheRS expression library 
E. coli cells outfitted with ytRNAPheAAA and yPheRS library was expressed in the presence 
of 2Nal (a). Weakly fluorescent cells that contain active yPheRS variants were enriched by 
FACS (b). GFP6 in the collected cells was expressed in the absence of 2Nal (c). Highly 
fluorescent cells that contain selective yPheRS variants were enriched by FACS (d). After 
two rounds of screening, ten colonies were isolated from the enriched cells and 
characterized (e).     
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Figure 6: A schematic diagram describing the concept of breaking the degeneracy of the 
genetic code.  
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Chapter 2 
Site-Specific Incorporation of Phenylalanine Analogs into Proteins in Vivo by an 
Engineered Yeast Phenylalanyl-tRNA Synthetase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work in this chapter was performed in collaboration with Pin Wang, Soojin Son, and 
Yi Tang.  
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Abstract 
Aminoacyl-tRNA synthetases (aaRSs) catalyze the aminoacylation reaction to 
establish the rules of the genetic code.  Precise manipulation of synthetase activity can alter 
aminoacylation specificity to attach non-canonical amino acids to the cognate transfer 
RNAs (tRNA).  The codon-anticodon interaction between messenger RNA (mRNA) and 
tRNA determines which amino acid is delivered into a growing polypeptide chain. Thus 
introduction of nonnatural amino acids into proteins in vivo relies heavily on manipulation 
of amino acid specificity of the aaRS.   In this report, we describe the generation and 
characterization of a mutant phenylalanyl-tRNA synthetase (PheRS) from Saccharomyces 
cerevisiae with a point mutation (T415G) in the α-subunit of the enzyme.  The rationale for 
the mutation is to allow binding of bulkier amino acid substrates. The promiscuous 
substrate specificity of this mutant was extensively explored by ATP-PPi exchange assays 
in vitro. A broad activation profile toward many nonnatural amino acids was observed.  A 
phenylalanine auxotrophic E. coli strain transformed with this mutant synthetase and 
cognate suppressor tRNA enable the assignment of an amber nonsense codon to the amino 
acid tryptophan (Trp) or to the nonnatural amino acid 3-(2-naphthyl)alanine. Expression 
strains engineered as phenylalanine, tryptophan double auxotrophs or phenylalanine, 
tryptophan and lysine triple auxotrophs outfitted with this pair of mutant synthetase and 
tRNA makes possible the efficient incorporation of p-bromophenyl-, p-iodophenyl-, and p-
azidophenylalanine into recombinant proteins. Therefore, this synthetase and its cognate 
tRNA could serve as “21st” pair for site-specific incorporation of novel amino acid into 
proteins in vivo. 
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Introduction 
Aminoacyl-tRNA synthetases (aaRSs) insure the high fidelity of transforming 
genetic code sequences into biologically functional proteins through a two-step 
aminoacylation reaction.1-6  In the first step, the cognate amino acid is activated by aaRS in 
presence of ATP to form the amino acid adenylate; subsequently aaRS catalyzes the 
esterification reaction to join the amino acid to the 2’- or 3’-OH of the terminal 
ribonucleotide of its cognate tRNA.  Through the aminoacylation reaction, the rules of the 
genetic code are settled; the strict correlation between triple nucleotide code and amino 
acid is established with the assistance of the aaRS.2,7,8 Manipulation of such a reaction 
could alter the genetic code to allow incorporation of novel amino acid into proteins in 
vivo.9,10  
With depletion of the intracellular pool of one natural amino acid and use of the 
corresponding bacterial auxotrophic cells, the rates of aminoacylation can be perturbed to 
enable charging of the nonnatural amino acid supplemented in the culture medium as a 
surrogate into cognate tRNA.9   Through subsequent translation by ribosomal machinery, 
the genetic code is re-assigned and the nonnatural amino acid is incorporated into proteins.  
We have successfully implemented such a method to incorporate alkenes,11 alkynes,12 alkyl 
azide13 and fluorinated side chains14 into proteins.  After enhancing the cellular 
aminoacylation reactivity by over-expression of wild-type aaRS in the host, we found that 
some sluggish amino acid analogs could also be introduced into proteins.14-16 The method 
described above requires the cellular wild-type aaRSs to recognize these novel amino acids.  
Engineering new synthetase activity is almost inevitable when one wants to incorporate 
amino acids that are not recognized by the wild-type enzymes.  To date, we and others have 
39 
 
shown that the re-design of the synthetic site of synthetase17-19 and the attenuation of the 
editing function of synthetase20,21 could be two complementary strategies to further expand 
our ability to introduce nonnatural amino acid into proteins.   
We have shown that this multi-site incorporation method can utilize altered sets of 
20 amino acids to design and engineer proteins and protein-like macromolecules.9 By 
manipulation of both synthetase and tRNA in the host, one can also accomplish site-
specific introduction of a single copy of a novel amino acid into proteins in vivo.22-31 This 
method is derived from an in vitro approach to nonnatural amino acid incorporation 
through nonsense (stop codon) suppression, in which a stop codon (amber codon) was 
suppressed by a suppressor tRNA that had been chemically misacylated with the amino 
acid analog of interest.32-36 Such a chemical method to alter the aminoacylation in vitro 
suffers from the technical difficulty and the intrinsic low yield of protein production, which 
limits its application.  In 1998, Furter modified the cellular aminoacylation reaction by 
imparting a “twenty-first pair” comprising a yeast suppressor tRNA and a yeast 
phenylalanyl-tRNA synthetase (yPheRS).26 This approach allowed site-specific 
incorporation of L-p-fluorophenylalanine in vivo in response to an amber codon.  More 
recently Schultz and colleagues have devised powerful selection methods to find useful 
mutant forms of tyrosyl-tRNA synthetase from archaebacterium Methanococcus 
jannaschii.10,37 By introduction of such a mutant and a cognate suppressor, many 
nonnatural amino acids have been incorporated into proteins in vivo.10,22-25,28-31,38-46  
In this report, we present a rationally designed variant of yPheRS with new amino 
acid specificity, allowing incorporation of a variety of phenylalanine analogs (2-4, 7, and 8) 
into proteins site-specifically.  The variant of yPheRS contains a single T415G mutation at 
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the active site of the synthetase, which was shown to be very effective to open up the 
binding pocket.  We performed a study on the amino acid activation kinetics of this mutant 
and found that this mutant can activate several interesting and useful aromatic amino acids 
(1-8). We also observed that this variant activates tryptophan (Trp, 6) 82-fold faster than 
cognate substrate phenylalanine (Phe, 1). A phenylalanine auxotrophic bacterial strain 
transformed with such a mutant and cognate suppressor tRNA can assign analog 7 to the 
amber codon with high fidelity (>90%).  Such a transformed strain also allows the 
incorporation of 2-4 into proteins at the amber site with misincorporation of Trp.  Further 
refinements of such a system by constructing a Phe/Trp/Lys triple auxotrophic strain enable 
us to incorporate analog 2-4 into the desired amber site with fidelity of 86%, 82%, and 
90%, respectively.   
 
Materials and Methods 
Materials.  Amino acids 1, 5 and 6 were obtained from Sigma (St. Louis, MO). Amino 
acids 2-4, and 7 were purchased from Chem-Impex (Wood Dale, IL). Amino acid 8 was 
purchased from Biosynth International (Naperville, IL).  [32P]-labeled sodium 
pyrophosphate was purchased from NEN Life Science (Boston, MA).   
 
Plasmid Construction for Synthetase Expression.  The yPheRS gene was amplified from 
template plasmid pUC-ASab226,47 encoding the α- and β-subunits of PheRS gene with a 
14-base pair (bp) intergenic sequence containing a translational reinitiation site upstream of 
the ATG start codon of the β-subunit gene.   The following primers were used for PCR: 5’-
CGA TTT TCA CAC AGG ATC CAG ACC ATG AAT CTA G-3’ (primer 1 with 
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restriction site BamHI) and 5’-GAC GGC CAG TGA ATT CGA GCT CGG TAC-3’ 
(primer 2 with restriction site KpnI).   The resulting DNA was introduced into the BamHI 
and KpnI sites of pQE32 to give pQE32-yFRS.  The mutant yPheRS was generated by 
using the 4-primer mutagenesis method.  Two complementary oligonucleotides, designated 
as primer 3 (5’-CTA CCT ACA ATC CTT ACG GCG AGC CAT CAA TGG AAA TC-
3’) for the forward primer and primer 4 (5’-GAT TTC CAT TGA TGG CTC GCC GTA 
AGG ATT GTA GGT AG-3’) for the reverse primer, were synthesized to carry the specific 
mutation at position 415 of the α-subunit of yPheRS.  In the initial two reactions, primer 
1/primer 4 and primer 2/primer 3 were added into individual tubes and two DNA fragments 
were generated from these two PCRs.  With the mixture of two reaction products and 
additional outside primers, a 3400 bp fragment of DNA was obtained and purified.  This 
DNA was subjected to digestion by BamHI and KpnI and inserted into pQE32 to yield 
pQE32-T415G.  The cloned enzymes contain the N-terminal sequence 
MRGSHHHHHHGIQTMNLE to facilitate protein purification.  The entire yPheRS gene 
was sequenced for each of these constructs.  Proofreading polymerase Pfx (Invitrogen) was 
used for all PCR amplication described in this work.   
 
Synthetase Expression and Purification.   The plasmids pQE32-yFRS and pQE32-
T415G were individually transformed into E. coli strain BLR (Novagen) to form 
expression strains BLR(pQE32-yFRS) and BLR(pQE32-T415G).  Synthetase expression 
was conducted in LB media.  At an OD of 0.6, expression of the wild-type and mutant 
forms of yPheRS was induced with 1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) 
for 4 hours.  Cells were harvested and proteins were purified over a nickel-nitrilotriacetic 
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acid affinity column under native conditions according to the manufacturer’s protocol 
(Qiagen).  Imidazole in the elution buffer was removed by desalting column (Bio-rad) and 
proteins were eluted into a buffer containing 50 mM Tris-HCl (pH=7.5), 1 mM DTT.  
Aliquots of proteins were stored at -80oC with 50% of glycerol.   
 
Amino Acid Activation Assay.   The amino acid-dependent ATP-PPi exchange reaction 
was used to evaluate the activation of amino acid analogs by yPheRS.  This assay was 
performed in 200 µL of reaction buffer containing 50 mM HEPES (pH=7.6), 20 mM 
MgCl2, 1 mM DTT, 2 mM ATP and 2 mM [32P]-PPi with specific activity of 0.2-0.5 
TBq/mol.  Depending on the rate of activation of the analog by the synthetase, the amino 
acid concentration varied from 10 µM to 5 mM and the enzyme concentration varied from 
10 nM to 100 nM.  Aliquots (20 µL) were removed from the reaction solution at various 
time points and quenched into 500 µL of buffer solution containing 200 mM NaPPi, 7% 
w/v HClO4 and 3% w/v activated charcoal.  The charcoal was spun down and washed 
twice with 500 µL of 10 mM NaPPi and 0.5% HClO4 solution.   The [32P]-labeled ATP 
absorbed into the charcoal was quantified via liquid scintillation methods.  The specificity 
constants were calculated by nonlinear regression fit of the data to a Michaelis-Menten 
model.   
 
Plasmid and Strain Construction for in Vivo Incorporation Assays.  pQE16 (Qiagen), 
chosen as the expression plasmid, encodes the marker protein murine dihydrofolate 
reducase (mDHFR) with a C-terminal hexa-histidine tag under control of a bacteriophage 
T5 promoter and t0 terminator.  A Quick-change mutagenesis kit was used to place an 
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amber codon (UAG) at position 38 of mDHFR (mDHFR (38Am)) (with two 
complementary oligonucletides (5’-CCG CTC AGG AAC GAG TAG AAGTAC TTC 
CAA AGA ATG-3’; 5’-CAT TCT TTG GAA GTA CTT CTA CTC GTT CCT GAG 
CGG-3’) to afford pQE16am.  The mutant yPheRS (T415G) gene was amplified from 
pQE32-T415G and a constitutive tac promoter with an abolished lac repressor binding site 
was added upstream of the start codon of this gene.26  The entire expression cassette was 
inserted into the PvuII site of pQE16 to yield pQE16am-T415G. The mutant yeast 
suppressor tRNA (mutRNAPhe(CUA)) was constitutively expressed under control of an lpp 
promoter. The expression cassette for mutRNAPhe(CUA) was inserted into pREP4 to form 
pREP4-tRNA as described by Furter.26 A Phe auxotrophic strain AFK10, Hfr(Cavalli) 
pheS13rel-1 tonA22 thi T2R pheA18), constructed in this laboratory,26 was used as the 
expression strain.  A Phe/Trp double auxotrophic strain AFW (K10, Hfr(Cavalli) 
pheS13rel-1 tonA22 thi T2R pheA18, trpB114) and a Phe/Trp/Lys triple auxotrophic strain 
AFWK (K10, Hfr(Cavalli) pheS13rel-1 tonA22 thi T2R pheA18, trpB114, lysA) were 
prepared by P1 phage-mediated transduction with trpB::Tn10 and lysA::Tn10 transposons.     
 
Analog Incorporation Assay in Vivo.  The auxotrophic strains AF, AFW, and AFWK 
were transformed with the plasmids pQE16am-T415G and pREP4-tRNA to afford 
expression strains AF [pQE16am-T415G/pREP4-tRNA] and AWF [pQE16am-
T415G/pREP4-tRNA] respectively.  Expression of mDHFR (38Am) was investigated in 20 
mL cultures.  The E. coli expression strains were grown in M9 minimal medium 
supplemented with glucose, thiamin, MgSO4, CaCl2, 20 amino acids (at 25 mg/L), and 
antibiotics (kanamycin and ampicillin).  When cells reached an OD600 of 1.0, they were 
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sedimented by centrifugation, washed twice with cold 0.9% NaCl, and shifted to 
supplemented M9 medium containing 17 amino acids (at 25 mg/L), 3 mM analog of 
interest, and the indicated concentrations of Phe, Trp and Lys. Protein expression was 
induced by addition of isopropyl-β-D-thiogalactopyranoside (1 mM).  After 4 hours, cells 
were pelleted and the protein was purified by passage through a Ni-NTA spin column 
according to the supplier’s instructions (Qiagen).  
 
Compositional Analysis of Mutant mDHFR.  Mutant mDHFR (38Am) was purified 
under denaturing conditions and isolated in elution buffer (8 M urea, 100 mM NaH2PO4, 10 
mM Tris, pH = 4.5).  For trypsin digestion, 10 µL of the solution was diluted into 90 µL of 
75 mM (NH4)2CO3 and the pH was adjusted to 8.  2 µL of modified trypsin (Promega, 0.2 
µg/µL) was added.  The sample was incubated at room temperature overnight.  For 
digestion by endoproteinase Lys-C, 10 µL of the solution was diluted into 90 µL of 25 mM 
Tris-HCl, pH = 8 and 1 mM EDTA and pH was adjusted to optimal working pH 8 for Lys-
C.  2 µL of Lys-C (Calbiochem, 0.2 µg/µL) was added and the reaction was incubated at 37 
oC for 10 hours.  The digestion reaction was stopped by addition of 2 µL trifluoroacetic 
acid (TFA).  The solution was subjected to ZipTipC18 (Millipore) purification and the 
digested peptides were eluted with 3 µL of 50% CH3CN, 0.1% TFA, of which 1 µL was 
used for matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) 
analysis with µ-cyano-4-hydroxycinnamic acid and 2,5-dihydroxybenzoic acid as the 
matrix.  The analysis was performed on a PerSeptive Biosystems (Framingham, 
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Massachusetts) Voyager DE PRO MALDI-TOF mass spectrometer operating in linear and 
positive ion modes.   
LC-MS/MS analysis of protease-digested peptides was conducted on Finnigan LCQ 
ion trap mass spectrometer with HPLC pump and ESI probe.  3 µL of digested peptide 
solution eluted from ZipTipC18 was diluted with 20 µL of distilled water and injected into 
the HPLC pump.  Peptides were separated by Magic C18 column (Michrom, 5µL, 200Å, 
0.3x150mm) and eluted at a flow rate of 30 µL/min using a linear gradient of 0-60% of 
acetonitrile in 45 min.  The column eluent was transferred to the electrospray source and 
tandem mass sequencing was carried out by fragmentation of the precursor ion with m/z 
corresponding to the protease-digested fragment (residues 26-39; NGDLPWPPLRNEZK) 
including an amber site at position 38 of mutant mDHFR (38Am). 
 
Results and Discussion 
Rationales for Engineering New Synthetase Specificity.  Engineering the new synthetase 
specificity toward amino acid analogs is one of the critical steps for the successful 
implementation of the general strategy to incorporate nonnatural amino acids into proteins 
in vivo.29 We have been especially interested in exploring the possibilities of incorporating 
substituted phenylalanine (Figure 2) such as p-bromophenylalanine (2), p-
iodophenylalanine (3), p-azidophenylalanine (4), and 3-(2-naphthyl)alanine (7). These non-
proteinogenic amino acids either carry chemical functionality not present in proteins or are 
characterized by enhanced hydrophobic interactions.   The crystal structure of Thermus 
thermophilus PheRS (tPheRS) complexed with phenylalanine is available48 and the 
46 
 
sequence identity (vs Saccharomyces cerevisiae) in the active site region is about 40% 
(Figure 1).  We used this crystal structure as a starting point for the design of a mutant yeast 
PheRS that charges the nonnatural amino acids of interest. Safro and colleagues identified 
two residues, V261 and A314, which constitute a back-wall structure to hold substrate 
phenylalanine and play an important role to hinder binding of amino acids larger than Phe 
into the active site of T. thermophilus PheRS.49 In fact, an E. coli PheRS variant prepared 
by mutation of the corresponding residues (T251G and A314G, Figure 1), has been shown 
to exhibit relaxed substrate specificity.17 In S. cerevisiae PheRS, the corresponding residues 
are T415 and G460.  We reasoned that mutation from T415 to G might enlarge the active 
site to accommodate larger phenylalanine analogs.   
 
Synthetase Expression and Purification.  The wild-type yPheRS gene was obtained by 
PCR amplification of vector pUC-ASab2 encoding the α- and β-subunits of yeast PheRS 
(our assignment of α- and β-subunits are opposed to what was assigned by Sanni; we 
followed the tradition that the catalytic subunit of PheRS is designated the α-
subunit.47,48,50). A 14-bp intergenic sequence obtained from upstream region of the E. coli 
pheST gene was inserted in the middle of the α- and β-subunits of yeast PheRS. Four-
primer mutagenesis was employed to create the mutant T415G.  The synthetases were 
over-expressed by E. coli BLR strains under control of the bacteriophage T5 promoter.  An 
N-terminal hexa-histidine tag fused to the α-subunit of yPheRS facilitated purification of 
the enzymes under native conditions. Both E. coli and yeast synthetases are α2β2 hetero-
tetramers and their molecular weights for each subunit are rather different (α(ePheRS)=37 
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kDa; α(yPheRS)=57 kDa; β(ePheRS)=87 kDa; β(yPheRS)=67.5). SDS-PAGE analysis of 
purified yPheRS indicated no observable contamination by E. coli PheRS.  The intensities 
of the bands for the α- and β-subunits are not stoichiometric (the α-subunit is stronger than 
the β-subunit); Sanni and colleagues reported a similar observation and suggested that this 
result stems from proteolysis of the β-subunit and from one β-fragment co-migrating with 
the α-subunit.47  So a fraction of the purified yPheRS used in our experiments must be 
inactive. Our aim is to investigate the altered substrate specificity from the mutation 
(T415G for α-subunit) and compare the ability of the mutant enzyme to activate different 
amino acid analogs (2-8) in vitro; as long as we paralleled the measurement and used the 
same batch of the enzyme, it is still possible to deduce the specificity constants for the 
different analogs and make comparisons.  
 
Amino Acid Specificity of Mutant Yeast PheRS.  The activities of the yPheRS variant 
with Phe analogs (2-8) were examined via amino acid-dependent ATP-PPi exchange assay.  
Kinetic parameters for amino acid 1-8 were shown in Table 1. Our measured value of Km 
for 1 by the wild-type yeast PheRS matched previously reported values,51 although the 
obtained kcat was lower than that reported,51 and this difference might come from the 
different buffer conditions and different methods to determine the enzyme concentration.  
The efficiency kcat/Km for 1 by the mutant T415G is reduced approximately 40-fold 
compared to 1 by the wild-type enzyme.  The loss of catalytic activity is apparent in both 
the increasing value of Km and decreasing value of kcat, which suggests that the T415G 
mutation significantly impairs both the binding and catalytic events for 1.  However, this 
mutant exhibited higher activity for analogs 2-4 and 6-8, with values of kcat/Km ranging 
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from 8- to 58-fold higher than that for Phe (1).  It appears that the mutation effectively 
opens up the active site of the synthetase so that T415G favors binding and catalysis of 
bulkier substrates.  Canonical amino acid Trp (6) showed especially high activity, as 
manifested by 82-fold higher specificity constant than that of 1.  
 
Site-Specific Incorporation of Phe Analogs into mDHFR (38Am) in Vivo Using a 
Phenylalanine Auxotrophic Strain.  To test the utility of the engineered yPheRS to 
incorporate aromatic amino acid analogs into proteins in vivo at programmed sites, a 
constitutive expression system for the mutant synthetase was constructed.  An amber stop 
codon was placed at residue 38 of the marker protein mDHFR (38Am), which was 
equipped with a C-terminal hexa-histidine tag followed by an ochre stop codon (Figure 3). 
The levels of full length protein production were examined by SDS-PAGE analysis.  
Without over-expression of suppressor mutRNAPhe(CUA), we did not obtain detectable 
levels of full length mDHFR (38Am).52 As a positive control, we co-expressed wild-type 
yPheRS with mutRNAPhe(CUA), and efficient suppression by phenylalanine was 
observed.52  When mutant yPheRS was co-expressed with mutRNAPhe(CUA) in the 
presence of analogs 2-8 (3 mM), full length mDHFR (38Am) was formed.52 Overall 
protein yields varied depending on the analogs used and were ca. 2-10 mg/L, estimated by 
SDS-PAGE. The same strain yield of mDHFR without amber codon in minimal medium 
was approximately 25 mg/L.  
It should be noted that the observed pattern of protein expression by SDS-PAGE 
does not necessarily mean that the analogs of interest are inserted at the amber codon 
position. Proteolytic peptide analysis was performed by MALDI-MS and liquid 
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chromatography tandem mass spectrometry for purified protein samples.  Our protocol for 
digestion by endoproteinase Lys-C yielded two peptides in the mass range 1,600-1,800 Da; 
these fragments were assigned to residues 26-39 (Peptide A) and 40-53 (Peptide B) of 
mDHFR (38Am) (Figure 3). Peptide A includes an amber codon at the 38th position; 
Peptide B contains a single phenylalanine residue at position 41.  In a control experiment, 
in which mDHFR (38Am) was expressed in medium supplemented with 1 (3 mM) (Figure 
4a), the mass of Peptide A indicates that 1 was incorporated into the amber site. Our in 
vitro assay shows that T415G mutant synthetase activates 6 82-fold faster than 1; while our 
in vivo translational experiment reveals that 1 is favored over 6 to enter amber site, despite 
the fact that Phe auxotrophic strain can still synthesize 6.  In the medium supplemented 
with 7 (3 mM) and 1 (0.03 mM), we unambiguously confirmed incorporation of 7 into the 
amber site as shown in Figure 4b; Peptide A was shifted up in mass by 50 Da, consistent 
with the increased mass of 7 relative to 1; and Peptide B was unchanged in mass, indicating 
that the Phe codon site is decoded as 1. Liquid chromatography tandem mass spectrometry 
was employed to confirm the sequence of Peptide A. The precursor ion at m/z 867.7 Da, 
which corresponds to the doubly charged ion of Peptide A, was separated and fragmented 
with an ion trap mass spectrometer.  As shown in Figure 5, the sequence obtained from the 
spectrum clearly reveals site-specific incorporation of 7 into mDHFR at position 38; we 
could find no indication of any other amino acid at the amber site after carefully checking 
all possible peptides with masses that could be associated with Peptide A, suggesting that 
the fidelity of incorporation of 7 is better than 95%.  The kinetics of activation of 7 and 1 
by mutant yPheRS showed that the efficiency (kcat/Km) for 7 is 1,500±100 (M-1s-1) (Table 
1), 8-fold larger than that for 1.  Therefore, when the ratio of 7 to 1 in the culture medium is 
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high (100 to 1), tRNAPhe(CUA) should be charged predominantly with 7, consistent with 
our observation of high percentage incorporation of 7 into proteins at amber sites.   
Similar analyses show incorporation of 2-4 into mDHFR (38Am). As a 
representative, incorporation of 2 into mDHFR (38Am) was shown (Figure 4c). We 
observed competitive misincorporation of Trp (6) and lysine (Lys, 8) at the amber site.  
Incorporation of Trp is not surprising in view of the in vitro data. The rates of activation of 
2-4 by T415G are 10-33% of that of 6 (Table 1).  Therefore, 6 is able to compete 
significantly with 2-4 for the attachement into mutRNAPhe(CUA) and insertion into the 
amber site.  Lys misincorporation at the amber codon is likely due to mischarging of Lys to 
mutRNAPhe(CUA) by E. coli lysyl-tRNA synthetase (eLysRS), because mutRNAPhe(CUA) 
has U36 and A73, which are the main identity elements for eLysRS .53,54 No observation of 
misincorporation of 6 or 8 with 7 (Figure 4b) could be due to the better recognition of 7 by 
mutant synthetase than that of 2-4 (Table 1) and the better charging of 7 into 
mutRNAPhe(CUA) by mutant synthetase than that of eLysRS.       
 
Site-Specific Incorporation of Phe Analogs into mDHFR in Vivo Using a Phe/Trp 
Double Auxotrophic Strain.  To test our hypothesis of intracellular tryptophan inhibiting 
the incorporation of analogs (2-4), we decided to construct a Phe/Trp double auxotrophic 
strain so that the cellular concentration of Trp could be controlled.  This strain, designated 
AFW, was transformed with mutant yPheRS, mDHFR (38Am) and mutRNAPhe(CUA) 
genes to form a new expression system.  In order to confirm our ability to control the 
cellular pool of Trp in this new strain, we performed a comparison experiment where we 
set one high concentration of Trp (3 mM) and one low concentration of Trp (0.03 mM) in 
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M9 minimal medium to examine the effect on site-specific incorporation of 2 (3 mM) in 
response to an amber stop codon. Proteolytic cleavage of mDHFR (38Am) by trypsin 
generated two peptides in the mass range 1550-1800 Da, which consistently appeared in 
the mass spectra and could be assigned to residues 26-39 (Peptide A) and 85-98 (Peptide C) 
of mDHFR (Figure 4, Figure 5). Peptide C contains a single phenylalanine residue at 
position 95. MALDI-MS analysis revealed that Trp concentration has a significant effect 
on incorporation of 2.  As shown in Figure 6a, 2 is incorporated into mDHFR along with 
Trp; the ratio of MALDI signal intensities suggests that 2 and 6 are incorporated at 
comparable rates at the amber site, although signal intensity and the peptide concentration 
are not strictly correlated.  In contrast, as we lowered the Trp concentration to 0.03 mM, the 
signal for Trp incorporation greatly decreased; the amber position was mostly assigned by 
analog 2 (Figure 6b).  Since the biosynthesis of Trp in the auxotrophic strain is impeded, 
cellular concentration of Trp is dependent on the amino acid transport from medium to 
cytoplasm.  Our previous work showed that the cellular concentration of 2 is 14-17 times 
higher than that of Phe in the Phe auxotrophic strain cultured in media supplemented with 2 
mM of 2 and 0.12 mM of Phe.19 Compared with Trp, we believe that the 10-fold lower 
amino acid activation of 2 by mutant yPheRS (Table 1) can be compensated by high 
concentration of 2 inside the cells; mutRNAPhe(CUA) is charged mostly with 2.  However, 
we observed that Lys was still misincorporated at amber codon (Figure 6b).  
 
Site-Specific Incorporation of Phe Analogs into mDHFR in Vivo Using a Phe/Trp/Lys 
Triple Auxotrophic Strain. Based on our hypothesis that Lys was mischarged into 
mutRNAPhe(CUA) by eLysRS, we decided to control the intracellular concentration of Lys 
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by constructing a Phe/Trp/Lys triple auxotrophic strain (AFWK).  When a high 
concentration of Lys (0.2 mM) was supplemented into the medium, misincorporation of 
Lys was detected (Figure 6b).  However, when low concentration of Lys (0.01 mM) was 
supplemented into the medium, the signal for the peptide containing Lys at amber codon is 
no longer detected (Figure 6c). In conclusion, under the condition that high concentrations 
of 2 and low concentrations of Phe, Trp and Lys were supplemented into the medium, 
incorporation of 2 is predominant at the programmed amber stop codon in mDHFR 
(38Am) with 86% fidelity. Further experiments on analog 3 (Figure 6d) and analog 4 
manifest a similar pattern of the site-directed analog incorporation with 82% and 90% 
fidelity, respectively.52   
 
Conclusions 
The amino acid binding pocket of yeast PheRS can be engineered very simply to 
accommodate a variety of aromatic side chain functionalities.  Cells outfitted with mutant 
yeast synthetase (T415G) and suppressor tRNA can site-specifically incorporate several 
amino acid analogs (2-4, and 7) into proteins in response to the UAG codon.  Coupled with 
recent reports from several laboratories,22-25,27,29-31,38-42,44,45,55-57 these results begin to 
demonstrate that the import of heterologous synthetase pairs should constitute a general 
strategy for site-specific incorporation of amino acids into proteins in vivo.  Chemical and 
physical properties of these new side chains can enlarge our ability to manipulate proteins 
and provide us additional tools to study and design new functions of 
biomacromolecules.29,33,41,58-60 For instance, bromine (2) and iodine (3) once introduced 
into proteins can facilitate phasing of crystallographic data and therefore be useful in X-ray 
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diffraction studies of protein structure.  Photoactivity of aryl azide (4) can be used for 
intramolecular crosslinking and protein immobilization.61 Hydrophobic nature of 
naphthalene (7) can be applied to design specific ligand-receptor recognition.62 Chemical 
utilities of these side chains equip us with new means to site-specifically modify proteins, 
most of which are orthogonal to natural amino acid side chains in the proteins.  Proteins 
with aryl-halide side chains can be subjected to palladium-mediated coupling reactions to 
attach molecules containing the ethynyl group.63 Azide chains in the proteins can be 
applied to staudinger ligation to tether molecules associated with the triarylphosphine 
group.13  Recently, there is a growing interesting in possible bioconjugation of proteins 
using copper(I)-catalyzed azide-alkyne cycloaddition reactions.64-66 Our group is currently 
doing these investigations using recombinant proteins biosynthesized in vivo in the 
engineered bacterial hosts described in this report. 
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Figure 1: (a) Sequence alignment of PheRS variants from Thermus thermophilus, 
Escherichia coli, Saccharomyces cerevisiae. Only portions of sequences flanking the V261 
and A314 positions in T. thermophilus are shown.  The sequences adjacent to V261 and 
A314 are highly conserved.  The equavilent residues in E. coli and  S. cerevisiae that 
correspond to residues V261 and A314 in T. thermophilus are shown in red.  (b) 
Stereoview of active site of PheRS from T. thermophilus.  Substrate phenylalanine is 
shown in yellow.   
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Figure 2:  Amino acids involved in this study.  (1) phenylalanine; (2) p-
bromophenylalanine; (3) p-iodophenylalanine; (4) p-azidophenylalanine; (5) tyrosine; (6) 
trytophan; (7) 3-(2-naphthyl)alanine; and (8) L-lysine. 
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Table 1:  Kinetic parameters for ATP-PPi exchange of amino acids (1-7) by the  
mutant yeast PheRS   
 
Amino Acid Enzyme Km (µM) kcat (s-1) kcat/Km (M-1s-1) kcat/Km (rel)* 
1 T415G 264±42 0.05±0.002 180±30 1 
2 T415G 22±3 0.03±0.001 1,500±200 8 
3 T415G 12±2 0.05±0.001 4,400±800 24 
4 T415G 11±3 0.05±0.002 4,600±1,200 25 
5 T415G 757±149 0.04±0.003 48±10 1/4 
6 T415G 20±5 0.30±0.006 15,000±4,000 82 
7 T415G 27±2 0.04±0.001 1,600±100 8 
      
1 Wild-type 68±20 0.52±0.093 7,600±2,700 41 
*relative to kcat/Km for 1 by T415G 
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Figure 3:  Amino acid sequence of marker protein mDHFR (38Am).  Four proteolytic 
peptide fragments (Peptide A, Peptide B, and Peptide C) used for MALDI-MS and LC-
MS/MS analyses are underscored.  The positions with amber codon and ochre codon are 
labeled.   
 
 
 
MRGSGIMVRPLNSIVAVSQNMGI
GKNGDLPWPPLRNEZKYFQRM
TTTSSVEGKQNLVIMGRKTWFSI
PEKNRPLKDRINIVLSRELKEPPR
GAHFLAKSLDDALRLIEQPELAS
KVDMVWIVGGSSVYQEAMNQP
GHLRLFVTRIMQEFESDTFFPEID
LGKYKLLPEYPGVLSEVQEEKGI
KYKFEVYEKKGSRSHHHHHHuaa 
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amber codon (UAG) 
Peptide C 
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Figure 4:  MALDI-MS of proteolytic peptide fragments derived from mDHFR expressed 
in media supplemented with (a) 1 (3 mM); (b) 7 (3 mM)/1 (0.03 mM); (c) 2 (3 mM)/1 
(0.03). mDHFR (38Am) was expressed in phenylalanine auxotrophic strain (AF) 
transformed with the mutant yeast PheRS and cognate suppressor tRNA.  No tryptophan is 
added, except that 1 mM of Trp is supplemented in (c).  Protein was digested by 
endoproteinase Lys-C.  Peptide B, containing one Phe codon, remains the same for all the 
experimental conditions, indicating normal Phe codons are assigned as Phe.  Peptide A 
contains one amber codon; the residue responding to this codon is designated as Z. In case 
of Lys misincorporation into Peptide A (c), C-terminal Lys was further cleaved to produce 
a shorter Peptide A (NGDLPWPPLRNEK).    
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Figure 5:  The tandem mass spectrum of Peptide A (NGDLPWPPLRNEZK) derived from 
mDHFR (38Am) expressed in media supplemented with 7 (3 mM)/1 (0.03 mM).  mDHFR 
(38Am) was expressed in phenylalanine auxotrophic strain (AF) transformed with the 
mutant yeast PheRS and cognate suppressor tRNA.  Partial sequence of PWPPLRNE and 
residue Z (corresponds to 7) of Peptide A can be assigned from the annotated y and b ion 
series respectively. 
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Figure 6: MALDI-MS of proteolytic peptide fragments of mDHFR (38Am) expressed in 
media supplemented with (a) 2 (3 mM)/6 (3 mM)/1 (0.03 mM)/8 (0.2 mM); (b) 2 (3 mM)/6 
(0.01 mM)/1 (0.03 mM)/8 (0.2 mM); (c) 2 (3 mM)/6 (0.01 mM)/1 (0.03 mM)/8 (0.01 mM); 
(d) 3 (3 mM)/6 (0.01 mM)/1 (0.03 mM)/8 (0.01 mM). mDHFR (38Am) was expressed in 
an phenylalanine, tryptophan and lysine triple auxotrophic strain (AFWK) transformed 
with the mutant yeast PheRS and cognate suppressor tRNA.  The purified mDHFR (38Am) 
was digested by modified trypsin. Peptide C, containing one Phe codon, remains the same 
for all the experimental conditions, indicating normal Phe codons are assigned as Phe.  
Residue Z, the amino acid incorporated in response to the amber codon, is assigned based 
on the mass units of Peptide A.   
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Chapter 3 
Design of a Bacterial Host for Site-Specific Incorporation of p-Bromophenylalanine 
into Recombinant Proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The text in this chapter is reprinted with permission from Kwon, I.; Wang, P.; Tirrell, D. 
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Abstract 
Introduction of a yeast suppressor tRNA (ytRNAPheCUA) and a mutant yeast 
phenylalanyl-tRNA synthetase (yPheRS (T415G)) into an E. coli expression host allows 
in vivo incorporation of phenylalanine analogs into recombinant proteins in response to 
amber stop codons. However, high fidelity incorporation of non-natural amino acids is 
precluded in this system by mischarging of ytRNAPheCUA with tryptophan (Trp) and 
lysine (Lys). Here we show that ytRNAPheCUA and yPheRS can be re-designed to achieve 
high fidelity amber codon suppression through delivery of p-bromophenylalanine (pBrF). 
Two strategies were used to reduce misincorporation of Trp and Lys. First, Lys 
misincorporation was eliminated by disruption of a Watson-Crick base pair between 
nucleotides 30 and 40 in ytRNAPheCUA. Loss of this base pair reduces mischarging by the 
E. coli lysyl-tRNA synthetase. Second, the binding site of yPheRS was re-designed to 
enhance specificity for pBrF. Specifically, we used the T415A variant, which exhibits 
five-fold higher activity toward pBrF as compared to Trp in ATP-PPi exchange assays. 
Combining mutant ytRNAPheCUA and yPheRS (T415A) allowed incorporation of pBrF 
into murine dihydrofolate reductase in response to an amber codon with at least 98% 
fidelity.  
 
Introduction  
Non-natural amino acids carrying a wide variety of novel functional groups have 
been incorporated into recombinant proteins in both prokaryotic and eukaryotic cells.1-24 
Although global replacement of natural amino acids with non-natural analogs is useful 
for many purposes,1,16,25,26 there are situations in which single-site substitution by a non-
natural amino acid is required. In such circumstances, a codon must be assigned uniquely 
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to the non-natural amino acid. Amber (UAG),2,4,7-9,27-29 ochre (UAA),30,31 opal (UGA) 
stop codons, 30,32 and four base codons32,33 have been explored for this purpose. The 
amber codon has been used most widely,2,8,9,27-29 because it is the least common stop 
codon in E. coli and because several naturally occurring suppressor tRNAs recognize it 
efficiently.34,35 Use of the amber codon to encode non-natural amino acids requires 
outfitting the cell with an “orthogonal pair” comprising a suppressor tRNA and a cognate 
aminoacyl-tRNA synthetase (aaRS) that operate independently of the endogenous 
synthetase-tRNA pairs in E. coli.  The site-specific incorporation of a non-natural amino 
acid into recombinant proteins via this strategy was reported by Furter in 1998,9 and the 
Schultz laboratory has developed powerful selection methods to identify heterologous 
synthetases and tRNAs.2,22,32,36,37 The tyrosyl pair derived from the archaebacterium 
Methanococcus jannaschii has been especially useful in this regard.38   
In a complementary approach, rational modification and virtual screening 
methods have been used to design the amino acid binding pocket of the E. coli PheRS 
(ePheRS).5,39 On the basis of the crystal structure of the PheRS (tPheRS) from Thermus 
thermophilus, Safro and colleagues proposed that Val 261 and Ala 314 in the amino acid 
binding pocket are critical in the discrimination of Phe from its amino acid competitors.40 
Sequence alignment indicates that Ala 314 in tPheRS corresponds to Ala 294 in ePheRS, 
and the Hennecke group showed that the substrate specificity of ePheRS can be relaxed 
by a point mutation at Ala 294. The A294G mutant was shown to enable incorporation of 
para-chlorophenylalanine into recombinant proteins.41 A subsequent computational 
simulation, consistent with the Safro prediction, identified two cavity-forming mutations 
(T251G and A294G) in ePheRS binding pocket. These two mutations led to relaxed 
substrate specificity and efficient in vivo replacement of Phe by para-
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acetylphenylalanine (pAcF).5 Sequence alignment shows that Thr 415 in yPheRS is 
equivalent to Thr 251 in ePheRS. We therefore anticipated that the yPheRS (T415G) 
variant would activate a variety of Phe analogs.42 However, when the T415G variant was 
co-transformed with ytRNAPheCUA into an E. coli host, substantial misincorporation of 
Trp and Lys was observed. Use of a triple auxotrophic E. coli host (Phe, Trp, and Lys) led 
to good incorporation (85-95%) of a variety of novel aromatic amino acids in response to 
amber codons,32 but the limited specificity of this expression system prompted us to 
consider its refinement.    
In this report, we describe the design of a bacterial host capable of high fidelity 
site-specific incorporation of para-bromophenylalanine (pBrF) in response to an amber 
codon.  Introduction of aryl halides, such as pBrF19,22 or para-iodophenylalanine 
(pIF)13,22 into recombinant  proteins allows site-specific modification via versatile 
palladium catalyzed cross-coupling reactions with terminal alkene or alkyne reaction 
partners.43-48 In order to achieve high fidelity incorporation of pBrF, two different 
strategies were applied to reduce misincorporation of Trp and Lys, while providing good 
yields of recombinant protein. First, Lys misincorporation was eliminated by 
modification of the sequence of ytRNAPheCUA to reduce mischarging of ytRNAPheCUA by 
eLysRS.  Second, the binding site of yPheRS was re-designed to enhance specificity for 
pBrF. Finally, the combined use of these two strategies provided high fidelity amber 
codon suppression through delivery of pBrF.   
 
Materials and Methods 
Materials. Unless otherwise noted, reagents were obtained from commercial suppliers 
and were used without further purification. Natural amino acids were from Sigma (St. 
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Louis, MO), and [3H]-amino acids from Amersham Pharmacia Biotech (Piscataway, NJ). 
pBrF was obtained from Chem-Impex (Wood Dale, IL).  Purified total yeast tRNA was 
purchased from Roche Biochemical (Indianapolis, IN). The nickel-nitrilotriacetic acid 
affinity column and repressor plasmid pREP4 were from Qiagen (Valencia, CA). E. coli 
strain BLR (RecA- derivative of BL21) was purchased from Novagen (Madison, WI).  
 
Plasmid Construction for Synthetase Expression. Genes encoding the α- and β-
subunits of yPheRS were amplified from template plasmid pUC-ASab29,49 and inserted 
between  the BamHI and KpnI sites of pQE32 to give pQE32-yPheRS. pQE32-T415G 
and pQE32-T415A were constructed from pQE32-yPheRS by PCR mutagenesis at 
position 415 of the α-subunit of yPheRS by use of a QuikChange mutagenesis kit 
(Stratagene). Two complementary oligonucleotides, 5’-CT ACC TAC AAT CCT TAC 
GCC GAG CCA TCA ATG GAA ATC-3’ for the forward primer and 5’-GAT TTC CAT 
TGA TGG CTC GGC GTA AGG ATT GTA GGT AG-3’ for the reverse primer, were used 
to introduce the T-to-A mutation at position 415 of the α-subunit of yPheRS. The entire 
yPheRS gene was verified by DNA sequencing for each of these constructs.  
Proofreading polymerase Pfx was used in all PCR described in this work.  The E. coli 
lysS gene was amplified by PCR from template plasmid pXLysKS1,48 by using two 
primers, 5’-GCA CTG ACC ATG GCT GAA CAA CAC GCA CAG-3’ (which includes 
an NcoI restriction site) and 5’-GGA CTT CGG ATC CTT TCT GTG GGC GCA TCG C-
3’ (which carries a BamHI restriction site). The resulting DNA was inserted between the 
NcoI and BamHI sites of pQE60 to yield pQE60-eLysS. The cloned enzymes contained 
N-terminal or C-terminal hexa-histidine tags to facilitate protein purification.  
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Synthetase Expression and Purification.   The plasmids pQE32-yPheRS, pQE32-
T415G, pQE32-T415A, and pQE60-eLysS were individually co-transformed with a 
repressor plasmid pREP4 into E. coli strain BLR to form expression strains BLR 
(pQE32-yFRS), BLR (pQE32-T415G), BLR (pQE32-T415A), and BLR (pQE60-eLysS), 
respectively.  Synthetase expression was conducted in 2xYT media with 100 µg/mL of 
ampicillin and 35 µg/mL of kanamycin. At an OD of 0.6, expression of each of the 
synthetase variants was induced with 1 mM IPTG. After four hours, cells were harvested 
and proteins were purified over a nickel-nitrilotriacetic acid affinity column under native 
conditions according to the manufacturer’s protocol (Qiagen).  The imidazole in the 
elution buffer was removed by a desalting column (Amersham Lifescience) and proteins 
were eluted into a buffer containing 50 mM Tris-HCl (pH=7.5), 1 mM DTT.  Aliquots of 
proteins were stored in -80 oC in 50% glycerol. Concentrations of the yPheRS variants 
and eLysRS, the lysS gene product, were determined by UV absorbance at 280 nm using 
calculated extinction coefficients50 of 99,060 and 29,420 cm-1 M-1 for yPheRS and 
eLysRS, respectively. 
 
Amino Acid Activation Assay.   The amino acid-dependent ATP-PPi exchange reaction 
was used to determine the kinetics of activation of amino acid analogs by yPheRS. The 
reaction buffer consisted of 50 mM N-(2-hydroxethyl) piperazine-N'-(2-ethanesulfonic 
acid) (potassium-HEPES) (pH=7.6), 20 mM MgCl2, 1 mM dithiothreitol (DTT), 2 mM 
adenosine triphosphate (ATP) and 2 mM [32P]-pyrophosphate (PPi) (NEN Life Science) 
with specific activity of 10-50 Ci/mol.  The amino acid concentration varied from 10 µM 
to 2.5 mM and the enzyme concentration varied from 10 nM to 100 nM.  Aliquots (20 
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µL) were removed from the reaction solution at various time points and quenched into 
500 µL of buffer solution containing 200 mM NaPPi, 7% w/v HClO4 and 3% w/v 
activated charcoal.  The charcoal was sedimented by centrifugation and washed twice 
with 500 µL of 10 mM NaPPi and 0.5% HClO4 solution.   The [32P]-labeled ATP absorbed 
on the charcoal was quantified via liquid scintillation methods.  The specificity constants 
were calculated by a nonlinear regression fit of the data to a Michaelis-Menten model.   
 
Plasmid Construction for ytRNAPhe  Expression. The mutant yeast amber suppressor 
tRNA (ytRNAPheCUA) was constitutively expressed under control of an lpp promoter. The 
expression cassette for ytRNAPheCUA was inserted into the repressor plasmid pREP4 to 
form pREP4_ytRNAPhe as described by Furter.9 A mutant yeast suppressor 
ytRNAPheCUA_30U40G (ytRNAPheCUA_UG) was constructed from ytRNAPheCUA by use of a 
QuikChange mutagenesis kit. Two complementary oligonucleotides, designated as primer 
UG_f (5’- GAA CAC AGG ACC TCC ACA TTT AGA GTA TGG CGC TCT CCC -3’) 
for the forward primer and primer UG_r (5’- GGG AGA GCG CCA TAC TCT AAA TGT 
GGA GGT CCT GTG TTC -3’) for the reverse primer, were used to introduce the desired 
mutations at positions 30 and 40 of the yeast suppressor tRNA. The resulting plasmid 
carrying the gene encoding ytRNAPheCUA_UG is designated pREP4_ytRNAPhe_UG.  In 
order to construct plasmids for in vitro transcription of ytRNAPhe, the ytRNAPheCUA and 
ytRNAPheCUA_UG genes were amplified from pREP4_ytRNAPhe and 
pREP4_ytRNAPhe_UG, respectively. At the end of the tRNA sequence, a BstNI site was 
inserted to allow linearization prior to transcription. A T7 promoter sequence was added 
for in vitro transcription of ytRNAPhe by T7 RNA polymerase. The following primers 
were used for PCR: 5’-CTG GGT AAG CTT CGC TAA GGA TCT GCC CTG GTG 
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CGA ACT CTG-3’ (which includes restriction sites for HindIII and BstNI) and 5’-GAT 
TAC GGA TTC CTA ATA CGA CTC ACT ATA GCG GAC TTA GCT C-3’ (which 
carries an  EcoRI restriction site and a T7 promoter sequence).  The resulting DNA 
fragments were introduced between the HindIII and EcoRI sites of pUC18 to yield 
pUC18_ytRNAPhe_CUA and pUC18_ytRNAPhe_UG, respectively. In order to facilitate 
DNA manipulation, a BstNI site close to the T7 promoter sequence of 
pUC18_ytRNAPhe_CUA was removed to increase the size of the DNA fragment 
containing the ytRNAPheCUA gene from 180 bp to 500 bp after BstNI digestion. Two 
complementary oligonucleotides, 5’-CGG AAG CAG AAA GTG TAA AGA GCG GGG 
TGC CTA ATG AGT G-3’ for the forward primer and 5’-CAC TCA TTA GGC ACC 
CCG CTC TTT ACA CTT TAT GCT TCC G-3’ for the reverse primer, were used to 
introduce this mutation.  
 
In Vitro Transcription. Linearized DNAs were prepared by BstNI digestion of 
pUC18_ytRNAPhe_CUA and pUC18_ytRNAPhe_UG as described previously.51 In vitro 
transcription of linearized DNA templates, and purification of transcripts were performed 
as described previously with minor alterations.52 The in vitro transcription of linearized 
DNA to produce 76-mer tRNA transcripts was performed with the Ambion T7-
MEGAshortscript kit. Transcripts were isolated by extraction with 25:24:1 
phenol:CHCl3:isoamyl alcohol. The organic layer was re-extracted with water and a 24:1 
CHCl3:isoamyl alcohol extraction was performed on the aqueous layers. The water layer 
was then mixed with an equal volume of isopropanol, precipitated overnight at -20°C, 
pelleted, dried, and re-dissolved in water. Unreacted nucleotides in the tRNA solution 
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were eliminated using CHROMA SPIN-30 DEPC-H2O (BD Bioscience) spin columns. 
Concentrations of the transcripts were determined by UV absorbance at 260 nm.  
 
Aminoacylation Assay.  Aminoacylation of wild-type ytRNAPheGAA with Phe and Trp by 
yPheRS variants was performed as described earlier.51 Aminoacylation reactions were 
carried out in buffer (100 µL) containing 30 mM HEPES (pH=7.45), 15 mM MgCl2, 4 
mM DTT, 25 mM KCl, and 2 mM ATP at 30 °C. Purified yeast total tRNA was used in 
the assay at a final concentration of 4 mg/mL (ytRNAPheGAA concentration approximately 
2.24 µM).  For aminoacylation with Phe, 13.3 µM [3H]-Phe (5.3 Ci/mmol) and 80 nM 
yPheRS variants were used; for aminoacylation with Trp, 3.3 µM [3H]-Trp (30.0 
Ci/mmol) and 160 nM yPheRS variants were used. Aminoacylation of ytRNAPhe 
transcripts reactions was carried out in buffer (100 µL) containing 100 mM potassium-
HEPES (pH=7.4), 10 mM MgCl2, 1 mM DTT, 0.2 mM EDTA, 2 mM ATP, and 4 
units/mL yeast inorganic pyrophosphatase (Sigma) at 37°C for eLysRS. For 
aminoacylation with Lys, 4 µM of ytRNAPhe transcript, 1.1 µM [3H]-Lys (91 Ci/mmol) 
and 80 nM eLysRS were used. The tRNAs were annealed before use by heating to 85 oC 
for 4 min in annealing buffer (60 mM Tris, pH=7.8, 2 mM MgCl2) followed by slow 
cooling to room temperature. Reactions were initiated by adding the enzyme and 10 µL 
aliquots were quenched by spotting on Whatman filter disks soaked with 5% 
trichloroacetic acid (TCA).  The filters were washed for three 10 min periods in ice-cold 
5% TCA, washed in ice-cold 95% ethanol, and counted via liquid scintillation methods.  
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Strain and Plasmid Construction for in Vivo Incorporation of pBrF. A Phe/Trp 
double auxotrophic strain (AFW) and a Phe/Trp/Lys triple auxotrophic strain (AFWK) 
were constructed from the Phe auxotrophic strain AF (K10, Hfr(Cavalli) pheS13rel-1 
tonA22 thi T2R pheA18, trpB114)9 by P1 phage-mediated transposon transduction as 
described previously.42 pQE16 (Qiagen) was chosen as the expression plasmid; pQE16 
bears a gene encoding the marker protein murine dihydrofolate reducase (mDHFR) 
outfitted with a C-terminal hexa-histidine tag under control of a bacteriophage T5 
promoter and t0 terminator.  A QuikChange mutagenesis kit with two complementary 
oligonucleotides (5’-CCG CTC AGG AAC GAG TAG AAGTAC TTC CAA AGA ATG-
3’; 5’-CAT TCT TTG GAA GTA CTT CTA CTC GTT CCT GAG CGG-3’) was used to 
place an amber codon (TAG) at the 38th position of mDHFR; the resulting plasmid was 
designated pQE16am.  The mutant yPheRS genes T415G and T415A were amplified 
from pQE32-T415G and pQE32-T415A, respectively,  and a constitutive tac promoter 
with an abolished lac repressor binding site was added upstream of the start codon of this 
gene.9 The resulting expression cassettes were inserted into the PvuII site of pQE16 to 
yield pQE16am-T415G and pQE16am-T415A. 
 
In Vivo Incorporation of pBrF.  The auxotrophic strains AF, AFW, and AFWK were 
transformed with pQE16am and pREP4_ytRNAPhe vectors to enable pBrF incorporation. 
mDHFR expression was investigated in 20 mL cultures.  The E. coli expression strains 
were grown in M9 minimal medium supplemented with glucose, thiamin, MgSO4, CaCl2, 
20 amino acids (at 25 µg/mL), and antibiotics (35 µg/mL of kanamycin and 100 µg/mL 
of ampicillin).  When the cultures reached an OD600 of 0.8-1.0, cells were sedimented by 
centrifugation, washed twice with cold 0.9% NaCl, and shifted to expression media 
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supplemented with 17 amino acids (at 20 µg/mL), 6 mM of pBrF, and the indicated 
concentrations of Phe, Trp and Lys. Protein expression was induced by addition of 1 mM 
IPTG.  After four hours, cells were pelleted by centrifugation, and the protein was 
purified on a Ni-NTA spin column under denaturing conditions according to the 
supplier’s instructions (Qiagen).  After purification, expression levels of mDHFR were 
determined by UV absorbance at 280 nm using a calculated extinction coefficient50 of 
24,750 cm-1 M-1.  
 
Quantitative Analysis of pBrF Incorporation by Liquid Chromatography Mass 
Spectrometry (LC-MS). LC-MS and LC/MS/MS analyses of tryptic digests of mDHFR 
were conducted on a Finnigan LCQ ion trap mass spectrometer equipped with an HPLC 
pump and ESI probe. Mutant mDHFR was prepared in elution buffer (8 M urea, 100 mM 
NaH2PO4, 10 mM Tris, pH=4.5). After concentration of the protein by ultracentrifugation 
(Millipore), 10 µL of the concentrate was diluted into 90 µL of 75 mM NH4HCO3 for 
trypsin digestion.  Modified trypsin (1 µL, Promega, 0.2 µg/ µL) was added.  The sample 
was incubated at 37 °C for 2 to 6 h and the reaction was stopped by addition of 12 µL of 
5% trifluoroacetic acid (TFA) solution. Digested peptide solution was subjected to 
desalting on a C18 Vydac Microspin column (The Nest group) and eluted with 50 µL of 
80% acetonitrile/20% 0.1% w/v formic acid. The peptide solution eluted from the 
Microspin column was dried, redissolved in 10% acetonitrile/90% 0.1% TFA solution, 
and injected into the HPLC.  Peptides were separated on a Magic C18 column (Michrom, 
300 Å, 0.3x150 mm) and eluted at a flow rate of 30 µL/min using a gradient of 10-95% 
of solvent A (90% acetonitrile/10% 0.1 M aqueous acetic acid solution) and solvent B 
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(2% acetonitrile/98% 0.1 M aqueous acetic acid solution) for 30 min.  The column eluent 
was introduced to the electrospray source and sequencing was carried out by 
fragmentation of the precursor ion corresponding to the fragment bearing the residue at 
position 38 of mutant mDHFR.   
 
Results and Discussion 
Aminoacylation of ytRNAPheCUA and ytRNA
Phe
CUA_UG with Lys. When the yeast 
phenylalanine amber suppressor (ytRNAPheCUA_WT) was co-expressed with wild-type 
yPheRS in Furter’s E. coli expression strain, 60% of the amber codon sites were decoded 
as Lys.9 Use of the G37A mutant of ytRNAPheCUA_WT (ytRNAPheCUA) reduced the extent 
of Lys misincorporation to 5%.9 Because insertion of Lys in response to the amber codon 
is likely a consequence of charging of ytRNAPheCUA by the E. coli lysyl-tRNA synthetase 
(eLysRS), we modified ytRNAPheCUA to eliminate cross-reactivity with eLysRS. We 
focused on the base pair between nucleotides 30 and 40, which is thought to enhance 
recognition of yeast isoleucine amber suppressor (ytRNAIleCUA) by eLysRS.53 Buttcher 
and coworkers showed that introduction of a wobble base pair between nucleotides 30 
and 40 reduced charging of ytRNAIleCUA by eLysRS.53 Similarly, we generated a mutant 
yeast phenylalanine amber suppressor (ytRNAPheCUA_UG) containing the wobble base pair 
30U-40G, and compared the rates of charging of ytRNAPheCUA and ytRNAPheCUA_UG with 
Lys by eLysRS (Figure 1).54 As expected, the rate of aminoacylation of ytRNAPheCUA_UG 
was about three-fold lower than that of ytRNAPheCUA (Figure 1); however, there was only 
about a 40% reduction in the rate of aminoacylation of ytRNAPheCUA_UG with Phe as 
compared to that of ytRNAPheCUA. Since ytRNAPheCUA variants are competitively 
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aminoacylated by either eLysRS or yPheRS, the three-fold reduction in the rate of 
aminoacylation by eLysRS was expected to reduce the level of Lys-charged ytRNAPhe.     
 
Occupancy of the Amber Site. Occupancy of the amber site in mDHFR-38Am was 
analyzed by LC-MS/MS (Figure 2). The results are summarized in Table 1. LC-MS/MS 
has been used successfully for quantitative analysis of protein modification.43 Mutant 
mDHFR containing the amber codon at the 38th position (mDHFR_38Am) was expressed 
in E. coli strains (AF, AFW, and AFWK) co-transformed with pQE16_yPheRS (T415G) 
and either pREP4_ytRNAPhe_CUA or pREP4_ytRNAPhe_UG. We focused on Peptide 38 
(residues 26-39; NGDLPWPPLRNEAmK) which contains the amber site. Peptide 38 
variants containing Trp and pBrF are designated Peptides W38 and Z38, respectively. 
When Lys is incorporated in response to the amber codon, there are two consecutive 
lysines at the C-terminus of Peptide 38, and the C-terminal Lys can be further cleaved by 
trypsin. The fully cleaved (NGDLPWPPLRNEK) and partially cleaved 
(NGDLPWPPLRNEKK) variants of Peptide K38 were designated K38S (short) and 
K38L (long), respectively.  Peptides K38S, K38L, W38 and Z38 were readily separated 
by liquid chromatography (Figure 2a), and the relative yields of the four variants were 
determined by comparing the integrated areas of the corresponding chromatographic 
signals. Furthermore, the fragment ion masses could be unambiguously assigned (data 
not shown), confirming the identity of the amino acid inserted in response to the amber 
codon. The amplitude of the most intense signal in the chromatograms in Figure 2 is ca. 
1x108 (instrument-dependent arbitrary units) compared to a noise level of ca. 5x105, 
suggesting that misincorporation of natural amino acids can be analyzed at the 0.5% 
level. 
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Reduced Lys Misincorporation by ytRNAPheCUA_UG. When mDHFR(38Am) was 
expressed in a triple auxotrophic E. coli host (AFWK) outfitted with ytRNAPheCUA and 
yPheRS (T415G) in medium supplemented with 0.03 mM Phe, 0.01 mM Trp, 1 mM Lys 
and 6 mM pBrF, Lys misincorporation was observed at a level of 7.6% (Figure 2a). The 
level of Lys misincorporation could be reduced to 2.7% by restricting the Lys 
concentration to 0.01 mM (Table 1). However, when ytRNAPheCUA_UG was co-
transformed into E. coli strain AFWK with yPheRS (T415G), Lys misincorporation was 
not detected, even in media supplemented with 1.0 mM Lys (Figure 2b). Considering the 
detection limit of the ESI MS detector, this establishes an upper limit of 0.5% Lys 
misincorporation. Similar results were obtained with Phe auxotrophic strain AF outfitted 
with ytRNAPheCUA_UG (Figure 2e); the Lys auxotrophic strain is not required to eliminate 
Lys misincorporation.  
 
Redesign of Phenylalanyl-tRNA Synthetase.  Although use of ytRNAPheCUA_UG 
eliminated Lys at the amber site, ca. 10% Trp misincorporation was still detected (Figure 
2b). Trp misincorporation could result from mischarging of ytRNAPheCUA with Trp either 
by yPheRS or by E. coli tryptophanyl-tRNA synthetase (eTrpRS). Because 
misincorporation of Trp was not detected in the absence of yPheRS (T415G), 
mischarging of ytRNAPheCUA by eTrpRS is probably negligible. However, the Trp-
dependent ATP-PPi exchange rate of yPheRS (T415G) was comparable to that observed 
for pBrF (Table 2). Therefore, mischarging of ytRNAPheCUA with Trp by yPheRS (T415G) 
is the more likely explanation for Trp misincorporation at the amber codon.  We 
speculated that yPheRS (T415A) might exclude Trp.                
82 
 
 
ATP-PPi Exchange and Aminoacylation of ytRNAPhe Catalyzed by yPheRS Variants. 
The kinetics of amino acid-dependent ATP-PPi exchange catalyzed by three variants of 
yPheRS (wild-type, T415G, and T415A) were measured; the kinetic parameters are 
reported in Table 2. Wild-type yPheRS activates neither Trp nor pBrF, whereas the 
T415G variant shows ten-fold higher activity toward pBrF and Trp as compared to Phe. 
As expected, the Trp-dependent ATP-PPi exchange rate of yPheRS (T415A) is ca. thirty-
fold lower than that of yPheRS (T415G). In contrast, the effects of the G415A mutation 
on the rates of activation of Phe and pBrF are much smaller (Table 2). Aminoacylation of 
ytRNAPheCUA with Phe was comparable for yPheRS (T415G) and for yPheRS (T415A) 
(Figure 3a); however, aminoacylation of ytRNAPheCUA with Trp by yPheRS (T415A) is 
much slower than that by yPheRS (T415G) (Figure 3b). 
The improved selectivity of yPheRS (T415A) with respect to exclusion of Trp 
may be understood at least in part on the basis of the side-chain volumes of the amino 
acid substrates and the active-site residues of the synthetase.  Replacement of Gly415 by 
Ala reduces the volume of the substrate-binding site by ca. 16 Å3.55 Occlusion of the 
binding site reduces the binding affinity of both Trp and pBrF, but because Trp is the 
larger of the two amino acids (by ca. 5 Å3), it suffers the larger reduction in affinity.  The 
G415A mutation increases Km by a factor of ca. 17 for Trp as compared to ca. 7 for pBrF 
(Table 2). 
  
High Fidelity Site-Specific Incorporation of pBrF. Use of expression hosts outfitted 
with yPheRS (T415A) reduced misincorporation of Trp at the amber site to levels below 
the limit of detection (Figure 2c-e).  Our initial studies used the triple auxotrophic 
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expression host AFWK. However, construction of the triple auxotroph was time-
consuming and the limited cellular pools of several of the natural amino acids reduced 
protein yield. In order to overcome these problems, a single (Phe) auxotrophic expression 
host (AF) outfitted with the yPheRS (T415A) and ytRNAPheCUA_UG was tested for pBrF 
incorporation. High fidelity incorporation of pBrF in response to the amber codon was 
observed (Figure 2e and Table 1), indicating that the triple auxotrophic expression host is 
not necessary. Furthermore, the AF expression host outfitted with yPheRS (T415A) and 
ytRNAPheCUA_UG yielded twice as much protein as the triple auxotroph (4.3 mg/L vs. 2.0 
mg/L) (Table 1).  
 
Conclusions 
We describe the engineering of a bacterial expression host that allows high 
fidelity incorporation of pBrF into recombinant proteins in response to amber stop 
codons. Rational modification of the yeast amber suppressor tRNA eliminated cross-
reactivity with the E. coli LysRS, while the substrate specificity of yPheRS was enhanced 
by a point mutation in the amino acid binding pocket.  When the modified yeast amber 
suppressor tRNA and the mutant yPheRS were co-expressed in a Phe auxotrophic E. coli 
expression host, at least 98% of the amber sites in full-length recombinant mDHFR were 
occupied by pBrF.  Aryl bromides at programmed positions should enable chemo-
selective ligation of proteins with terminal alkene or alkyne reaction partners.43  
 
Acknowledgments 
We thank Dr. P. Plateau for providing the plasmid pXLysKS1 and Dr. M. 
Shahgholi for assistance with mass spectrometry. We are grateful to Dr. K. Shin, Dr. J. 
84 
 
Petersson, and Dr. D. Beene for help with in vitro transcription of tRNA. We thank I. C. 
Tanrikulu for help with analysis of the PheRS crystal structure and for review of this 
manuscript. We also thank Dr. A. J. Link and K. E. Beatty for discussion and valuable 
comments on this project. This work was supported by National Institutes of Health grant 
GM62523.  
 
References 
1. Beatty, K. E.; Xie, F.; Wang, Q.; Tirrell, D. A. J. Am. Chem. Soc. 2005, 127, 14150-
14151. 
2. Bose, M.; Groff, D.; Xie, J. M.; Brustad, E.; Schultz, P. G. J. Am. Chem. Soc. 2006, 
128, 388-389. 
3. Budisa, N.; Pal, P. P. Biol. Chem. 2004, 385, 893-904. 
4. Chin, J. W.; Cropp, T. A.; Anderson, J. C.; Mukherji, M.; Zhang, Z. W.; Schultz, P. G. 
Science 2003, 301, 964-967. 
5. Datta, D.; Wang, P.; Carrico, I. S.; Mayo, S. L.; Tirrell, D. A. J. Am. Chem. Soc. 2002, 
124, 5652-5653. 
6. Dedkova, L. M.; Fahmi, N. E.; Golovine, S. Y.; Hecht, S. M. J. Am. Chem. Soc. 2003, 
125, 6616-6617. 
7. Deiters, A.; Cropp, T. A.; Mukherji, M.; Chin, J. W.; Anderson, J. C.; Schultz, P. G. J. 
Am. Chem. Soc. 2003, 125, 11782-11783. 
8. Deiters, A.; Geierstanger, B. H.; Schultz, P. G. ChemBioChem 2005, 6, 55-58. 
9. Furter, R. Protein Sci. 1998, 7, 419-426. 
85 
 
10. Hendrickson, T. L.; de Crecy-Lagard, V.; Schimmel, P. Annu. Rev. Biochem. 2004, 
73, 147-176. 
11. Ibba, M.; Stathopoulos, C.; Soll, D. Curr. Biol. 2001, 11, R563-R565. 
12. Kiick, K. L.; Weberskirch, R.; Tirrell, D. A. FEBS Lett. 2001, 505, 465-465. 
13. Kirshenbaum, K.; Carrico, I. S.; Tirrell, D. A. ChemBioChem 2002, 3, 235-237. 
14. Kwon, I.; Kirshenbaum, K.; Tirrell, D. A. J. Am. Chem. Soc. 2003, 125, 7512-7513. 
15. Link, A. J.; Mock, M. L.; Tirrell, D. A. Curr. Opin. Biotechnol. 2003, 14, 603-609. 
16. Link, A. J.; Tirrell, D. A. J. Am. Chem. Soc. 2003, 125, 11164-11165. 
17. Link, A. J.; Vink, M. K. S.; Tirrell, D. A. J. Am. Chem. Soc. 2004, 126, 10598-10602. 
18. Sakamoto, K.; Hayashi, A.; Sakamoto, A.; Kiga, D.; Nakayama, H.; Soma, A.; 
Kobayashi, T.; Kitabatake, M.; Takio, K.; Saito, K.; Shirouzu, M.; Hirao, I.; 
Yokoyama, S. Nucleic Acids Res. 2002, 30, 4692-4699. 
19. Sharma, N.; Furter, R.; Kast, P.; Tirrell, D. A. FEBS Lett. 2000, 467, 37-40. 
20. Tang, Y.; Tirrell, D. A. J. Am. Chem. Soc. 2001, 123, 11089-11090. 
21. Wang, L.; Brock, A.; Herberich, B.; Schultz, P. G. Science 2001, 292, 498-500. 
22. Wang, L.; Xie, J. M.; Deniz, A. A.; Schultz, P. G. J. Org. Chem. 2003, 68, 174-176. 
23. Xie, J. M.; Schultz, P. G. Curr. Opin. Chem. Biol. 2005, 9, 548-554. 
24. Zhang, Z. W.; Gildersleeve, J.; Yang, Y. Y.; Xu, R.; Loo, J. A.; Uryu, S.; Wong, C. 
H.; Schultz, P. G. Science 2004, 303, 371-373. 
25. Lim, V. I. J. Mol. Biol. 1995, 252, 277-282. 
26. Tang, Y.; Ghirlanda, G.; Petka, W. A.; Nakajima, T.; DeGrado, W. F.; Tirrell, D. A. 
Angew. Chem.Int. Ed. 2001, 40, 1494-1496. 
27. Cload, S. T.; Liu, D. R.; Froland, W. A.; Schultz, P. G. Chem. Biol. 1996, 3, 1033-
1038. 
86 
 
28. Cornish, V. W.; Benson, D. R.; Altenbach, C. A.; Hideg, K.; Hubbell, W. L.; Schultz, 
P. G. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 2910-2914. 
29. Mendel, D.; Cornish, V. W.; Schultz, P. G. Annu. Rev. Biophys. Biomol. Struct. 1995, 
24, 435-462. 
30. Kohrer, C.; Sullivan, E. L.; RajBhandary, U. L. Nucleic Acids Res. 2004, 32, 6200-
6211. 
31. Kohrer, C.; Yoo, J. H.; Bennett, M.; Schaack, J.; RajBhandary, U. L. Chem. Biol. 
2003, 10, 1095-1102. 
32. Anderson, J. C.; Schultz, P. G. Biochemistry 2003, 42, 9598-9608. 
33. Hohsaka, T.; Muranaka, N.; Komiyama, C.; Matsui, K.; Takaura, S.; Abe, R.; 
Murakami, H.; Sisido, M. FEBS Lett. 2004, 560, 173-177. 
34. Thorbjarnardottir, S.; Uemura, H.; Dingermann, T.; Rafnar, T.; Thorsteinsdottir, S.; 
Soll, D.; Eggertsson, G. J. Bacteriol. 1985, 161, 207-211. 
35. Yoshimura, M.; Inokuchi, H.; Ozeki, H. J. Mol. Biol. 1984, 177, 627-644. 
36. Liu, D. R.; Magliery, T. J.; Pasternak, M.; Schultz, P. G. Proc. Natl. Acad. Sci. U. S. 
A. 1997, 94, 10092-10097. 
37. Santoro, S. W.; Wang, L.; Herberich, B.; King, D. S.; Schultz, P. G. Nat. Biotechnol. 
2002, 20, 1044-1048. 
38. Cropp, T. A.; Schultz, P. G. Trends Genet. 2004, 20, 625-630. 
39. Wang, P.; Vaidehi, N.; Tirrell, D. A.; Goddard, W. A. J. Am. Chem. Soc. 2002, 124, 
14442-14449. 
40. Fishman, R.; Ankilova, V.; Moor, N.; Safro, M. Acta Crystallogr. D. Biol. 
Crystallogr. 2001, 57, 1534-44. 
41. Ibba, M.; Kast, P.; Hennecke, H. Biochemistry 1994, 33, 7107-7112. 
87 
 
42. Wang, P., Ph.D. thesis, California Institute of Technology, Pasadena, 2003. 
43. Kodama, K.; Fukuzawa, S.; Nakayama, H.; Kigawa, T.; Sakamoto, K.; Yabuki, T.; 
Matsuda, N.; Shirouzu, M.; Takio, K.; Tachibana, K.; Yokoyama, S. ChemBioChem 
2006, 7, 134-139. 
44. Nguefack, J. F.; Bolitt, V.; Sinou, D. Tetrahedron Lett. 1996, 37, 5527-5530. 
45. Sakakibara, Y.; Ido, Y.; Sasaki, K.; Sakai, M.; Uchino, N. Bull. Chem. Soc. Jpn. 1993, 
66, 2776-2778. 
46. Schoenbe.A; Heck, R. F. J. Org. Chem. 1974, 39, 3327-3331. 
47. Yoneyama, M.; Kakimoto, M.; Imai, Y. Macromolecules 1988, 21, 1908-1911. 
48. Yoneyama, M.; Konishi, T.; Kakimoto, M. A.; Imai, Y. Makromol. Chem., Rapid 
Commun. 1990, 11, 381-386. 
49. Sanni, A.; Walter, P.; Ebel, J. P.; Fasiolo, F. Nucleic Acids Res. 1990, 18, 2087-2092. 
50. Gill, S. C.; Vonhippel, P. H. Anal. Biochem. 1989, 182, 319-326. 
51. Sampson, J. R.; Uhlenbeck, O. C. Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 1033-1037. 
52. Nowak, M. W.; Gallivan, J. P.; Silverman, S. K.; Labarca, C. G.; Dougherty, D. A.; 
Lester, H. A., In vivo incorporation of unnatural amino acids into ion channels in 
Xenopus oocyte expression system. In Ion Channels, Pt B, 1998, Vol. 293, pp 504-
529. 
53. Buttcher, V.; Senger, B.; Schumacher, S.; Reinbolt, J.; Fasiolo, F. Biochem. Biophys. 
Res. Commun. 1994, 200, 370-377. 
54. Nishikawa and coworkers used an alternative strategy to reduce misacylation of yeast 
amber suppressor tRNATyr by eLysRS. Fukunaga, J.; Yokogawa; T., Ohno; 
Nishikawa, K. J. Biochem. 2006, 139, 689-696. In. 
88 
 
55. Volumes were estimated as solvent-excluded volumes (1.4 Å probe) by using 
Chem3D Pro 5.0 (CambridgeSoft: Cambridge, MA) 
 
 
 
 
89 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Aminoacylation of ytRNAPheCUA (■) and ytRNAPheCUA_UG (●) with Lys by 
eLysRS. The reaction was carried out at 37°C in mixtures containing 2 mM ATP, 1.1 µM 
[3H]-Lys, 80 nM eLysRS, and 4 µM of ytRNAPheCUA or ytRNAPheCUA_UG.  
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Figure 2: LC-MS chromatograms of tryptic digests of mDHFR. Peptide 38 (residues 26-
39; NGDLPWPPLRNEAmK; Am indicates an amber codon) contains an amber codon at 
the 38th position. Peptide 38 variants containing Lys (Peptides K38S and K38L), Trp 
(Peptide W38), and pBrF (Peptide Z38) were separated and detected by MS. mDHFRs 
were synthesized in a triple auxotrophic expression host outfitted with: (a) ytRNAPheCUA 
and yPheRS (T415G); (b) ytRNAPheCUA_UG and yPheRS (T415G); (c) ytRNAPheCUA and 
yPheRS (T415A); (d) ytRNAPheCUA_UG and yPheRS (T415A); or in a single auxotrophic 
strain with ytRNAPheCUA_UG and yPheRS (T415A) (e). The expression media were 
supplemented with 6.0 mM pBrF, 0.01 mM Trp, 1.0 mM Lys, 0.03 mM Phe (a, b and c) 
or 0.01 mM Phe (d, e and f), and 25 µg/mL of 17 amino acids. 
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Figure 3: Charging of Phe (a) and Trp (b) by wild-type yPheRS (■), yPheRS (T415G) 
(▲) and yPheRS (T415A) (●). Reactions were carried out at 30°C in mixtures 
containing 2.24 µM ytRNAPheGAA, 2 mM ATP, and either (a) 13.3 µm [3H]-Phe and 80 
nM yPheRS variants or (b) 3.3 µm [3H]-Trp and 160 nM yPheRS variants in 
aminoacylation buffer.    
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Table 1:  Occupancy of amber sites and expression yields.  
Occupancy of amber sites (%) 
Host strain yPheRS ytRNAPhe 
Lys Trp pBrF 
Yield 
(mg/L)a 
AFWKb T415G CUAc 7.6 9.5 83 1.4 ± 0.4 
AFWK T415G CUA 2.7d 10.2 87 1.5 ± 0.2 
AFWK T415G CUA_UGe NDf 10.4 90 1.4  ± 0.1 
AFWK T415A CUA 2.7 ND 97 3.1 ± 0.3 
AFWK T415A CUA_UG ND ND > 98 2.0 ± 0.2 
AFg T415A CUA_UG ND ND > 98 4.3 ± 0.4 
a Volumetric yields are given as mg of purified mDHFR_38Am per liter of culture 
volume. 
b Triple (Phe, Lys, and Trp) auxotrophic E. coli strain.  
c,e The ytRNAPheCUA and ytRNAPheCUA_UG are designated as CUA and CUA_UG, 
respectively. 
d 0.01 mM of Lys was supplemented into the media rather than 1.0 mM. 
f Not detected in either LC/MS or MALDI analyses. 
g Single (Phe) auxotrophic E. coli strain.  
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Table 2:  Kinetic parameters for ATP-PPi exchange of amino acids by the wild-type 
yPheRS, yPheRS (T415G), and yPheRS (T415A) variant.   
 
Amino 
Acid Enzyme Km (µM) kcat (s
-1) kcat/Km         (M-1s-1) 
kcat/Km 
(rel)a 
Phe T415A 185±56 0.207±0.02 1,163±240 2.1 
Trp T415A 913±310 0.129±0.01 152.4±49 0.28 
pBrF T415A 255±73 0.217±0.03 892±220 1.6 
Phe T415G 499±51 0.278±0.06 553.0±79 1.0 
Trp T415G 55.0±24 0.261±0.08 5,001±1,000 9.0 
pBrF T415G 36.3±5.0 0.211±0.09 6,116±3,400 11 
Phe Wild-type 29.2±9.8 0.302±0.13 10,669±3,700 19 
pBrF Wild-type NDb ND ND ND 
a Relative to kcat/Km for Phe by T415G.  
b Not detected. 
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Chapter 4 
Site-Specific Incorporation of Tryptophan Analogs into Recombinant Proteins in 
Vivo 
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Abstract 
An expansion of the number of genetically encoded tryptophan (Trp) analogs in 
Escherichia coli has been restricted by two limitations. First, Trp analogs inactive in the 
native E. coli translation system could not be incorporated into proteins. Second, most of 
the previous attempts to incorporate Trp analogs have been limited to global replacement 
of all Trp residues throughout a target protein. Here we show that a rationally designed 
yeast phenylalanyl-tRNA synthetase (yPheRS (T415G)) efficiently activated four Trp 
analogs: 6-chlorotrytophan (6ClW), 6-bromotryptophan (6BrW), 5-bromotrytophan 
(5BrW), and benzothienylalanine (BT), which were not utilized by the endogenous E. 
coli translational system. Introduction of the yPheRS (T415G) and a mutant yeast 
phenylalanine amber suppressor (ytRNAPheCUA_UG) into an E. coli expression host 
allowed the site-specific incorporation of three Trp analogs: 6ClW, 6BrW, and BT, into 
murine dihydrofolate reductase in response to amber stop codons with at least 98% 
fidelity. Subsequently, all three Trp analogs were introduced at the Trp66 position in the 
chromophore of a cyan fluorescent protein (CFP) to investigate changes in spectral 
properties. CFP variants containing Trp analogs showed a blue-shift in the fluorescence 
emission peak as well as in the absorption maximum. In particular, a CFP variant with BT 
featured an unusually large Stokes’ shift (56 nm). As shown in this report, an expanded 
set of the genetically encoded Trp analogs would enable the design of new proteins with 
novel properties. 
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Introduction 
Tryptophan (Trp) is an attractive target for protein engineering for several reasons. 
First, it is the main source of UV absorbance and fluorescence of proteins. Second, Trp is 
involved in various interactions in proteins, such as ligand binding1-3 and DNA-protein 
interaction.4,5 Third, numerous Trp analogs are available through diverse indole chemistry. 
Fourth, it is the rarest amino acid,6 and so its substitution by other amino acids minimally 
perturbs structure.7 Ever since 7-azatryptophan and 2-azatryptophan were first 
incorporated into proteins in E. coli in the 1950s,8,9 many researchers have tried to 
replace Trp with Trp analogs. In the last few decades, a residue-specific incorporation 
method utilizing a Trp auxotrophic strain realized the incorporation of various Trp 
analogs containing fluoro, hydroxyl, methyl, amino, selenophene, and thienyl functional 
groups.10-12 Fluorinated Trp analogs, in particular, have been used in 19F-NMR 
studies.13,14 Trp analogs containing selenophene and thienyl functional groups were used 
in the X-ray crystallography of proteins.15,16 Aminotryptophan was used to design 
protein-based pH sensors17 and greatly changed the spectral properties of fluorescent 
proteins.18  
Although diverse Trp analogs have been introduced into proteins, further 
expansion of the genetic code for Trp has been restricted by two limitations. First, Trp 
analogs incorporated into proteins in E. coli have so far been limited to the substrates for 
the native E. coli translation system. Therefore, a large number of Trp analogs, such as 
benzothienylalanine (BT), 5-methyltryptophan, 6-methyltryptophan, 6-aminotryptophan, 
and 5-cyanotryptophan, were found not to be incorporated into proteins.10 Recently, 
several research groups have devised various methods to introduce translationally 
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inactive nonnatural amino acids into recombinant proteins in E. coli.10,12,19 
Overexpression of aminoacyl-tRNA synthetase (aaRS),20,21 utilization of attenuated 
editing mutant aaRS,22,23 rational design of the binding pocket of aaRS,24,25 and screening 
of an aaRS library26,27 have been effective in expanding the genetic code for leucine, 
isoleucine, valine, methionine, phenylalanine, and tyrosine. Recently, Schultz and 
colleagues modified Bacillus stearothermophilus trytophanyl-tRNA synthetase 
(BsTrpRS) to incorporate 5-hydroxytryptophan into a recombinant protein in mammalian 
cells.28 However, until now there have been no reports about modification of substrate 
specificity of aaRS to expand the number of genetically encoded Trp analogs in E. coli. 
In this report, we have shown that the rational design of the binding pocket of yPheRS 
can expand the genetic code for Trp in E. coli.         
Second, most of the previous attempts to incorporate Trp analogs have been 
limited to the global replacement of Trp throughout a protein. Although Trp is the rarest 
amino acid, the replacement of Trp with Trp analogs at non-permissive sites could result 
in the loss of function. For example, the replacement of three Trp residues in barstar with 
4-aminotryptophans greatly reduced its stability due to increased polarity of 4-
aminotryptophan at position 53 inside the protein core.11 In order to overcome such a 
limitation, we have explored the feasibility of site-specific incorporation of Trp analogs 
into recombinant proteins in E. coli, which would allow incorporation of Trp analogs 
only at permissive sites. In 1998, Furter showed site-specific incorporation of p-
fluorophenylalanine into murine dihydrofolate reductase (mDHFR) in E. coli through the 
use of an orthogonal yPheRS/ytRNAPhe pair.29 More recently, Schultz and colleagues 
have developed powerful screening methods to change the substrate specificity of 
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tyrosyl-tRNA synthetase (mjTyrRS) derived from Methanococcus jannaschii toward 
nonnatural amino acids.19,26,30 E. coli strains equipped with the screened orthogonal 
mjTyrRS/mjtRNATyr pairs have allowed incorporation of diverse Phe and Tyr analogs into 
proteins in a site-specific manner. Tirrell and colleagues refined the orthogonality of the 
yPheRS/ytRNAPhe pair and the specificity of yPheRS to achieve high fidelity 
incorporation of p-bromophenylalanine into proteins in vivo.25  
In this report, we describe the design of a bacterial host to achieve site-specific 
incorporation of Trp analogs into a recombinant protein in response to an amber stop 
codon in E. coli. Since no orthogonal tryptophanyl-tRNA synthetase/tRNATrp pairs have 
been reported for E. coli translation systems, we needed an alternate orthogonal pair. Our 
previous studies showed that a rationally designed yPheRS (T415G) variant efficiently 
activates Trp as well as various Phe analogs.25,31 We hypothesized that the relaxed 
substrate specificity of yPheRS (T415G) may allow it to recognize a variety of Trp 
analogs. Therefore, a mutant yPheRS (T415G) and a mutant yeast amber suppressor 
(ytRNAPheCUA_UG)32 were introduced into an E. coli expression strain to insert Trp analogs 
at a specific site in a protein. Four Trp analogs, BT, 6ClW, 6BrW, and 5BrrW, were 
examined for incorporation in vivo. In our preliminary studies, none of the four Trp 
analogs tested were incorporated at UGG codons, even in a Trp auxotrophic E. coli strain 
under a Trp-depleted condition (data not shown). BT is isosteric to Trp and so might 
result in minimal perturbation of a protein structure upon the replacement of Trp. 
Introduction of aryl halides into recombinant proteins can allow for site-specific 
modification through a palladium-catalyzed coupling reactions with alkenes and 
alkynes.33,34 Bromine and iodine, once introduced into proteins, can facilitate the phasing 
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of crystallographic data and therefore can be useful in X-ray diffraction studies of protein 
structures.35 As expected, introduction of an orthogonal yeast PheRS (T415G) 
/ytRNAPheCUA_UG pair into E. coli expression strains enabled high-fidelity (ca. 98%) 
incorporation of BT, 6BrW, and 6ClW into mDHFR in a site-specific manner.   
The E. coli strain, equipped with an engineered orthogonal pair, has been used to 
change the spectral properties of fluorescent proteins. Considering that Trp is a main 
contributor to UV absorbance and the fluorescence of proteins, it is not surprising that the 
replacement of Trp with other amino acids resulted in changes in the spectral properties 
of proteins in many different ways. Schultz and his colleagues have characterized the 
spectral properties of green fluorescent protein (GFP) variants containing various Phe 
analogs in the chromophore.36 Fluorescence emission peaks of all GFP variants were 
blue-shifted to some extent, depending on the electron-donating ability of the Phe analogs. 
Similarly, Budisa and his colleagues replaced Trp residues in either GFP or the cyan 
fluorescent protein (CFP) with translationally active Trp analogs.11 In particular, the 
fluorescence emission peak of 4-aminotryptophan in the chromophore of a fluorescent 
protein was red-shifted significantly.18 In this report, we have explored whether we could 
design novel spectral classes of fluorescent proteins containing Trp analogs that would be 
translationally inactive for the endogenous E. coli translation system. Specifically, we 
replaced a Trp residue in the chromophore of a CFP variant (CFP6) with 6ClW, 6BrW, 
and BT to generate CFP6_6ClW, CFP6_6BrW, and CFP6_BT, respectively. Similar to 
halogenated Phe analogs, fluorescence emission peaks of CFP6_6ClW and CFP6_6BrW 
were blue-shifted. However, quantum yields of halogenated Trp analogs were 3- to 4-fold 
higher than their Phe counterparts. CFP6_BT exhibited a larger Stokes’ shift (56 nm) than 
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that of CFP6 (ca. 40 nm).  
  
Materials and Methods 
Materials.  Amino acids 1-2 were obtained from Sigma (St. Louis, MO). 3 and 4 
were purchased from Biosynth International (Naperville, IL). 5 and 6 were from Aldrich 
(St. Louis, MO) and Chem-Impex (Wood Dale, IL), respectively. [32P]-labeled sodium 
pyrophosphate was purchased from NEN Life Science (Boston, MA).   
 
Amino Acid Activation Assay.  The kinetics of activation of amino acids by the 
yPheRS (T415G) variant were determined by the amino acid dependent adenosine 
triphosphate (ATP)-[32P]-pyrophosphate (PPi) exchange reaction. The plasmid 
construction, expression, and purification of the yPheRS (T415G) variant with C-terminal 
hexa-histidine tag were described previously.25 The assay buffer contained 50 mM N-(2-
hydroxethyl) piperazine-N'-(2-ethanesulfonic acid) (potassium-HEPES) (pH=7.6), 20 
mM MgCl2, 1 mM dithiothreitol (DTT), 2 mM ATP, and 2 mM [32P]- PPi. The amino acid 
concentrations varied from 100 nM to 2.5 mM and the enzyme concentration varied from 
100 nM to 400 nM.  Aliquots (20 µL) of solution were quenched at various time points 
in 500 µL of buffer solution containing 200 mM NaPPi, 7% w/v HClO4 and 3% w/v 
activated charcoal. The charcoal was centrifuged and washed three times with 500 µL of 
10 mM NaPPi and 0.5% HClO4 solution. The [32P]-labeled ATP absorbed on the charcoal 
was counted via liquid scintillation methods.  The kinetic parameters were calculated by 
a nonlinear regression fit of the data to a Michaelis-Menten model.  
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Strain and Plasmid Construction for in Vivo Incorporation Assays.  pQE16am-
T415G25 encodes a murine dihydrofolate reductase (mDHFR) outfitted with a C-terminal 
hexa-histidine tag and an amber codon at position 38 . The GFPUV gene was cloned from 
pGFPuv (Clontech) and inserted into the PstI site of pQE9 (Qiagen) to yield a 
pQE9_GFPUV plasmid. A series of QuikChange mutations (Stratagene) were performed 
on GFPUV gene to generate a GFP6 gene containing four sequence changes (F64L, S65T, 
S99F, and T153M) (see Chapter 6). Either an amber codon (UAG) or a tryptophan codon 
(UGG) was inserted at position 66 of GFP6 by QuikChange mutagenesis using two 
complementary pairs of oligonucleotides, Am66_f (5’-CTT GTC ACT ACT CTG ACC 
TAG GGT GTT CAA TGC TTT TCC-3’)/Am66_r (5’-GGA AAA GCA TTG AAC ACC 
CTA GGT CAG AGT AGT GAC AAG-3’) and W66_f (CTT GTC ACT ACT CTG ACC 
TGG GGT GTT CAA TGC TTT TCC-3’)/W66_r (5’-GGA AAA GCA TTG AAC ACC 
CCA GGT CAG AGT AGT GAC AAG-3’), to yield pQE9_CFP6_66Am and 
pQE9_CFP6, respectively. The entire expression cassette from either CFP6_66Am or 
CFP6 was inserted between the AatII and NheI sites of pQE16am-T415G to generate 
pQE9_CFP6_66Am-T415G or pQE9_CFP6-T415G, respectively. pREP4_ytRNAPhe_UG 
was used to constitutively express a mutant yeast amber suppressor tRNA 
(ytRNAPheCUA_UG) shows minimal cross-reactivity with the E. coli lysyl-tRNA 
synthetase.25 A Phe/Trp double auxotrophic strain (AFW) was derived from the Phe 
auxotrophic strain AF (K10, Hfr(Cavalli) pheS13rel-1 tonA22 thi T2R pheA18, trpB114) 
by P1 phage-mediated transposon transduction as described previously.25,31  The double 
auxotrophic strain, AFW, was co-transformed with either pQE16am-T415G or 
pQE9_CFP6_66Am-T415G, and with pREP4_ytRNAPhe_UG to yield expression strains 
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AFW[pQE16am-T415G/pREP4_ytRNAPhe_UG] or AFW[pQE9_CFP6_66Am-
T415G/pREP4_ytRNAPhe_UG], respectively. DH10B (Invitrogen) E. coli strain was co-
transformed with pQE9_CFP6-T415G and pREP4_ytRNAPhe_UG to generate 
DH10B[pQE9_CFP6-T415G/pREP4_ytRNAPhe_UG].  
 
In Vivo Incorporation Assays. E. coli expression strains were grown in M9 minimal 
medium supplemented with 0.4% glucose, 35 mg/L thiamin, 1mM MgSO4, 1mM CaCl2, 
20 amino acids (at 25 mg/L), 35 mg/L kanamycin, and 200 mg/L ampicillin. The 
overnight culture was diluted 20-fold in fresh M9 minimal medium. The cells were 
grown to an OD600 between 0.9 and 1.0, sedimented by centrifugation, and washed twice 
with cold 0.9% NaCl. The cell pellet was resuspended in fresh M9 minimal medium 
containing 18 amino acids (at 25 mg/L), 3 mM analog of interest, and the indicated 
concentrations of Phe and Trp. After 10 min, 1 mM of isopropyl-β-D-
thiogalactopyranoside (IPTG) was added to induce protein expression. After 4 hours, 
cells were pelleted and kept at -80 °C.  
A different procedure was used for expression strain DH10B[pQE9_CFP6-
T415G/pREP4_ytRNAPhe_UG]. A single colony was inoculated into 5 mL of 2xYT 
medium and grown overnight. 5 mL of the overnight culture was transferred to 100 mL of 
fresh 2xYT medium. When the cultures reached an OD600 of 0.6, 1 mM IPTG was added 
to induce protein expression. After 3 hours, cells were sedimented and stored at -80 °C. 
Whole cell lysates were analyzed by SDS-PAGE.   
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Quantitative Analysis of Analog Incorporation by Liquid Chromatography Mass 
Spectrometry (LC-MS).  Quantitative analysis of amber codon occupancy by various 
amino acids was performed by LC-MS as described previously.25 In a minor alteration, 
mutant mDHFR was purified on a Ni-NTA spin column under denaturing conditions 
according to the supplier’s instructions (Qiagen). After purification, mutant mDHFR 
concentrations were determined by UV absorbance at 280 nm using a calculated 
extinction coefficient37 of 24,750 cm-1 M-1. After concentration of the protein by 
ultrafiltration (Millipore), 10 µL of the solution was diluted into 90 µL of 75 mM 
(NH4)2CO3 for trypsin digestion.  1 µL of modified trypsin (Promega, 0.2 µg/µL) was 
added. The samples were incubated for 2 hrs at 37 oC. The reaction was quenched by 
addition of 13 µL of 5% trifluoroacetic acid (TFA) solution. The solution was then 
directly subjected to LC-MS/MS analysis. LC-MS/MS analysis of protease-digested 
peptides was conducted on a QSTAR XL LC-MS/MS system (Applied Biosystems/MDS 
SCIEX) with HPLC system (NanoLC-2DTM, Eksigent Technologies) and ESI probe. 
Peptides were separated on a C18 reversed column (3 µm, 300Å, 0.1 x 70mm) and eluted 
at a flow rate of 0.2 µL/min using a gradient of 0-50% of solvent B (89% 
acetonitrile/10% H2O/0.02% TFA/1% formic acid) and solvent A (2% acetonitrile/97% 
H2O/0.02% TFA/1% formic acid) in 55 min. The column eluent was transferred to the 
electrospray source and sequencing was carried out by fragmentation of the precursor ion 
corresponding to the peptide containing the residue at position 38 of mutant mDHFR.    
 
Fluorescent Protein Isolation. Fluorescent proteins were purified by Ni-NTA affinity 
chromatography according to the manufacturer’s protocol (Qiagen) under native 
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conditions. Purified proteins were desalted over a Sephadex PD-10 column (Amersham 
Pharmacia, Piscataway, NJ) using 20 mM Tris-HCl, 1 mM EDTA, pH 8.0. Protein 
samples other than CFP6 were further purified by ammonium sulfate precipitation.38  
Dry ammonium sulfate was added to the bright fluorescent solution to 40% saturation 
(about 1.6 M). Then solutions were incubated on ice for 25 min and the precipitated 
proteins were removed by centrifugation at 14,000 rpm for 15 min at 4 oC. Dry 
ammonium sulfate was added to the fluorescent supernatants to 70% saturation (about 2.8 
M). The solutions were incubated on ice for 30 min and the fluorescent proteins were 
collected by centrifugation at 14,000 rpm for 30 min at 4 oC. The fluorescent proteins 
were resuspended in 20 mM Tris-HCl, 1 mM EDTA, pH 8.0 and desalted over 
polyacrylamide P-6 columns (Bio-rad) using 20 mM Tris-HCl, 1 mM EDTA, pH 8.0 
buffer. Protein concentrations were determined by the BCA protein assay kit (Pierce 
Biotechnology, Rockford, IL) using bovine serum albumin as a reference.     
 
Characterization of Spectral Properties.  Absorption spectra of fluorescent proteins 
were measured on a Cary 50 UV-visible spectrophotometer (VARIAN, Palo Alto, CA). 
Protein samples were diluted to four different concentrations (0.1 < ODλmax < 0.5). 
Extinction coefficients were calculated by applying Beer’s law to the absorption spectra 
of diluted protein samples. A molar mass of 30,287 Da was used for all fluorescent 
proteins. Fluorescence spectra were measured on a PTI QuantaMaster fluorescence 
spectrofluorometer (Photon Technology International, Birmingham, NJ) at a scan rate of 
1 nm/s. For the quantum yield calculation, protein samples in assay buffer and fluorescein 
(Invitrogen) in borate buffer (pH 9.1) were adjusted to similar OD (ODλex < 0.1). The 
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fluorescence emission spectra were recorded with excitation at the maxima in the 
corresponding excitation spectra. The emission spectra were corrected by the correction 
functions supplied with the instrument. The quantum yields of fluorescent proteins were 
calculated by comparing the integrated intensities of the corrected emission spectra with 
that of fluorescein of known quantum yield (0.91).39    
 
Results and Discussion 
Rational Design of yPheRS and Choice of Trp Analogs.  In order to increase the 
number of genetically encoded Trp analogs, we engineered the substrate specificity of 
yPheRS. Studies of the crystal structure of PheRS (tPheRS) derived from Thermus 
thermophilus revealed that Val 261 in the amino acid binding pocket is critical for 
distinguishing Phe from other non-aromatic amino acids.40 Sequence alignments showed 
that Val 261 in tPheRS corresponds to Thr 415 in yPheRS. Introduction of a single 
mutation (Thr to Gly) at position 415 in the binding pocket of yPheRS (yPheRS 
(T415G)) created extra room to accommodate various Phe analogs.25,31 There was an 
interesting finding that yPheRS (T415G) activated Trp and 2-naphthylalanine as well as 
substituted Phe analogs. Considering the spectrum of nonnatural amino acids recognized 
by yPheRS (T415G), we hypothesized that yPheRS (T415G) may activate Trp analogs. In 
order to achieve site-specific incorporation of Trp analogs, we needed to choose Trp 
analogs that can be recognized by yPheRS (T415G) but by the native E. coli translation 
system. We have chosen four Trp analogs (6ClW, 6BrW, 5BrW, and BT) that can not be 
utilized by the endogenous E. coli translational system. Based on previous data,10,11 we 
proposed a model for the adaptability of Trp analogs to the binding pocket of E. coli 
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TrpRS (eTrpRS) (Figure 2). Recognition of Trp analogs by eTrpRS depends on the size 
and position of substituents on the indole ring. Methyl (ca. 16.8 Å3),41 amino (ca. 12.3 
Å3), and fluorine groups (ca. 3.2 Å3) were the largest functional groups tolerated at the 
C4, C5 and C6 positions of the indole ring, respectively.10 Therefore, introduction of 
bulkier groups at each position would result in translationally inactive Trp analogs. Based 
on our hypothetical model, we chose three translationally inactive Trp analogs, 3, 4, and 5 
containing chlorine (ca. 14.3 Å3) or bromine (ca. 20 Å3) at the C6 position, and bromine 
at the C5 position of the indole ring. Additionally, we chose 6, known as an 
translationally inactive Trp analog.42 Replacement of the nitrogen in the indole ring of 
Trp with other hetero-atoms, such as selenium, sulfur, or oxygen, results in translationally 
inactive amino acids.15,42 As expected, none of the four Trp analogs (3-6) were 
incorporated into proteins, even in Trp auxotrophic E. coli strain under Trp depleted 
conditions (data not shown).  
 
Activation of Trp Analogs by yPheRS (T415G).  The relative rates of activation of 
Phe, Trp and Trp analogs (1-6) by yPheRS (T415G) were examined by ATP-PPi exchange 
assays. The kinetic parameters are shown in Table 1. Derivatives of Trp (3-6) revealed 
different activities with respect to substitution at different positions of the indole ring. 
Substitution at position 6 (3 and 4) was highly favorable; 3 displayed the highest activity 
among all the analogs we tested. The increase in side-chain volume upon replacement of 
2 with 3 (ca. 39 Å3) matched very well the cavity (ca. 39 Å3) generated by the T415G 
mutation in the binding pocket of yPheRS. 4 exhibited a kcat/Km value comparable to that 
of Trp. Notably, 4 showed 7-fold larger Km value than that of 3, indicating less favorable 
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binding of 4 to the binding pocket of yPheRS. This result is consistent with the fact that 
the calculated increase in side-chain volume (45 Å3) upon replacement of 2 with 4 is 
larger than the cavity generated by the T415G mutation. Substitution at position 5 of the 
indole ring was less favorable than that at position 6. The activation rate of 5 by yPheRS 
(T415G) was one half of that of 4. Replacement of an imine in the indole ring with a 
sulfur atom reduced binding to yPheRS (T415G). The Km of 6 was 3-fold greater than 
that of 1. However, the activation rate of 6 by yPheRS (T415G) was 6.4-fold faster than 
that of 2. The spectrum of activity of the yPheRS (T415G) supported our proposal that 
the yPheRS (T415G) may recognize Trp analogs.   
 
Site-Specific Incorporation of Trp Analogs into mDHFR in Vivo. To investigate the 
utility of yPheRS (T415G) to incorporate Trp analogs into proteins in vivo, mDHFR was 
chosen as a test protein. An amber stop codon was placed at the 38th position of mDHFR 
to generate mDHFR_38Am. The expression of full length mDHFR_38Am with various 
Trp analogs (3-6) was examined by SDS-PAGE analysis (Figure 3). All of the Trp 
analogs supported expression of full length mDHFR_38Am. The band intensities of 
mDHFR_38Am variants were in the order of 4 > 3 > 5 > 6. Although expression of full 
length mDHFR_38Am strongly indicated that the amber stop codon was suppressed, it 
should be noted that the mDHFR_38Am expression does not necessarily mean that the 
Trp analogs were incorporated at the amber site. In order to verify incorporation of Trp 
analogs at the amber site, the occupancy of the site in mDHFR_38Am by various amino 
acids was determined by LC-MS/MS analysis. Trypsin digestion of purified 
mDHFR_38Am variants generated diverse peptide fragments. Among them, a peptide 
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containing the amber site (residues 26-39, NGDLPWPPLRNEAmK) was designated as 
peptide 38. Peptide 38 variants containing Phe, Trp or Trp analogs were separated on a 
C18 reversed phase column and relative yields were determined by comparing the 
integrated areas of the corresponding signals in the chromatogram. The results are 
summarized in Table 2. Furthermore, the identity of each peptide was confirmed by 
tandem-mass spectrometry. As a representative, the identity of peptide 38 containing 
6BrW at the amber site was determined from the spectrum shown in Figure 4. We 
observed that 3, 4, and 6 occupied at least 98% of the amber sites in full length 
mDHFR_38Am (Table 2). However, 5 occupied only 2% of the amber site, though it was 
efficiently activated by yPheRS (T415G). Instead, 2 occupied 97% of the amber site. The 
discrepancy between in vitro activation and in vivo incorporation for 5 could be 
rationalized by the model proposed by Sisido and colleagues for the adaptability of non-
natural amino acids to the E. coli ribosome.43 The model suggests that the E. coli 
ribosome has the ability to define the allowed and excluded regions of the aromatic 
groups of aryl-L-alanines to be bound for further translation. The addition of bromine 
increases the volume of the indole ring by 20 Å3. We reason that the addition of bromine 
at the C5 position of the indole ring may result in exclusion of 5 by the ribosome. 
Another interesting finding from the experiment for analog 5 is that at similarly low 
concentrations of Phe and Trp in the culture medium, Phe was incorporated into the 
amber site instead of Trp. According to our in vitro activation assays, Trp was activated 
18-fold faster than Phe by yPheRS (T415G). This discrepancy between the results of in 
vitro activation assays and in vivo translation might be explained by elevated Trp 
degradation in the presence of Trp analogs. Expression of tryptophanase, a major enzyme 
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involved in Trp degradation, is regulated by tryptophan-induced transcription 
antitermination in E. coli.44,45 Even 1-methyltryptophan, a Trp analog, acted as an 
effective inducer in vitro.45 Therefore, we reasoned that supplementation of 5 into the 
culture medium accelerated Trp degradation via formation of tryptophanase and reduced 
the intracellular concentration of Trp levels lower than that of Phe. Since the 
ytRNAPheCUA_UG charged with 5 was rejected in ribosome, the ytRNAPheCUA_UG charged 
with 2 was dominantly utilized for translation. 
Expression yields of mDHFR_38Am with various Trp analogs were determined 
by measuring the concentration of purified mDHFR_38Am. The results are summarized 
in Table 2. One interesting finding was that 4 provided 25% higher expression level of 
mDHFR_38Am as compared to 3 despite its 3.5-fold lower kcat/Km value. This 
discrepancy can be rationalized by higher kcat of 4 than that of 3. The concentration (3 
mM) of Trp analogs supplemented into culture medium was at least 900-fold higher than 
Km values of both 3 and 4. In such a case, the kcat value became more important than 
kcat/Km in determining relative activation rates. Therefore, 4 with 60% higher kcat value 
than that of 3 could be more efficiently used for protein translation.       
 
Spectral Analysis of Fluorescent Proteins. The spectral properties of CFP6 and 
CFP6_66Am proteins containing Trp analogs are summarized in Table 3. Absorption 
maxima, emission maxima, and extinction coefficient of CFP6 were consistent with 
literature values.46 Compared to CFP6, CFP6_6ClW and CFP6_6BrW showed blue-shifts 
of 14 nm in the fluorescence emission maxima (Figure 6). Similar trends were found in 
previous work in which Tyr at position 66 of GFP was replaced by p-
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bromophenylalanine.36 In addition, solution studies indicated that the absorption and 
fluorescence spectra of fluorinated tryptophans were blue-shifted;16 the electron-
withdrawing property of halogen functional groups can account for the blue-shift in the 
fluorescence emission peak. Compared with CFP6, the quantum yields of the 
CFP6_6ClW and CFP6_6BrW decreased 2.5 to 3-fold (Table 3), probably due to 
collisional perturbation of spin-orbital coupling in the π-electron orbitals of the 
fluorophore by the halogen atom.47 CFP6_BT showed blue-shifts of 16 and 34 nm in 
fluorescence emission and absorption maxima, respectively. Similar blue-shift in 
absorption maxima in CFP variants was observed by replacing a tryptophan with sulfur 
containing tryptophan surrogates, such as β-(thieno[2,3-b]pyrrolyl)-L-alanine ([2.3]Tpa) 
and β-(thieno[3,2-b]pyrrolyl)-L-alanine ([3.2]Tpa).16 Extinction coefficient of CFP6_BT 
(8,100 M-1cm-1) was similar to those of CFP variants containing either [2,3]Tpa (6840 M-
1cm-1) or [3,2]Tpa (6350 M-1cm-1). Introduction of either [2,3]Tpa or [3,2]Tpa in the 
chromophore of CFP resulted in the disappearance of fluorescence;16 however, CFP6_BT 
exhibited substantial fluorescence, with quantum yield only 3-fold smaller than that of 
CFP6. CFP6_BT is the only fluorescent protein containing a sulfur atom in its 
chromophore. CFP6_BT has several advantages as a fluorescence resonance electron 
transfer (FRET) partner. It can be efficiently excited by a common violet diode laser 
(405-415 nm), which can simplify cell screening on the basis of FRET signals. In 
addition, the Stokes’ shift of CFP6_BT (56 nm) is larger than that of CFP6 (37 nm). This 
large Stokes’ shift is advantageous for fluorescence measurements, since it allows 
emission photons to be detected against a low background and isolated from excitation 
photons. CFP and yellow fluorescent protein (YFP) have been commonly used as a FRET 
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pair. Because the fluorescence emission spectrum of CFP_BT (Figure 6 b) overlaps the 
excitation spectrum of GFP, it can be used as a FRET partner with GFP. 
 
Conclusions 
In this paper, we have shown that properly engineered E. coli strains can allow 
high-fidelity incorporation of Trp analogs into recombinant proteins in response to an 
amber stop codon. Rational modification of the binding pocket in yPheRS enabled 
activation of Trp analogs (3-6). When the engineered yPheRS and the yeast amber 
suppressor tRNA were introduced into a Phe/Trp auxotrophic E. coli expression host, at 
least 98% of the amber sites in recombinant mDHFR were occupied by Trp analogs (3, 4 
and 6). In a subsequent experiment, three Trp analogs (3, 4, and 6) were introduced at the 
Trp66 position of CFP. CFP variants containing Trp analogs (4, 5, and 6) in the 
chromophore showed blue-shifts in fluorescence emission and absorption maxima. In 
particular, CFP6BT provided unusually large Stokes’ shift (56 nm). Introduction of aryl 
bromides into recombinant proteins should allow site-specific modification via bio-
orthogonal palladium-catalyzed coupling reactions. An expanded set of genetically 
encoded Trp analogs should enable design of new proteins with novel properties.   
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Figure 1: Amino acids involved in this study. (1) tryptophan, (2) phenylalanine, (3) 6-
chlorotryptophan, (4) 6-bromotryptophan, (5) 5-bromotryptophan, (6) 
benzothienylalanine.  
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Figure 2: A hypothetical model for the adaptability of Trp analogs to the binding pocket 
of eTrpRS. Position and size of substituents on the indole ring that can be tolerated in the 
binding pocket of eTrpRS are represented as circles. Indole rings containing larger 
substituents can not fit into the binding pocket of eTrpRS. 
 
 
 
 
 
 
 
 
 
 
N
H
R
C4
C5
C6
C7
Binding pocket 
of eTrpRS 
120 
 
 
 
 
 
 
 
 
 
 
Figure 3: SDS-PAGE analysis of mDHFR_38Am expression. Cells were equipped with 
yPheRS (T415G) and ytRNAPheCUA_UG. Cultures were supplemented with 18 amino acids 
(at 25 mg/L), one of Trp analogs (at 3 mM) and the indicated concentrations of Phe and 
Trp. Lane 1: molecular weight standards, lane 2: before induction, lane 3: 6ClW, 0.03 
mM Phe and 0.01 mM Trp, Lane 4: 6BrW, 0.015 mM Phe and 0.05 mM Trp, lane 5: 
5BrW, 0.03 mM Phe and 0.01 mM Trp, lane 6: BT, 0.01 mM Phe and 0.0025 mM Trp. 
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Figure 4: Tandem mass spectrum of the peptide (NGDLPWPPLRNEZK). The partial 
sequence DLPWPPLRNEZ containing 6BrW (Z) can be confirmed by assigning masses 
of series of fragmented ions (b and y). 
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Figure 5: Crystal structure of enhanced cyan fluorescent protein (PDB code 1OXD)18 (a). 
The chromophore is shown in black. Chromophores of CFP6 variants containing 1, 3, 4, 
and 6 (b). 
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Figure 6: Absorption (a) and fluorescence emission spectra (b) for CFP6 variants 
containing different Trp analogs at the Trp66 position.  
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Table 1:  Kinetic parameters for ATP-PPi exchange by the yPheRS (T415G) 
Amino 
Acid Km (µM) kcat (s
-1) kcat/Km   (M-1s-1) kcat/Km (rel)a
Phe (2) 55±14 0.20±0.11 3,500±1,100 1 
Trp (1) 2.8±1.6 0.15±0.003 63,200±34,600 18 
6ClW (3) 0.51±0.21 0.11±0.04 224,100±15,300 64 
6BrW (4) 3.4±1.3  0.18±0.11 61,800±53,900 18 
5BrW (5) 0.62±0.02 0.021±0.002 33,900±3,600 9.7 
BT (6) 8.1±3.7 0.15±0.06 22,500±18,000 6.4 
a relative to kcat/Km for Phe by yPheRS (T415G) 
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Table 2: Occupancy of amber sites and expression yields  
Occupancy of amber sites (%) Trp analogs 
Phe Trp Lys Naa 
Yield 
(mg/L)a 
Trp (1) 0.4 ± 0.5 NDb 1.2 ± 1.3 98.4 ± 1.7 5.4 ±  0.3 
6ClW (3) 0.4 ± 0.7 ND ND 99.6 ± 0.7 6.8 ± 1.3 
6BrW (4) 97.0 ± 1.4 0.3 ± 0.6 0.7 ± 0.5 1.8 ± 0.7 3.6 ± 0.6 
BT (6) 0.6 ± 0.6 0.7 ± 0.6 0.9 ± 1.5 97.9 ± 2.4 2.8 ± 0.6 
a Volumetric yields are given as mg of purified mDHFR_38Am per liter of culture.  
b Not detected in LC-MS analysis. 
 
126 
 
 
Table 3: Spectral properties of CFP6 variants    
 
 
amino acid at 
position 66 
absorption 
maximum (nm) 
extinction coefficient 
(M-1 cm-1) 
emission 
maximum (nm) quantum yield 
Trp (1) 449 25900 ± 1000 488 0.14 ± 0.008 
6ClW (3) 430 19800 ± 6400  474 0.050 ± 0.001 
6BrW (4) 430 20600 ± 3800 474 0.058 ± 0.001 
BT (6) 415 8100 ± 1100 472 0.048 ± 0.008 
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Chapter 5 
Breaking the Degeneracy of the Genetic Code 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The text in this chapter is reprinted with permission from Kwon, I.; Kirshenbaum, K.; 
Tirrell, D. A. J. Am. Chem. Soc. 2003, 125, 7512-7513, Copyright 2003 Am. Chem. Soc.  
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Abstract 
A mutant yeast phenylalanine transfer RNA (ytRNAPheAAA) containing a modified 
(AAA) anticodon was generated to explore the feasibility of breaking the degeneracy of 
the genetic code in Escherichia coli.  By using an E.coli strain co-transformed with 
ytRNAPheAAA  and a mutant yeast phenylalanyl-tRNA synthetase, we demonstrate 
efficient codon-biased replacement of phenylalanine (Phe) by L-3-(2-naphthyl)alanine 
(2Nal), a non-proteinogenic analog.  Site-specific incorporation of 2Nal in response to 
UUU codons was confirmed by mass spectrometric analysis of recombinant murine 
dihydrofolate reductase.  These results illustrate a general method for increasing the 
number of distinct, genetically-encoded amino acids available for protein engineering and 
for exploration of the chemistry and physics of protein-like macromolecules. 
 
Introduction 
Organisms use a canonical set of 20 amino acids to generate the proteins that 
sustain the life of the cell. In recent years, several laboratories have pursued an expansion 
in the number of genetically-encoded amino acids, by using either a nonsense suppressor 
or a frameshift suppressor tRNA to incorporate non-canonical amino acids into proteins 
in response to amber or four-base codons, respectively.1-10 Such methods have worked 
well for single-site insertion of novel amino acids; however, their utility in multi-site 
incorporation is limited by modest (20-60%) suppression efficiencies.1, 5, 11  
Efficient multi-site incorporation has been accomplished by replacement of natural 
amino acids in auxotrophic E. coli strains,12-15 and by using aminoacyl-tRNA synthetases 
with relaxed substrate specificity or attenuated editing activity.14, 16 Although this method 
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provides efficient incorporation of analogs at multiple sites, it suffers from the limitation 
that the novel amino acid must “share” codons with one of the natural amino acids. We 
present here a potential solution to this coding problem.  
 
Material and Methods              
Materials.  All chemical reagents were of analytical grade, obtained from commercial 
suppliers, and used without further purification unless otherwise noted.  L-3-(2-
naphthyl)alanine and other natural amino acids were obtained from Sigma (St. Louis, 
MO).    
   
Strains and Plasmids.  An E. coli strain XL1-Blue (Stratagene) was used for plasmid 
propagation and isolation. A Phe auxotrophic strain K10-F6∆ (K10, Hfr(Cavalli) 
pheS13rel-1 tonA22 thi T2R pheA18)4 was a gift from Rolf Furter (University of 
Massachusetts).  Plasmids carrying modified yeast tRNAPhe variants were derived from 
pRO1174  in which yeast tRNAPhe expression cassette was inserted at the SnaI site of the 
pREP4 (Qiagen).  Plasmids for expression of mDHFR and overexpression of mutant 
yeast phenylalanyl-tRNA synthetases (yPheRS) were derived from pRO1484 in which 
yPheRS genes under constitutive tac promoter control was inserted at the PvuII site of 
pQE16 (Qiagen).  
 
Construction of Plasmid Carrying Mutant Yeast tRNAPhe.  pREP4_ytRNAPhe_AAA 
containing a mutant yeast tRNAPhe with a modified anticodon (AAA) (ytRNAPheAAA) was 
generated by PCR mutagenesis kit (Stratagene) using pRO1174 as a template.   
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Construction of Plasmid Carrying mDHFR and Mutant Yeast Phenylalanyl-tRNA 
Synthetase.  An intact mDHFR expression cassette was obtained by endonuclease 
restriction of pQE16 at the AatII and NheI sites.  This expression cassette was inserted 
between the AatII and NheI sites of pRO148 to generate pQE16_mDHFR_yPheRS.  A 
mutation of threonine to glycine at the 415th position of α-subunit of yPheRS was 
performed by PCR mutagenesis kit (Stratagene) using pQE16_mDHFR_yPheRS as a 
template to generate pQE16_mDHFR_yPheRS (T415G).   
 
Protein Expression and Purification.  Cultures of K10-F6∆ outfitted with 
pREP4_ytRNA_AAA and pQE16_mDHFR_yPheRS (T415G) were grown in M9 
minimal medium supplemented with 0.4% (w/v) of glucose, 0.1 mM of CaCl2, 1.0 mM of 
MgSO4, 35 µg/mL of thiamine, 20 amino acids (25 mg/L), 100 µg/mL of ampicillin, and 
35 µg/mL of kanamycin.  When an optical density of the culture reached 0.8 to 1.0 at 
600nm (OD600), the cultures were centrifuged for 7 min (6,000 rpm) at 4 °C.  The cell 
pellets were washed twice with 0.9% (w/v) of NaCl solution.  The cells were resuspended 
in M9 minimal medium supplemented with 18 amino acids (25 mg/L) and indicated 
amounts of 2Nal and Phe. After 10 min incubation, 1 mM of isopropyl-1-thio-β-D-
galactopyranoside (IPTG) was added to induce mDHFR protein expression.  The OD600 
of the culture was measured 4 hrs after induction. Then the cells were harvested by 
centrifugation for 10 min (6,000 rpm) at 4°C and stored at -70°C.  After thawing, 
mDHFR proteins were purified under denaturing conditions according to manufacturer’s 
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protocol (Qiagen). Protein expression was evaluated by SDS-PAGE with coomassie blue 
staining.  Loading of the gel was normalized for cell densities as determined by OD600.   
 
Amino Acid Analysis. The purified mDHFR solutions were concentrated 10-fold by 
ultrafiltration (Millipore) followed by a buffer exchange against 0.1% trifluoroacetic acid 
(TFA) solution. Samples were submitted to the Molecular Structure Facility at the 
University of California, Davis, for amino acid analysis on a Beckman 6300 instrument 
(Fullerton, CA).   
 
Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI–MS) 
Analysis.  The purified mDHFR solutions were desalted by ZipTipC18 (Millipore) and 
eluted with 3 µL of 50% CH3CN/0.1% TFA. 1 µL was used for matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) analysis with sinapinic acid (30% 
(v/v) of acetonitrile and 70% (v/v) of 0.1% TFA solution) as the matrix. The analysis was 
performed on a PerSeptive Biosystems (Framingham, Massachusetts) Voyager DE PRO 
MALDI-TOF mass spectrometer operating in linear and positive ion modes.  For MALDI-
MASS analysis of tryptic digests of purified mDHFR, 10 µL of the concentrated protein 
solution was added to 90 µL of 75 mM ammonium bicarbonate solution.  2 µL of 0.2 g/L 
of modified trypsin (Promega) was added, and the solution was incubated at 37°C for 2.0 
hrs. 12 µl of 5% TFA solution was added to quench the reaction. Chromatography on 
ZiptipC18 columns (Millipore) provided purified peptide samples (1 µL), which were added 
to 2,5-dihydroxybenzoic acid (DHB) MALDI matrix solution for MALDI-MASS analysis.  
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Results and Discussion 
The genetic code is degenerate, in that the protein biosynthetic machinery utilizes 
61 mRNA sense codons to direct the templated polymerization of a set of 20 amino acid 
monomers.17  Just two amino acids, methionine and tryptophan, are encoded by unique 
mRNA triplets. Re-assignment of degenerate sense codons therefore offers the prospect 
of a substantially expanded genetic code and a correspondingly enriched set of building 
blocks for natural and artificial proteins. 
As a test case for establishing the feasibility of breaking the degeneracy of the 
code, we chose the biosynthetic machinery responsible for incorporation of phenylalanine 
(Phe) into the proteins of E. coli.  Phe is encoded by two codons, UUC and UUU.  Both 
codons are read by a single ytRNA, which is equipped with the anticodon sequence 
GAA.  The UUC codon is therefore recognized through standard Watson-Crick base-
pairing between codon and anticodon; UUU is read through a G-U wobble base pair at 
the first position of the anticodon.18 Thermal denaturation of RNA duplexes has yielded 
estimates of the Gibbs free energies of melting of G-U, G-C, A-U, and A-C base pairs as 
4.1, 6.5, 6.3, and 2.6 kcal/mol, respectively, at 37oC.19  Thus the wobble base pair, G-U, 
is less stable than the Watson-Crick base pair, A-U.  On this basis, we proposed that a 
mutant ytRNAPhe outfitted with the AAA anticodon (ytRNAPheAAA) might be engineered 
to read UUU codons faster than wild-type ytRNAPhe.  If ytRNAPheAAA can then be 
charged selectively with an amino acid analog, one should be able to accomplish codon-
biased incorporation of the analog at multiple sites in recombinant proteins.  With respect 
to reading of UUC, an unmodified A in the first position of the anticodon is known to 
read codons ending with C, as well as U, in the absence of ytRNAs containing G in the 
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first anticodon position.20-22  However, the binding of E. coli tRNAPheGAA should 
dominate the binding of ytRNAPheAAA owing to differences in the stability of A-C and G-
C base pairs (see above). 
The approach used here is a modification of the method introduced by Furter for 
site-specific insertion of amino acid analogs in vivo.4 The method involves introduction 
into E. coli of a heterologous aminoacyl-tRNA synthetase and its cognate tRNA.  If 
cross-charging between the heterologous pair and the translational apparatus of the host is 
slow or absent, and if the analog is charged only by the heterologous synthetase, insertion 
of the analog can be restricted (or at least biased) to sites characterized by productive 
base-pairing between the heterologous tRNA and the messenger RNA of interest. 
In order to test these ideas, we prepared a yeast tRNAPhe (ytRNAPheAAA) with an 
altered anticodon loop.  The first base (G34) of the ytRNAPhe anticodon (GAA) was 
replaced with A to provide specific Watson-Crick base-pairing to the UUU codon.  
Furthermore, G37 in the extended anticodon site was replaced with A in order to increase 
translational efficiency.10, 23  We believe that charging of yeast tRNAPheAAA by E. coli 
PheRS can be ignored, because the aminoacylation rate of yeast tRNAPheAAA by E. coli 
PheRS is known to be 0.1% of that of E.coli tRNAPheGAA.24  
Since wild-type yeast PheRS does not activate amino acids significantly larger 
than phenylalanine, a mutant form of the synthetase with relaxed substrate specificity was 
prepared in order to accommodate L-3-(2-naphthyl)alanine (2Nal).10 On the basis of prior 
work from this laboratory,16 the mutant yeast PheRS (yPheRS (T415G)) was prepared by 
introduction of a Thr415Gly mutation in the α-subunit of the synthetase.  The kinetics of 
activation of 2Nal and Phe by yPheRS (T415G) was analyzed in vitro via the 
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pyrophosphate exchange assay.  The specificity constant (kcat/KM) for activation of 2Nal 
by yPheRS (T415G) was found to be 1.55x10-3 (S-1µM-1), 8-fold larger than that for 
Phe.10  Therefore, when the ratio of 2Nal to Phe in the culture medium is high, 
ytRNAPheAAA should be charged predominantly with 2Nal.  Recently, we have shown that 
2Nal can be incorporated with better than 95% efficiency via amber suppression in an E. 
coli strain co-transformed with yPheRS (T415G) and ytRNAPheCUA.  
Murine dihydrofolate reductase (mDHFR), which contains nine Phe residues, was 
chosen as the test protein. The expression plasmid pQE16 encodes mDHFR under control 
of a bacteriophage T5 promoter; the protein is outfitted with a C-terminal hexahistidine 
tag to facilitate purification via immobilized metal affinity chromatography. In this 
construct, four of the Phe residues of mDHFR are encoded by UUC codons, five by 
UUU. A full-length copy of the yPheRS (T415G) gene, under control of a constitutive tac 
promoter, was inserted into pQE16.  The gene encoding ytRNAPheAAA was inserted into 
the repressor plasmid pREP4 (Qiagen) under control of the constitutive promoter lpp.  E. 
coli transformants harboring these two plasmids were incubated in Phe-depleted minimal 
medium supplemented with 3 mM 2Nal, and then treated with 1 mM IPTG to induce 
expression of mDHFR.  Although the E. coli strain (K10-F6∆) used in this study is a Phe 
auxotroph,4 a detectable level of mDHFR was expressed even under conditions of 
nominal depletion of Phe (Figure 2), probably due to release of Phe through turnover of 
cellular proteins.  In negative control experiments, mDHFR was expressed in the absence 
of either ytRNAPheAAA or yPheRS (T415G).  mDFHR expression levels in these 
experiments were similar, indicating that neither ytRNAPheAAA nor yPheRS (T415G) 
significantly reduces the protein synthesis rate (Figure 2).  However, MALDI-MS spectra 
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and amino acid analyses of purified mDHFRs showed differences among samples 
prepared under these conditions (Table 1).  The molar mass of mDHFR prepared in the 
absence of 2Nal, ytRNAPheAAA, or yPheRS (T415G) was 23,287 daltons, precisely that 
calculated for His-tagged mDHFR.  However, when ytRNAPheAAA and yPheRS (T415G) 
were introduced into the expression strain and 2Nal was added to the culture medium, the 
observed mass of mDHFR was 23,537 daltons. Because each substitution of 2Nal for Phe 
leads to a mass increment of 50 daltons, this result is consistent with replacement of five 
Phe residues by 2Nal.  No detectable mass shift was found in the absence of either 
ytRNAPheAAA or yPheRS (T415G), confirming that the intact heterologous pair is required 
for incorporation of 2Nal. For mDHFR isolated from the strain harboring the 
heterologous pair, amino acid analysis indicated replacement of 4.4 of the 9 Phe residues 
by 2Nal (Table 1). Without ytRNAPheAAA or yPheRS (T415G), no incorporation of 2Nal 
into mDHFR was detected by amino acid analysis.  
Because neither MALDI nor amino acid analysis of intact mDHFR shows which 
Phe residues have been replaced by 2Nal, tryptic digests were analyzed to determine the 
occupancy of individual Phe sites.  Tryptic digestion of mDHFR yields peptide fragments 
that are readily analyzed by MALDI mass spectrometry as shown in Figure 3.  Peptide 
1UUU (residues 184-191, YKFEVYEK) contains a Phe residue encoded as UUU, whereas 
Peptide 2UUC (residues 62-70, KTWFSIPEK) and Peptide 3UUC (residues 26-39, 
NGDLPWPPLRNEFK) each contain a Phe residue encoded by UUC.  In the absence of 
2Nal, Peptide 1UUU was detected with a monoisotopic mass of 1105.55 daltons, in accord 
with its theoretical mass (Figure 3A).  However, when 2Nal was added, a strong signal at 
a mass of 1155.61 daltons was detected, and the 1105.55 signal was greatly reduced in 
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intensity (Figure 3B). As described earlier, each substitution of 2Nal for Phe leads to a 
mass increase of 50.06 daltons; the observed shift in the experimental mass is thus 
consistent with replacement of Phe by 2Nal in response to the UUU codon.  Liquid 
chromatography-tandem mass spectrometry of Peptide 1UUU (Nal) was also carried out in 
order to determine more directly the origin of the observed increase in mass.  The 
fragment ion masses could be unambiguously assigned as shown in Figure 4, confirming 
replacement of Phe by 2Nal.  The ratio of MALDI signal intensities, though not 
rigorously related to relative peptide concentrations, suggests that 2Nal incorporation is 
dominant at the UUU codon.   
Similar analyses were conducted for Peptide 2UUC and Peptide 3UUC.  In the 
absence of added 2Nal, the observed masses of Peptides 2UUC and 3UUC are 1135.61 
(Figure 3A) and 1682.89 daltons (Figure 3D), respectively.  These observed masses 
match well the corresponding theoretical masses (1135.61 daltons for Peptide 2UUC, and 
1682.86 daltons for Peptide 3UUC). Upon addition of 2Nal to the expression medium, the 
signals at these masses (Figure 3B and 3E) were not substantially reduced, and only very 
weak signals were observed at masses of 1185.60 and at 1733.03, which would be 
expected for peptides containing 2Nal in place of Phe.  2Nal incorporation thus appears 
to be rare at UUC codons under the conditions used here for protein expression.  Other 
peptides containing encoded Phe show similar codon-biased selective incorporation of 
2Nal and Phe.   
There is at least a formal possibility that the observed codon-biased incorporation 
of 2Nal might be dependent on codon context rather than - or in addition to - codon 
identity.  In order to test this possibility, mutant mDHFR genes were prepared by 
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mutating the UUU codon in Peptide 1UUU to UUC, and the UUC codon in Peptide 3UUC to 
UUU. The resulting peptides were designated Peptide 1UUC and Peptide 3UUU, 
respectively.  In Peptide 1UUC, 2Nal incorporation was greatly reduced (Figure 3C), 
whereas for Peptide 3UUU, 2Nal is readily detected (Figure 3F). 2Nal incorporation is 
unambiguously codon-biased to UUU.  
 
Conclusions 
The results described here show conclusively that a heterologous pair comprising 
a genetically engineered tRNA and cognate aminoacyl-tRNA synthetase can be used to 
break the degeneracy of the genetic code in E. coli. This method should provide a general 
strategy for multi-site incorporation of non-canonical amino acids, without the 
requirement that one of the natural amino acids be excluded.  Introduction of more than 
one set of orthogonal pairs should allow several types of non-canonical amino acids to be 
incorporated in site-specific fashion.  Ongoing experiments address the quantitative 
selectivity and the generality of the approach demonstrated here. 
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Table 1: Molar masses and numbers of 2Nal residues observed for mDHFR samples 
prepared under various conditions   
ytRNAPheAAA + + - + 
yPheRS (T415G) + - + + 
2Nal (3mM) - + + + 
Phe (3mM) + - - - 
Mass of intact mDHFR 23287 23287 23287 23537 
Number of 2Nal residues NDa ND ND 4.4 
a. Not detected 
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Phenylalanine auxotrophic E. coli strain 
Figure 1: A strategy for multi-site incorporation of 2Nal into recombinant proteins by 
breaking the degeneracy of the phenylalanine codons. ytRNA images were obtained from 
the Protein Data Bank (www.rcsb.org/pdb/). 
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ytRNAPheAAA - + + + 
yPheRS (T415G) + - + + 
Induction + + + - 
 
 
 
 
 
 
 
 
Figure 2: SDS-PAGE analysis of mDHFR prepared in minimal media supplemented with 
3 mM 2Nal and free of exogenous Phe.  Conditions are noted at the top of each lane. Lane 
1 shows molecular weight standards. 
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Figure 3: Replacement of Phe by 2Nal can be detected in MALDI-MS spectra of tryptic 
fragments of mDHFR.  Peptide 1UUU (residues 184-191, YKFEVYEK) contains a Phe (F) 
residue encoded by UUU, whereas in Peptide 1UUC this codon has been mutated to UUC.  
Peptides 2 (residues 62-70, KTWFSIPEK) and 3 (residues 26-39, NGDLPWPPLRNEFK) 
are designated similarly.  Peptide 1UUU (Nal) refers to the form of the peptide containing 
2Nal in place of Phe.  In the absence of 2Nal, Peptide1UUU was detected at a mass of 
1105.55 (A).  Upon addition of 2Nal, a strong signal corresponding to Peptide 1UUU(Nal) 
was detected at m/z = 1155.61, and the signal for Peptide 1UUU was greatly reduced (B).  
For Peptide 1UUC, 2Nal incorporation was much less efficient (C). Signals corresponding to 
Peptides 2UUC (B) and 3UUC (E) were not substantially reduced upon addition of 2Nal, and 
only very weak signals for Peptides 2UUC (Nal) and 3UUC (Nal) were detected (B, E).  When 
the UUC codon in Peptide 3UUC is mutated to UUU, a strong signal for Peptide 3UUU (Nal) 
is detected (F). These data confirm that incorporation of 2Nal is strongly biased to UUU 
codons.    
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Figure 4: Tandem mass spectrum of Peptide 1UUU (Nal) YKF*EVYEK.  The doubly-
charged ion at 578.6 daltons was selected and fragmented.  The sequence of the peptide 
containing 2Nal (F*) can be read from the annotated b (black) or y (red) ion series. 
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Breaking the Degeneracy of the Leucine Codons in Escherichia coli 
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Abstract 
Previously we have shown that combination of yPheRS (T415G) and the mutant 
ytRNAPheAAA enables incorporation of 2Nal in response to UUU (Phe) codons. However, 
this method has two limitations. First, the yPheRS (T415G) activates Trp, which leads to 
Trp misincorporation.  Second, 2Nal was incorporated at UUC codons as well as UUU 
codons, due to the relaxed codon recognition of the AAA anticodon in ytRNAPheAAA. In 
order to enhance the selectivity of yPheRS, we performed high-throughput screening of a 
yPheRS library. The screen revealed a yPheRS variant (yPheRS_naph) with 6-fold higher 
relative activity toward 2Nal (vs. Trp) in ATP-PPi exchange assays. To enhance codon 
selectivity, we explored degenerate leucine codons instead of phenylalanine degenerate 
codons. Combined use of ytRNAPhe containing the CAA anticodon, which recognizes 
only the UUG (Leu) codon, and yPheRS_naph allowed incorporation of 2Nal into murine 
dihydrofolate reductase in response to six UUG codons with 50% fidelity, but not to other 
Leu codon sites.  
 
Introduction 
An expanded set of genetically encoded amino acids has allowed design of 
proteins with novel chemical, physical, or biological properties. Several methods have 
been developed to introduce nonnatural amino acids into recombinant proteins at 
programmed sites in vivo. First, residue-specific incorporation involves the global 
replacement of a particular natural amino acid with a nonnatural analog in target 
proteins.1-12 The strength of this technique lies in efficient protein translation and multi-
site incorporation of a nonnatural amino acid, because sense codons are re-assigned for a 
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nonnatural amino acid. However, its application could be restricted due to the exclusion 
of one natural amino acid for protein translation and lack of site-specificity. Second, 
single-site-specific incorporation involves utility of a heterologous orthogonal aminoacyl-
tRNA synthetase/tRNA pair and suppression of either a stop codon or a frameshift 
codon.13-20 Access to all 20 natural amino acids and site-specificity of the technique 
allows the incorporation of a nonnatural amino acid at a single site in a target protein with 
minimal perturbation of the native protein structure and function. However, application of 
the method is limited to the insertion of a nonnatural amino acid at only one or two 
positions in a target protein, due to moderate suppression efficiency.  
Although residue-specific incorporation and single-site-specific incorporation 
have been used for many different applications,21-27 one can envision other circumstances 
in which a nonnatural amino acid needs to be inserted at multiple positions in the 
presence of all twenty natural amino acids. For example, by introducing a nonnatural 
amino acid only at permissive sites in a target protein, the protein may be equipped with 
multiple reaction sites or probes with minimal loss of its native properties.  Multiple-
site-specific incorporation in vivo was realized in our lab by breaking the degeneracy of 
the Phe codons.28 The combined use of a mutant yeast phenylalanyl-tRNA synthetase 
(yPheRS (T415G)) and mutant yeast phenylalanyl-tRNA containing modified AAA 
anticodon (ytRNAPheAAA) that favors UUU Phe codons over UUC Phe codons, achieved 
efficient incorporation of 2Nal into mDHFR at five Phe sites encoded as UUU. Although 
the method successfully demonstrated the concept of breaking the degeneracy of the 
genetic code, its application has been restricted by two limitations.  
First, the rationally designed yPheRS (T415G) efficiently activated a natural 
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amino acid, Trp, due to the enlarged binding pocket generated by the T415G mutation.13 
The relaxed substrate specificity of yPheRS (T415G) showed several drawbacks. Cell 
growth rate decreased, likely due to misincorporation of Trp at Phe sites in essential 
proteins. Leaky expression of target protein even under uninduced conditions was 
prominent, perhaps due to the impaired repressor proteins. Furthermore, misincorporation 
of Trp as well as 2Nal was observed at Phe residues encoded as UUU codons, which 
prevented high fidelity incorporation of 2Nal at programmed sites. These drawbacks 
prompted us to pursue more selective yPheRS variants. Previously we reported that an 
other rationally designed yPheRS (T415A) showed 10-fold higher activity toward pBrF 
than Trp. However, yPheRS (T415A) did not exhibit enhanced selectivity toward pBrF 
against Phe.13 Therefore, we need to explore different approaches to obtain highly 
selective yPheRS variants. Aminoacyl-tRNA synthetases are known to be readily 
evolvable. Schultz and co-workers have developed powerful screening methods to 
change the substrate specificity of tyrosyl-tRNA synthetase (mjTyrRS) derived from 
Methanococcus jannaschii toward nonnatural amino acids.14,18,22,29 Recently our lab 
reported a novel screening method to adapt E. coli methionyl-tRNA synthetase to a 
reactive methionine analog, azidonorleucine.7 However, until now there have been no 
reports about evolving eukaryotic aminoacyl-tRNA synthetases to change their substrate 
specificity toward a nonnatural amino acid. In this report, we describe the high-
throughput screening of a yPheRS library to obtain yPheRS variants of which substrate 
specificity is changed to a nonnatural amino acid, 2Nal.   
Second, 2Nal was misincorporated at the unwanted sites (UUC codon) as well as 
programmed sites (UUU codon) due to relaxed codon recognition of the AAA anticodon 
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of ytRNAPheAAA. Misincorporation of a nonnatural amino acid at unwanted sites might 
cause perturbation or loss of native properties of the target protein.23,30 According to 
Crick’s wobble rules proposed in 1966,31 the base A in the first position of the anticodon 
recognizes only the base U in the third position of the codon. Therefore, the AAA 
anticodon was expected to recognize only UUU, not UUC codons. The discrepancy 
between the experimental result and Crick’s wobble rule may be explained by the 
expanded wobble rule proposed by Lim and Curran in 2001.32 The expanded wobble rule 
is based on new experimental finding32-39 and stereochemical modeling40-43 of codon-
anticodon interactions. The expanded wobble rule indicates that A in the first position of 
the anticodon can recognize all four bases in the third position of the codon, though its 
affinity to C is lower than that to U.  
Due to the poor discrimination of UUU codon froms UUC by the AAA anticodon 
of ytRNAPhe, we explored breaking the degeneracy of leucine (Leu) codons. Several 
considerations recommend degenerate Leu codons. First, Leu is encoded as six codons: 
UUA, UUG, CUA, CUG, CUU, and CUC. Discrimination of UUG from CUN (N = 
A/U/G/C) codons should be highly efficient due to discrimination at the first position in 
codon.  Second, our existing yeast orthogonal pair should be readily adapted to the 
incorporation of Phe analogs in response to UUG codons. In practical terms, 
generalization of the concept of breaking the degeneracy of the genetic code is limited by 
the availability of orthogonal pairs. Third, the modified CAA anticodon would more 
efficiently discriminate UUG from UUA. According to the expanded wobble rules, C in 
the first position of the anticodon recognizes only G in the third position of the codon. In 
this report, we show that an engineered ytRNAPhe containing a modified CAA anticodon 
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(CAA) can completely discriminate UUG from the remaining five Leu codons, and 
achieve incorporation of 2Nal at multiple programmed sites in recombinant proteins.                
 
Materials and Method 
Materials.  Unless otherwise noted, reagents were obtained from commercial suppliers 
and were used without further purification. 2Nal was purchased from Chem-Impex 
(Wood Dale, IL). Restriction enzymes were obtained from New England Biolabs 
(Beverly, MA). Quikchange mutagenesis kits were purchased from Stratagene (La Jolla, 
CA). Nickel-nitrilotriacetic acid affinity columns and plasmid pREP4 were obtained from 
Qiagen (Valencia, CA). DNA primers were obtained from Integrated DNA Technologies 
(Coralville, IA) and Operon Technologies (Huntsville, AL). Sequences of the DNA 
primers used in this research are listed in Appendix C. 
 
Preparation of E. coli hosts.  Preparation of the Phe/Trp double auxotrophic strain 
(AFW) and the Phe/Trp/Lys triple auxotrophic strain (AFWK) was described 
previously.13 A Phe/Leu double auxotrophic strain, MPC390 (leuB6(Am), PheA18::Tn10), 
was obtained from the E. coli Genetic Stock Center (CGSC) at Yale University. A Phe 
auxotrophic derivative of DH10B (Stratagene) E. coli strain was prepared by chemical 
mutagenesis44 and designated DHF.   
 
Plasmid Construction for Reporter Gene Expression.  The GFPUV gene was 
amplified from pGFPuv (Clontech, Palo Alto, CA) using two primers (GFP1 and GFP2) 
containing a PstI restriction site. The amplified GFPuv gene was inserted into pQE9 
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(Qiagen) at the PstI site to generate pQE9_GFPUV. Since GFPUV has excitation maxima 
at 475 and 395 nm,45 it was mutated into an EGFP variant (GFP3)45 with excitation 
maximum at 488 nm suitable for FACS analysis. A series of PCR mutagenesis reactions 
were performed at four residues (F64L, S65T, S99F and T153M) using three pairs of 
complementary primers (F64LS65T_f/F64LS65T_r; S99F_f/S99F_r; 
T153M_f/T153M_r). The GFP3 gene expression cassette was inserted into 
pQE16_mDHFR_yPheRS (T415G)28 between the AatII and NheI restriction sites to 
generate pQE9_GFP3_yPheRS (T415G). GFP3 has twelve Phe residues, of which seven 
are encoded as UUC. A GFP variant (GFP6) was prepared by replacing all UUC Phe 
codons and one CUG Leu codon (at position 64) with UUU codons via gene fragment re-
assembly using sixteen primers (Primer 1–16). The GFP6 expression cassette was 
removed by restriction digestion with the AatII and NheI, and inserted into 
pQE9_GFP3_yPheRS (T415G) between the AatII and NheI sites to yield 
pQE9_GFP6_yPheRS (T415G). In order to introduce an extra copy of the lacI gene into 
pQE9_GFP6_yPheRS (T415G), the lacI gene expression cassette was amplified from 
pREP4 (Qiagen) with two primers (lacI_AflII_f and lacI_SacII_r). AflII and SacII 
restriction sites were introduced into pQE9_GFP6_yPheRS (T415G) by PCR reactions 
with two primers (pQE_AflII_f and pQE_SacII_r). The amplified lacI gene expression 
cassette was inserted into pQE9_GFP6_yPheRS (T415G) between the AflII and SacII 
sites to generate pQE9_GFP6_lacI_yPheRS (T415G). A GFP variant (GFP3_WC) 
containing 12 Phe residues encoded as only UUC codons were generated by the gene 
fragment reassembly method46 using twelve primers (Primer 1, 16, 17-26). The 
GFP3_WC gene expression cassette was ligated into pQE9_GFP6_lacI_yPheRS (T415) 
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between the AatII and NheI sites to yield pQE9_GFP3_WC_lacI_yPheRS (T415G). 
Information of the marker proteins used in this work is summarized in Appendix B.   
 
Construction of yPheRS Library.  Four residues (N412, T415, S418 and S437) in the 
active site of yPheRS were saturated by two step PCR mutagenesis. First, NNK (N = 
A/U/G/C; K = G/U) degenerate codons were introduced into the 437th position in the α-
subunit of yPheRS by PCR mutagenesis with two complementary primers (437_f and 
437_r) using pQE9_GFP6_lacI_yPheRS (T415G) as a template. The PCR product was 
digested by DpnI for 1 hr at 37 °C and transformed into XL-1 blue (Stratagene) 
competent cells. The plasmids isolated from the culture of transformants were used as a 
template for the second PCR mutagenesis with one pair of complementary primers 
(412_415_418_f and 412_415_418_r) to saturate the 412th, 415th and 418th positions in 
the α-subunit of yPheRS. The PCR product was digested by DpnI for 1 hr at 37 °C and 
desalted on a spin column. The eluted plasmids were transformed into ElectroTen-Blue 
electro-competent cells (Stratagene) according to the manufacturer’s protocol, and 
plasmids were isolated from the culture of pooled transformants. The plasmid fragments 
encoding yPheRS were removed by digestion with NsiI and BglII restriction enzymes and 
ligated to the large fragments of pQE9_GFP6_lacI_yPheRS (T415G) obtained by 
digestion with NsiI and BglII. The ligated plasmids were desalted and transformed into 
ElectroTen-Blue electro-competent cells to generate six million transformants. The 
yPheRS library plasmids (P_yFS_20) were isolated from the culture of pooled 
transformants.     
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Construction of Expression Library.  pREP4_ytRNA_AAA, prepared previously,28 
was transformed into DHF electro-competent cells to generate DHF_AAA cells. The 
P_yFS_20 library was transformed into DHF_AAA electro-competent cells to generate 
the yPheRS expression library (L_01) consisting of ten million transformants. The 
transformants were transferred to 0.5 L 2xYT media with 200 µg/mL ampicillin and 35 
µg/mL kanamycin. When OD600 reached 1.0, glycerol stocks were prepared and kept in a 
-80 °C freezer.  
 
Screening of yPheRS Library.  A half mL of glycerol stock of the expression library 
was inoculated into 100 mL of M9 minimal medium supplemented with glucose, thiamin, 
MgSO4, CaCl2, 20 amino acids (at 25 mg/L), antibiotics (35 µg/mL of kanamycin and 
200 µg/mL of ampicillin). When the culture reached an OD600 of 0.6–0.8, cells were spun 
down, washed twice with ice-cold 0.9% NaCl, and shifted to expression medium 
supplemented with 18 amino acids (at 25 mg/L), and the indicated concentrations of Phe, 
Trp and 2Nal. Expression of GFP was induced by addition of 1 mM IPTG. After 3 hrs, 1 
mL of the culture (based on OD of 1.0) was collected and washed twice with 0.5 mL of 
PBS (pH 7.4). 300 µL of cells were diluted with 3 mL of distilled water, and then 
subjected to cell sorting using a MoFlo cell sorter (DakoCytomation, Ft. Collins, CO). 
The excitation and emission wavelengths were 488 and 525 nm, respectively. The library 
was subjected to both positive and negative screening (Figure 3). FACS gates were set 
based upon FSC/SSC and FL. In order to enrich active yPheRS variants, 5x104 weakly 
fluorescent cells were collected by positive screening in the first round. The screened 
cells were incubated in 2xYT medium containing 200 µg/mL of ampicillin and 35 µg/mL 
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of kanamycin. When OD600 reached 1.0, glycerol stocks of the cells were prepared. 0.1 
mL of the glycerol stocks was inoculated into 20 mL of M9 minimal medium containing 
20 amino acids. In order to enrich selective yPheRS variants, the top 1% of highly-
fluorescent cells were collected. One more negative screening was applied to enrich the 
population in bright cells. The positive and negative screening steps were repeated. 
Finally, one more positive screening was performed, and the collected cells were spread 
onto a 2xYT agar plate containing 35 µg/mL of kanamycin and 200 µg/mL of ampicillin. 
After overnight incubation at 37 °C, ten single colonies were isolated and subjected to 
characterization.   
 
Characterization of the Isolated Clones.  The ten single colonies were transferred to 
0.5 L 2xYT media with 200 µg/mL ampicillin and 35 µg/mL kanamycin. When OD600 
reached 1.0, glycerol stocks were prepared and kept in a -80 °C freezer. 200 µL of each 
glycerol stock was inoculated into minimal medium and incubated until OD600 reached 
0.6. The cultures were washed twice with 0.9% NaCl solution, and resuspended with 20 
mL of minimal medium supplemented with 18 amino acids, 50 µM Trp, and 5 µM Phe. 
The resuspended cells were divided into two fractions, and transferred into two flasks. 3 
mM 2Nal was supplemented into one of them. GFP6 was expressed by addition of 1 mM 
IPTG. After 3 hrs, 1 mL of the culture was collected, and washed twice with 0.5 mL of 
PBS (pH 7.4). 100 µL of cells were diluted with 3 mL of distilled water. Fluorescence 
intensities of the cells were analyzed by a MoFlo cell sorter. At least 20,000 events were 
collected in each measurement. Data were analyzed with Summit software 
(DakoCytomation). One positive clone showing weakly fluorescence with 2Nal and 
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highly fluorescence without 2Nal was subjected to further characterization. The plasmid 
isolated from the positive clone was subjected to DNA sequencing, which revealed that a 
yPheRS variant contained four mutations (N412G, T415G, S418C, and S437F). The 
yPheRS variant and the plasmid encoding it were designated yPheRS_naph and 
pQE9_GFP6_lacI_yPheRS_naph, respectively.     
   
Amino Acid Activation Assay.  pQE32-yPheRS (T415G) was prepared previously.13 
The plasmid fragment encoding yPheRS was removed from 
pQE9_GFP6_lacI_yPheRS_naph by digestion with NsiI and BglII, and then ligated with 
a large fragment of pQE32-yPheRS (T415G) generated by digestion with NsiI and BglII 
to yield pQE32-yPheRS_naph. Expression and purification of yPheRS variants were 
described previously.13 The kinetics of activation of amino acids by yPheRS (T415G) and 
yPheRS_naph were determined by the amino acid-dependent adenosine triphosphate 
(ATP)-[32P]-pyrophosphate (PPi) exchange assay. The assay buffer included 50 mM N-(2-
hydroxethyl) piperazine-N'-(2-ethanesulfonic acid) (potassium-HEPES) (pH=7.6), 20 
mM MgCl2, 1 mM dithiothreitol (DTT), 2 mM ATP, and 2 mM [32P]- PPi. The amino acid 
concentration varied from 100 nM to 10 mM and the enzyme concentration varied from 
100 nM to 800 nM. Detail procedures of the assay were described previously.13   
 
Construction of Plasmids and Expression Hosts for Incorporation of 2Nal at Phe 
Codons. The gene fragment containing four mutations in the binding pocket of 
yPheRS_naph was excised by NsiI and BglII digestion of 
pQE9_GFP6_lacI_yPheRS_naph and inserted into pQE16_mDHFR_yPheRS (T415G) 
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and pQE9_GFP3_WC_lacI_yPheRS (T415G) between the NsiI and BglII sites to 
generate pQE16_mDHFR_yPheRS_naph and pQE9_GFP3_WC_lacI_yPheRS_naph, 
respectively. Both pQE16_mDHFR_yPheRS (T415G) and pQE16_mDHFR_yPheRS 
naph were co-transformed with pREP4_ytRNAPhe_AAA into AFW competent cells to 
generate AFW [pQE16_mDHFR_yPheRS (T415G)/pREP4_ytRNAPhe_AAA] and AFW 
[pQE16_mDHFR_yPheRS_naph/pREP4_ytRNAPhe_AAA], respectively. In order to 
express intact mDHFR, pQE16 (Qiagen) and pREP4 plasmids were co-transformed into 
AFW competent cells to generate AFW [pQE16/pREP4]. Both 
pQE9_GFP6_lacI_yPheRS_naph and pQE9_GFP3_WC_lacI_yPheRS_naph were 
transformed into DHF_AAA electrocompetent cells to construct DHF 
[pQE9_GFP6_lacI_yPheRS_naph/pREP4_ytRNAPhe_AAA] and DHF 
[pQE9_GFP3_WC_lacI_yPheRS_naph/pREP4_ytRNAPhe_AAA], respectively. In order 
to determine Phe codon occupancy by various amino acids, the AGA (Arg) codon in the 
second position of GFP6 was mutated to either a UUU or a UUC (Phe) codon by PCR 
mutagenesis. The PCR reactions were conducted with two pairs of complementary 
primers (2F_UUU_f/2F_UUU_r; 2F_UUC_f/2F_UUC_r) using 
pQE9_GFP6_lacI_yPheRS_naph as a template to generate pQE9_GFP6 
(2FUUU)_lacI_yPheRS_naph and pQE9_GFP6 (2FUUC)_lacI_yPheRS_naph, 
respectively. Removal of a lac promoter and a lac operator, and replacement of a weak 
ribosome binding site with a stronger one in the upstream of α-subunit of yPheRS gene 
were performed by two QuickChange mutagenesis reactions using two pairs of 
complementary primers (R_lacP_f/R_lacP_r and 
Ins_SD_A_Del_lacO_f/Ins_SD_A_Del_lacO_r) using (2FUUU)_lacI_yPheRS_naph and 
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pQE9_GFP6 (2FUUC)_lacI_yPheRS_naph as templates to generate pQE9_GFP6 
(2FUUU)_lacI_SD_yPheRS_naph and pQE9_GFP6 (2FUUC)_lacI_SD_yPheRS_naph. 
Both pQE9_GFP6 (2FUUU)_lacI_SD_yPheRS_naph and pQE9_GFP6 
(2FUUC)_lacI_SD_yPheRS_naph were transformed into DHF_AAA electrocompetent 
cells to construct DHF [pQE9_GFP6 
(2FUUU)_lacI_SD_yPheRS_naph/pREP4_ytRNAPhe_AAA] and DHF [pQE9_GFP6 
(2FUUC)_lacI_SD_yPheRS_naph/pREP4_ytRNAPhe_AAA]. 
 
Residue- and Site-Specific Incorporation of 2Nal into Recombinant Proteins. The 
AAA anticodon of ytRNAPheAAA was mutated into GAA by PCR mutagenesis with one 
pair of primers (ytRNA-GAA_f/ytRNA-GAA_r) using pREP4_ytRNA_AAA as a 
template.  The resulting pREP4_ytRNA_GAA plasmid contained the ytRNAPheGAA gene. 
Both pQE9_GFP6 (2FUUU)_lacI_SD_yPheRS_naph and pREP4_ytRNAPhe_GAA were 
co-transformed into DHF competent cells to generate DHF [pQE9_GFP6 
(2FUUU)_lacI_SD_yPheRS_naph/pREP4_ytRNAPhe_GAA]. pREP4_ytRNA_UG was 
prepared previously.13 The yPheRS_naph gene fragment excised by NsiI and BglII 
digestion of pQE9_GFP6_lacI_SD_yPheRS_naph was inserted into pQE16_mDHFR 
(38Am)_yPheRS (T415G) between the NsiI and BglII sites to generate pQE16_mDHFR 
(38Am)_SD_yPheRS_naph. An AAG (Lys) codon was changed to a UAG codon at 
position 158 of GFP6 sequence in pQE9_GFP6_lacI_yPheRS_naph by PCR mutagenesis 
with one pair of complementary primers (K158_UAG_f/K158_UAG_r) to yield 
pQE9_GFP6 (158Am)_lacI_SD_yPheRS_naph. Both pQE16_mDHFR 
(38Am)_yPheRS_naph and pQE9_GFP6 (158Am)_lacI_SD_yPheRS_naph were co-
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transformed with pREP4_ytRNAPhe_UG into AFWK and DHF competent cells to 
construct AFKW [pQE16_mDHFR (38Am)_yPheRS_naph/pREP4_ytRNAPhe_UG] and 
DHF [pQE9_GFP6 (158Am)_lacI_SD_yPheRS_naph/pREP4_ytRNAPhe_UG], 
respectively.      
 
Construction of Plasmids and Expression Hosts for Incorporation of 2Nal at Leu 
Codons. The AAA anticodon of ytRNAPheAAA was mutated to CAA by PCR mutagenesis 
with primers ytRNA-CAA_f and ytRNA-CAA_r using pREP4_ytRNAPhe_AAA as a 
template to yield pREP4_ytRNAPhe_CAA. The expression cassette of mDHFR was 
excised from pQE16 (Qiagen) by digestion with AatII and NheI and inserted into 
pQE9_GFP6_lacI_yPheRS_naph between the AatII and NheI sites to generate 
pQE16_mDHFR_lacI_yPheRS_naph. In order to increase the number of Leu residues 
encoded as UUG, UUC and UUU (Phe) codons in position 38 and 95 of mDHFR were 
changed to UUG by PCR mutagenesis reactions with two complementary pairs of 
primers using pQE16_mDHFR_lacI_yPheRS_naph as a template to generate 
pQE16_mDHFR2_lacI_yPheRS_naph. PCR mutagenesis reaction was performed to 
mutate UUG to UUA at position 100 of mDHFR2 with two complementary primers 
(L100_UUA_f/L100_UUA_r) to yield pQE16_mDHFR2 (100UUA)_lacI_yPheRS_naph. 
Either pQE16_mDHFR2_lacI_yPheRS_naph or pQE16_mDHFR2 
(100UUA)_lacI_yPheRS_naph was co-transformed with ytRNAPheCAA into MPC390 
competent cells to yield MP 
[pQE16_mDHFR2_lacI_yPheRS_naph/pREP4_ytRNAPhe_CAA] or [pQE16_mDHFR2 
(100UUA)_lacI_yPheRS_naph/pREP4_ytRNAPhe_CAA], respectively. In order to 
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express intact mDHFR, pQE16 (Qiagen) and pREP4 were co-transformed into MPC390 
competent cells to generate MP [pQE16/pREP4]. In order to generate GFP with C-
terminal hexa-histidine tag (GFP3C), a PstI restriction site was added to pQE70 (Qiagen) 
using two complementary primers (PstI_70_f/PstI_70_r) to yield pQE70*. The coding 
sequence for GFP3 was excised by PstI digestion from pQE9_GFP3_yPheRS (T415G) 
and inserted into pQE70* at the PstI site to generate pQE70*_GFP3C. Expression 
cassette of GFP3C isolated from pQE70*_GFP3C was inserted into 
pQE9_GFP3_lacI_yPheRS_naph to yield pQE70*_GFP3C_lacI_yPheRS_naph. Lys 158 
in GFP3C was mutated to Leu (encoded as UUG) by PCR mutagenesis with two 
complementary primers (K158_UUG_f/K158_UUG_r) using 
pQE70*_GFP3C_lacI_yPheRS_naph as a template to yield pQE70*_GFP3C 
(158UUG)_lacI_yPheRS_naph. Both pQE70*_GFP3C_lacI_yPheRS_naph and 
pQE70*_GFP3C (158UUG)_lacI_yPheRS_naph were co-transformed with 
pREP4_ytRNAPhe_CAA into MPC390 competent cells to construct MP 
[pQE70*_GFP3C_lacI_yPheRS_naph/pREP4_ytRNAPhe_CAA] and MP 
[pQE70*_GFP3C (158UUG)_lacI_yPheRS_naph/ pREP4_ytRNAPhe_CAA], respectively. 
 
Expression of mDHFR Variants and GFP Variants in Vivo. Both AFW and AFWK 
expression strains co-transformed with pQE plasmid variants and pREP4 plasmid 
variants were grown in M9 minimal medium supplemented with 0.4 wt % glucose, 35 
mg/L thiamin, 1mM MgSO4, 1mM CaCl2, 20 amino acids (at 25 mg/L), 35 mg/L 
kanamycin, and 200 mg/L ampicillin. The overnight cultures of expression strains were 
diluted 20-fold in fresh M9 minimal medium and incubated at 37 °C. When cells reached 
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OD of 0.8 - 1.0, cells were spun down and washed twice with cold 0.9% NaCl. The 
cultures were resuspended in fresh M9 minimal medium supplemented with 18 amino 
acids (25 µg/mL), and the indicated concentrations of Phe, Trp, and 2Nal. After 10 min 
incubation, 1 mM of isopropyl-β-D-thiogalactopyranoside (IPTG) was added to induce 
expression of GFP at 30 °C. After 4 hours, cells were harvested and either kept at -80 °C 
or subjected to fluorescence measurement according to the procedures described earlier 
(see Characterization of the Isolated Clones). Whole cell lysates were analyzed by SDS-
PAGE. Due to slow growth of DHF and MPC390 expression hosts co-transformed with 
pQE plasmid variants and pREP4 plasmid variants, transformants were grown in 2xYT 
medium to prepare glycerol stocks first. Then glycerol stocks were inoculated into 
minimal medium supplemented with 20 amino acids (at 25 mg/L) and incubated 
overnight at 37 °C. The remaining steps were similar to those for AF and AFWK 
expression hosts.   
 
Quantitative Analysis of Codon Occupancy. Quantitative analysis of codon occupancy 
was performed by either N-terminal protein sequencing or LC-MS analysis of tryptic 
digests. The GFP6 (2UUU) and GFP6 (UUC) variants were expressed in minimal 
medium and purified by Ni-NTA affinity chromatography according to the 
manufacturer’s protocol (Qiagen) under denaturing conditions. The purified GFP variants 
were subjected to N-terminal protein sequencing using a 492 cLC Procise protein micro-
sequencer (Applied Biosystems, Foster City, CA). Occupancy of Phe codons in mDHFR 
and Leu codons in GFP was determined by LC-MS analysis. mDHFR  expressed in 
minimal medium were subjected to purification via Ni-NTA affinity chromatography 
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according to the manufacturer’s protocol (Qiagen) under denaturing conditions. After 
purification, expression levels of GFP and mDHFR were determined by UV absorbance 
at 280 nm using a calculated extinction coefficient of 20,010 cm-1 M-1 and 24, 750 cm-1 
M-1, respectively. The purified proteins were concentrated by ultrafiltration (Millipore). 
10 µL of the concentrate was diluted into 90 µL of 75 mM (NH4)2CO3 solution and then 1 
µL of modified trypsin (Promega, 0.2 µg/µL) was added. Reaction was carried out for 2-4 
hrs at 37 °C and quenched by addition of 13 µL of 5% trifluoroacetic acid (TFA) solution. 
The solution was then directly subjected to LC-MS analysis conducted on a LCT Premier 
XE MICROMASS MS system (MS Technologies, Montgomery Village, MD) with 
Acquity UPLCTM system (Waters, Milford, MA). Tryptic digests were separated by 
Acquity BEH300 C18 column (1.7 µm, 300 Å, 2.1 x 50mm) using a gradient of 5-95% of 
solvent B (90% of acetonitrile/10% of 0.1% formic acid solution) and solvent A (2% of 
acetonitrile/98% of 0.1% formic acid solution) in 10 min. The column eluent was 
transferred to the electrospray source and mass spectra were recorded. 
 
Results and Discussion 
Misincorporation of Trp into Recombinant Proteins in Response to UUU Codons.   
mDHFR was expressed in AFW [pQE16_mDHFR_yPheRS 
(T415G)/pREP4_ytRNAPhe_AAA] expression hosts in minimal medium supplemented 
with 18 amino acids (MM18_FW), 2.5 µM Phe, 3 mM Trp. Occupancy of the UUU 
codon sites was determined by LC-MS analysis of tryptic digests of mDHFR expressed 
with or without 3 mM 2Nal. We focused on Peptide 1 (residues 140-144; LFUUUVTR), 
which contains a Phe residue at position 141 as UUU. LC-MS analysis of Peptide 1 
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variants indicated that 10% of position 141 was occupied by Trp (Figure 1b). Trp 
misincorporation at UUU site can be explained by the relaxed substrate specificity of 
yPheRS (T415G). yPheRS (T415G) showed 2-fold higher kcat/Km for Trp than for 2Nal in 
ATP-PPi exchange assays (Table 1).  
 
Construction of yPheRS Library.  In order to enhance the specificity of yPheRS with 
respect to 2Nal, we explored high-throughput screening of a yPheRS library. On the basis 
of the crystal structure of the homologous PheRS (tPheRS) from Thermus thermophilus47 
and sequence alignment between tPheRS and yPheRS, four residues (N412, S418, T415, 
and S437) within 7 Å of the para position of the phenyl ring of Phe bound to yPheRS 
were subjected to saturation mutagenesis (Figure 2). PCR mutagenesis generated 6x106 
yPheRS transformants (see Materials and Methods), a population somewhat larger than 
the theoretical library size (106). By transforming yPheRS library plasmids into DHF 
expression hosts, 1x107 transformants were obtained and pooled to construct the yPheRS 
expression library.       
    
High-throughput Screening of yPheRS Library.  Screening of the yPheRS library 
entailed both positive and negative screenings to obtain active and selective yPheRS 
variants, respectively. Active synthetases would allow incorporation of either 2Nal or 
natural amino acids at non-permissive sites of GFP6, where amino acids other than Phe 
would lead to reduction in the fluorescence of cells. Our preliminary study showed that 
misincorporation of 2Nal at 12 Phe sites of GFP6 resulted in more than 20-fold reduction 
in fluorescence of cells, likely due to the perturbed folded structure of GFP6 (data not 
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shown). For positive screening, the yPheRS library was induced with 1 mM IPTG to 
express GFP6 in minimal medium supplemented with 3 mM 2Nal. The fluorescence 
histogram of yPheRS library cells expressing GFP6 was obtained by flow cytometry. The 
gate in the fluorescence channel was set to collect 1% of cells for which fluorescence was 
slightly above background. The 5x104 cells collected were regrown in 2xYT medium and 
subjected to negative screening to enrich cells containing selective yPheRS variants. The 
negative screening was based on the fact that synthetases selective for 2Nal should not 
misincorporate any natural amino acid at Phe sites in GFP6 but E. coli endogenous Phe 
orthogonal pair will incorporate Phe at the Phe sites. The resulting GFP6 would retain full 
intensity of fluorescence. For negative screening, GFP6 was expressed in minimal 
medium in the absence of 2Nal. The top 1% of cells in the fluorescence channel was 
collected to obtain 5x104 cells. The collected cells were regrown in 2xYT medium and 
entered a next round of screening. After two rounds of positive and negative screening, 
one more positive screening was carried out to enrich active yPheRS variants toward 
2Nal. A portion of the collected cells were spread on agar plates containing suitable 
antibiotics and ten colonies were subjected to further characterization.   
 
Characterization of the Selective yPheRS Variant.  One out of ten clones showed the 
fluorescence characteristics expected of a selective yPheRS variant. The other clones 
were false positives that have two peaks coincidently overlapped with the gates for 
sorting in the histogram of fluorescence. In the absence of 2Nal, cells expressing GFP6 
retained full intensity of fluorescence (Figure 4a). However, in the presence of 2Nal, cells 
expressing GFP6 showed substantially reduced intensity of fluorescence (Figure 4b). 
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Similar trends were observed in the visual comparison of fluorescence of cell pellets 
(Figure 4c). The plasmid DNA coding the selective yPheRS variant was isolated from the 
culture of the clone and subjected to further analysis. DNA sequencing analysis of the 
plasmid showed that there were mutations of all four positions (N412G, T415G, S418C, 
and S437F) in the binding pocket of yPheRS. The isolated yPheRS variant was 
designated yPheRS_naph .  
 
Amino Acid Activation Analysis by yPheRS_naph.  Activation of Phe, Trp and 2Nal 
by both yPheRS (T415G) and yPheRS_naph were examined in vitro. The kinetic 
parameters are listed in Table 1. yPheRS (T415G) showed 2-fold lower activity toward 
2Nal than Trp. However, the yPheRS_naph showed 6-fold higher activity toward 2Nal 
than Trp, which translates into 12-fold enhanced selectivity toward 2Nal (vs. Trp) 
compared to yPheRS (T415G). The yPheRS_naph also showed 17-fold higher activity 
toward 2Nal than Phe, while yPheRS (T415G) showed 8.4-fold higher activity. 
Previously we reported that rationally designed yPheRS (T415A) showed 10-fold higher 
activity toward pBrF than Trp. However, the activation of Phe by yPheRS (T415A) was 
comparable to that of pBrF. Therefore, yPheRS_naph is the first yPheRS variant that 
efficiently discriminates a nonnatural amino acid from all twenty natural amino acids. 
The poor binding of Phe and Trp by yPheRS_naph may be understood by loss of 
favorable interactions between the aromatic rings of the substrate and active-site residues 
of the synthetase. In a crystal structure of tPheRS,47 the side chain of Phe 258 (which 
corresponds to Asn 412 in yPheRS) makes direct contact with the phenyl ring of the 
substrate. Since the interaction makes the substrate recognition highly specific and very 
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favorable energetically, we can readily assume that N412G mutation in yPheRS would 
lead to poor binding of aromatic amino acid by the PheRS. However, the S418C mutation 
may not be critical to substrate specificity for 2Nal, because the yPheRS variant 
containing only three mutations (N412G, T415G and S437F) showed activity toward 
2Nal similar to that of yPheRS_naph in ATP-PPi exchange assays. Analysis of 
fluorescence changes upon incorporation of 2Nal revealed that omission of the S437F 
mutation leads to a loss of activity toward 2Nal (data not shown). Therefore, S437F 
mutation was thought to play a key role in discriminating 2Nal from both Phe and Trp.  
 
Elimination of Trp Misincorporation at UUU Codons by yPheRS_naph in Vivo.  
AFW [pQE16_mDHFR_yPheRS_naph/pREP4_ytRNAPhe_AAA] cells were induced to 
express mDHFR in MM18_FW medium supplemented with 2.5 µM Phe, 50 µM Trp and 
3 mM 2Nal. Peptide 1 (residues 140-144; LFUUUVTR), one of the tryptic fragments of 
purified mDHFR, contains a Phe residue encoded as UUU. Occupancy of the UUU site in 
Peptide 1 was investigated by LC-MS analysis. The results revealed that use of 
yPheRS_naph completely eliminated misincorporation of Trp at the UUU site (Figure 1c), 
while yPheRS (T415G) allowed misincorporation of Trp at the UUU site (Figure 1b). 
Similar results were obtained by N-terminal sequencing of purified intact GFP6 (2UUU). 
DHF [pQE9_GFP6_lacI_yPheRS_naph/pREP4_ytRNAPhe_AAA] cells were induced to 
express GFP6 (2UUU) in MM18_FW medium supplemented with 50 µM Trp and 3 mM 
2Nal. 80% and 20% of the UUU codon at the 2nd position of GFP6 (UUU) were decoded 
as 2Nal and Phe, respectively; but Trp was not detected at this position (Table 2).  
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Residue- and Single-Site-Specific Incorporation of 2Nal in Vivo. With an appropriate 
tRNA, the selective yPheRS_naph variant can be used for residue- and single-site-
specific incorporation of 2Nal into proteins. In order to realize residue-specific 
incorporation of 2Nal, DHF [pQE9_GFP6 
(2UUU)_lacI_yPheRS_naph/pREP4_ytRNAPhe_GAA] expression hosts were induced to 
express GFP6 (2UUU) in MM18_FW medium supplemented with 50 µM Trp and 3 mM 
2Nal. N-terminal sequencing of the purified GFP6 (2UUU) showed that 92% of position 
2 was occupied by 2Nal (Table 2), slightly higher than the 80% occupancy achieved by 
multiple-site-specific incorporation. The enhanced 2Nal incorporation may be a 
consequence of the known 12-fold higher aminoacylation rate for ytRNAPheGAA by 
yPheRS as compared to ytRNAPheAAA.48 Single-site-specific incorporation of 2Nal into 
mDHFR_38Am was achieved by AFWK 
[pQE16_mDHFR_yPheRS_naph/pREP4_ytRNAPhe_UG] in miminal medium 
supplemented with 25 µg/mL 17 amino acids (MM17_FWK), 50 µM Phe, 50 µM Trp, 50 
µM Lys, and 3 mM 2Nal. MALDI-MS analysis of tryptic digests of mDHFR_38Am 
revealed that 2Nal was dominant at the amber site. Neither Trp nor Phe was detected, 
confirming the high selectivity of yPheRS_naph toward 2Nal.           
 
Single-Site-Specific Incorporation of 2Nal into GFP in Vivo. Single-site-specific 
incorporation of 2Nal into GFP6 was investigated to determine whether a correctly folded 
fluorescent protein can be obtained upon the addition of a nonnatural amino acid. An 
AAG (Lys) codon was changed to an amber codon in position 158 in GFP6, which is 
known to be permissive to replacement of Lys with other natural amino acids or to 
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circular permutation.49 DHF [pQE9_GFP6 
(158Am)_lacI_yPheRS_naph/pREP4_ytRNAPhe_ UG] cells were used to express GFP6 
(158Am) in MM17_FWK medium supplemented with 50 µM Phe, 50 µM Trp, 50 µM 
Lys, and 3 mM 2Nal. The fluorescence of cells expressing full length of GFP6 (158Am) 
was 280-fold higher than that in uninduced conditions, which clearly indicated that 2Nal 
can be inserted into GFP6 without substantial reduction of fluorescence.       
 
Misincorporation of 2Nal at Unwanted Sites (UUC Codons) in Vivo.  Site-specific 
incorporation involves introduction of a nonnatural amino acid into a target protein only 
at programmed sites. Introduction of a nonnatural amino acid at unwanted site will 
diminish its advantages over the residue-specific incorporation method. Although AFW 
[pQE16_mDHFR_yPheRS (T415G)/pREP4_ytRNAPhe_AAA] realized incorporation of 
2Nal at programmed UUU codons in mDHFR (Figure 1c), misincorporation of 2Nal at 
UUC codons was also observed (Figure 1f). Similar results were observed in two GFP 
variants, GFP6 (2UUU) and GFP6 (2UUC), expressed in DHF [pQE9_GFP6 
(2UUC)_lacI_yPheRS_naph/pREP4_ytRNAPhe_AAA] and [pQE9_GFP6 
(2UUU)_lacI_yPheRS/pREP4_ytRNAPhe_AAA], respectively. Supplementation of 2.5 
µM; 5 µM Phe into expression medium lowered 2Nal misincorporation at the unwanted 
sites (UUC codons) from 34% to 20%; 6%. However, the incorporation level of 2Nal at 
the programmed sites (UUU codons) also decreased from 80% to 62%; 47% (Figure 6). 
Incorporation of 2Nal at UUC sites in GFP6 (ca. 20%) with supplementation of 2.5 µM 
Phe is higher than that in mDHFR (ca. 10%) (Figure 1f), which might be explained by 
more stable characteristics of GFP6 containing 2Nal as compared to mDHFR. Even 6% 
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of misincorporation of 2Nal at unwanted sites in a target protein could be unfavorable for 
the target protein to retain its native properties. As a test case, 2Nal misincorporation into 
GFP6_WC, which contains 12 unwanted sites, led to 10-fold reduction in the 
fluorescence of cells (Figure 8).  
We reasoned that misincorporation of 2Nal at UUC codon resulted from 
recognition of UUC codons by the AAA anticodon of ytRNAPheAAA. According to Crick’s 
wobble rule proposed in 1966,31 A in the first position of the anticodon can recognize 
only U in the third position of the codon. Therefore, UUC codon should not be 
recognized by the AAA anticodon. The discrepancy between the experimental results and 
Crick’s wobble rule may be explained by the expanded wobble rule proposed by Lim and 
Curran in 2001.32 According to the expanded wobble rule, A in the first position of the 
anticodon can recognize all four bases in the third position in codon. The base A in the 
first position of the anticodon favors bases in the order U > C > G > A, consistent with 
the codon-biased incorporation of 2Nal observed in this work.                 
 
Breaking the Degeneracy of the Leucine Codons.  According to the expanded wobble 
rules, C in the first position of the anticodon will recognize only G in the third position of 
the codon. Therefore, we hypothesized that ytRNAPheCAA (containing the modified CAA 
anticodon) would selectively recognize UUG codons. In order to test this hypothesis, 
mDHFR was expressed in MP 
[pQE16_mDHFR2_lacI_yPheRS_naph/pREP4_ytRNAPhe_CAA] cells. mDHFR contains 
twenty Leu codons, of which are six UUG, two UUA and twelve CUN (N = A/T/G/C). 
The expression level of mDHFR was 2.9 mg/L. Occupancy of each Leu codon by various 
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amino acids was determined by LC-MS analysis of tryptic digests of mDHFR expressed 
with and without 2Nal. We focused on four peptides. Peptide 3 (residues 165-180; 
LCUULCUCPEYPGVLCUCSEVQEEK) contains three Leu residues, encoded as CUU and 
CUC codons. Peptide 4 (residues 54-61; QNLCUGVIMGR) contains a Leu residue, 
encoded as a CUG codon. Peptide 5 (residues 62-70; LCUUIEQPELUUGASK) contains two 
Leu residues, encoded as CUU and UUG codons. Peptide 6 (residues 99-105; 
SLUUGDDALUUAR) contains two Leu residues, encoded as UUG and UUA codons. 2Nal 
was not detected at any CUN codon in Peptide 3 and 4 (Figure 8a-d). However, 50% of 
UUG codons in Peptide 5 and 6 were occupied by 2Nal (Figure 8e-h). In order to 
determine UUA codon occupancy by 2Nal, Peptide 6UUA was tested. Peptide 6UUA is the 
same as Peptide 6 except both Leu residues are encoded as UUA codons. Since the 
Peptide 6UUA variant containing 2Nal was not detected, we conclude that 2Nal 
incorporation is highly specific to the UUG codon.   
 
UUG Codon-Specific Incorporation of 2Nal. Previously we showed that 
misincorporation of 2Nal at unwanted UUC codons in GFP6_WC led to 10-fold 
reduction in fluorescence of cells, even though there are no UUU codons in GFP6_WC. 
Similar to GFP6_WC, we prepared GFP3 containing twenty three Leu codons, of which 
are no UUG, four UUA and nineteen CUN (N = A/T/G/C). In order to investigate effect 
of misincorporation of 2Nal at unwanted sites (Leu codons other than UUG), GFP3 was 
expressed in E. coli strain MP 
[pQE9_GFP3_lacI_yPheRS_naph/pREP4_ytRNAPhe_CAA]. The fluorescence intensities 
of cells expressing GFP3 without 2Nal or with 2Nal were compared (Figure 7c and d). 
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There was no detectable difference in the fluorescence of cells prepared under these two 
conditions, confirming the absence of misincorporation of 2Nal at Leu codons other than 
UUG.  
 
Minimal Perturbation of Native Properties of GFP upon Incorporation of 2Nal.  
Ideally introduction of a nonnatural amino acid should impart new properties to a target 
protein with minimal or no perturbation of native properties. As a test case, we chose 
fluorescence change of GFP variant upon 2Nal incorporation to evaluate perturbation of 
GFP structure. A UUG codon, an incorporation site for 2Nal, was introduced at the 158th 
position of GFP3 to generate GFP3 (158UUG) variant.  GFP3 (158UUG) variant was 
expressed in minimal medium supplemented with 17 amino acids (25 µg/mL), 50 µM 
Phe, 50 µM Trp, 1.25 µM Leu, and indicated concentration of 2Nal. There was no 
significant differences in fluorescence histograms of cells expressing GFP3 (158UUG) in 
the absence and presence of 2Nal, which meant that GFP3 (158UUG) retained its folded 
structure even upon 2Nal incorporation at the 158th position.    
  
Conclusions 
In this chapter, we have shown that the substrate specificity of yPheRS was 
altered to selectively recognize a nonnatural amino acid, 2Nal. As far as we know, this is 
the first report of high-throughput screening of a eukaryotic aminoacyl-tRNA synthetase 
library to obtain synthetase variants selective toward nonnatural amino acids. Use of the 
selective yPheRS_naph variant resulted in elimination of misincorporation of Trp at UUU 
codons, which was detected previously in experiments with yPheRS (T415G). Combined 
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use of yPheRS_naph and ytRNAPheCUA_UG realized high fidelity (ca. 98%) incorporation 
of 2Nal into proteins in response to an amber codon.  
Misincorporation of 2Nal at unwanted sites resulting from the relaxed codon 
recognition of the AAA anticodon of ytRNAPhe has been overcome by use of the more 
codon selective ytRNAPheCAA. The CAA anticodon of ytRNAPheCAA completely 
discriminates UUU codons from other five Leu codons. When both yPheRS_naph and 
ytRNAPheCAA were overexpressed in E. coli expression hosts, 50% of UUG codon sites 
were occupied by 2Nal, but no other Leu codon sites were occupied by 2Nal. Combined 
use of yPheRS_naph and the codon selective ytRNAPheCAA has realized multiple-site-
specific incorporation of 2Nal into proteins. We are working to improve the level of 
incorporation of 2Nal at programmed UUG sites   
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Figure 1: LC-MS chromatogram of tryptic digests of mDHFR. Peptide 1 (residues 140-
144; LFUUUVTR) contains a Phe residue encoded as UUU. Peptide 2 (residues 63-70; 
TWFUUCSIPEK) contains a Phe residue encoded as UUC codon. Peptide 1 variants 
containing Phe, Trp, and 2Nal were designated 1F, 1W, and 1Z, respectively. Peptide 2 
variants containing Phe and 2Nal were designated 2F and 2Z, respectively. These 
peptides were separated by LC and detected by MS. Unmodified mDHFR was 
synthesized in a Phe/Trp auxotrophic expression host (a and d) in 2xYT media. Modified 
mDHFRs were synthesized in a Phe/Trp auxotrophic expression host outfitted with 
ytRNAPheAAA and yPheRS (T415G) (b and e) or yPheRS_naph (c and f). The minimal 
expression media were supplemented with 18 amino acids (25 µg/mL), 2.5 µM Phe, 3 
mM Trp, and 3 mM 2Nal.    
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Figure 2: Phe substrate (red) and four residues (blue) within 7 Å of the para-position of 
the phenyl ring of the substrate inside the binding pocket of a homology model of 
yPheRS. These four residues were subjected to mutagenesis to generate a yPheRS library. 
The homology model of yPheRS was prepared by P. M. Kekenes-Huskey at Caltech. 
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Figure 3: A screening scheme for yPheRS library. GFP6 in yPheRS expression library E. 
coli cells outfitted with ytRNAPheAAA and yPheRS library was expressed in the presence 
of 2Nal (a). Weakly fluorescent cells that contain active yPheRS variants were enriched 
by FACS (b). GFP6 in the collected cells was expressed in the absence of 2Nal (c). 
Highly fluorescent cells that contain selective yPheRS variants were enriched by FACS 
(d). After two rounds of screening, ten colonies were isolated from the enriched cells and 
characterized (e). 
GFP expression 
without 2Nal 
cell sorting 
by FACS 
Characterization of the isolated cells 
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Figure 4: Fluorescence intensities of cells containing GFP6 expressed in minimal 
medium without 2Nal (a); with 2Nal (b). Visual comparison of fluorescence of cells 
containing GFP6 expressed in the absence of 2Nal (c left); in the presence of 2Nal (c 
right). 
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Figure 5: Fluorescence intensities of cells under uninduced conditions (a); cells 
expressing full length GFP6 (158Am) in the presence of 2Nal (b). The DHF E. coli 
strains were outfitted with ytRNAPheCUA_UG and yPheRS_naph. The expression media 
were supplemented with 18 amino acids (25 µg/mL), 50 µM Phe, 50 µM Trp, and 3 mM 
2Nal.    
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Figure 6: UUC and UUU codon occupancy by Phe and 2Nal. Both GFP6 (2UUC) and 
GFP6 (2UUU) were expressed in DHF expression hosts outfitted with yPheRS_naph and 
ytRNAPheAAA in minimal medium supplemented with 18 amino acids (25 µg/mL), 50 µM 
Trp, 3 mM 2Nal, and 0; 2.5 µM; 5.0 µM Phe. The UUC (a) and UUU (b) codon 
occupancy by Phe and 2Nal were determined by N-terminal sequencing.   
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Figure 7: Fluorescence intensities of cells expressing GFP variants. GFP3_WC was 
expressed in DHF expression hosts outfitted with yPheRS_naph and ytRNAPheAAA in 
minimal medium supplemented with 18 amino acids, 5.0 µM Phe, 50 µM Trp, and no 
2Nal (a); 3 mM 2Nal (b). GFP3 was expressed in MPC390 expression hosts outfitted 
with yPheRS_naph and ytRNAPheCAA in minimal medium supplemented with 17 amino 
acids, 1.25 µM Leu, 5.0 µM Phe, 50 µM Trp, and no 2Nal (c); 3 mM 2Nal (d).  
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Figure 8: LC-MS chromatogram of tryptic digests of mDHFR. Peptide 3 (residues 165-
180; LCUULCUCPEYPGVLCUCSEVQEEK) contains three Leu residues encoded as CUU 
and CUC codons. Peptide 4 (residues 54-61; QNLCUGVIMGR) contains a Leu residue 
encoded as CUG codon. Peptide 5 (residues 62-70; LCUUIEQPELUUGASK) contains two 
Leu residues encoded as CUU and UUG codons. Peptide 6 (residues 99-105; 
SLUUGDDALUUAR) contains two Leu residues encoded as UUG and UUA codons. 
Peptide 6UUA is the same as Peptide 6 except both Leu residues are encoded as UUA 
codon. Peptide 3; 4; 5; 6; 6UUA variants containing Leu and 2Nal were designated 3L and 
3Z; 4L and 4Z; 5L and 5Z; 6L and 6Z; 6UUAL and 6UUAZ, respectively. These peptides 
were separated by LC and detected by MS. Unmodified mDHFR was synthesized in the 
absence of 2Nal in a Phe/Leu auxotrophic expression host (a, c, e, and g) in 2xYT media. 
Modified mDHFRs were synthesized in a Phe/Leu auxotrophic expression host outfitted 
with ytRNAPheCAA and yPheRS_naph (b, d, f, h and i). The expression minimal media 
were supplemented with 17 amino acids (25 µg/mL), 1.25 µM Leu, 50 µM Phe, 50 µM 
Trp, and 3 mM 2Nal. No 3Z, 4Z, or 6UUAZ was detected by LC-MS analysis.   
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Figure 9: Fluorescence intensities of cells containing GFP3 (158UUG) expressed in 
minimal medium supplemented with 17 amino acids (25 µg/mL), 1.25 µM Leu, 5.0 µM 
Phe, and 50 µM Trp without 2Nal (a); with 3 mM 2Nal (b). MPC390 expression hosts 
were outfitted with yPheRS_naph and ytRNAPheCAA.     
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Table 1:  Kinetic parameters for ATP-PPi exchange by yPheRS (T415G) and 
yPheRS_naph   
 
a Relative to kcat/Km for Phe by yPheRS (T415G). 
b Relative to kcat/Km for Phe by yPheRS_naph. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amino 
Acid Enzyme Km (µM) kcat (s
-1) kcat/Km  (M-1s-1) kcat/Km (rel)
Phe T415G 55 ± 14 0.202 ± 0.11 3,500 ± 1,100 1a 
Trp T415G 2.83 ± 1.6 0.153 ± 0.003 63,200 ± 34,600 18a 
2Nal T415G 7.03 ± 0.14  0.208 ± 0.04 29,500 ± 5,800 8.4a 
Phe naph 11,000 ± 2,700 0.0095 ± 0.0021 0.855 ± 0.007 1b 
Trp naph 1,400 ± 600 0.0035 ± 0.0009 2.52 ± 0.44 2.9b 
2Nal naph 2,000 ± 700 0.030 ± 0.018 14.54 ± 4.22 17b 
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Table 2: Occupancy of UUU and UAG codons by various amino acids 
 
a The second position in the amino acid sequence of GFP6.  
b UUU and UAG codon occupancy was determined by N-terminal protein sequencing and 
LC-MS analysis, respectively.  
c Not detected. 
d The 38th position in the amino acid sequence of mDHFR_38Am.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Occupancy of codon (%)b Codon ytRNA 
2Nal Phe Lys 
UUUa ytRNAPheAAA 80 20 NDc 
UUU ytRNAPheGAA 92 8 ND 
UAGd ytRNAPheCUA_UG 98 ND 2 
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Appendix A   
Plasmid Information 
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Following are sequences and information on plasmids described in the thesis. 
 
1. pQE16_mDHFR_yPheRS (T415G)  (7765 bp) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T5 promoter and lac operon 7  -  87 bp 
 
mDHFR_His   115  -  660 bp 
 
yPheRS_alpha subunit 1226  -  2787 bp 
 
yPheRS_beta subunit  2802  -  4589 bp 
 
ColE1 origin   5972  -  5997 bp 
 
beta-lactamase  7560  -  6700 bp 
 
 
Full sequence     
 
CTC GAG AAA TCA TAA AAA ATT TAT TTG CTT TGT GAG CGG ATA ACA ATT ATA ATA 
GAT TCA ATT GTG AGC GGA TAA CAA TTT CAC ACA GAA TTC ATT AAA GAG GAG AAA 
TTA ACT ATG AGA GGA TCC GGC ATC ATG GTT CGA CCA TTG AAC TCG ATC GTC GCC 
GTG TCC CAA AAT ATG GGG ATT GGC AAG AAC GGA GAC CTA CCC TGG CCT CCG CTC 
AGG AAC GAG TTC AAG TAC TTC CAA AGA ATG ACC ACA ACC TCT TCA GTG GAA GGT 
AAA CAG AAT CTG GTG ATT ATG GGT AGG AAA ACC TGG TTC TCC ATT CCT GAG AAG 
AAT CGA CCT TTA AAG GAC AGA ATT AAT ATA GTT CTC AGT AGA GAA CTC AAA GAA 
191 
CCA CCA CGA GGA GCT CAT TTT CTT GCC AAA AGT TTG GAT GAT GCC TTA AGA CTT 
ATT GAA CAA CCG GAA TTG GCA AGT AAA GTA GAC ATG GTT TGG ATA GTC GGA GGC 
AGT TCT GTT TAC CAG GAA GCC ATG AAT CAA CCA GGC CAC CTT AGA CTC TTT GTG 
ACA AGG ATC ATG CAG GAA TTT GAA AGT GAC ACG TTT TTC CCA GAA ATT GAT TTG 
GGG AAA TAT AAA CTT CTC CCA GAA TAC CCA GGC GTC CTC TCT GAG GTC CAG GAG 
GAA AAA GGC ATC AAG TAT AAG TTT GAA GTC TAC GAG AAG AAA GGT TCC AGA TCT 
CAT CAC CAT CAC CAT CAC TAA GCT TAA TTA GCT GAG CTT GGA CTC CTG TTG ATA 
GAT CCA GTA ATG ACC TCA GAA CTC CAT CTG GAT TTG TTC AGA ACG CTC GGT TGC 
CGC CGG GCG TTT TTT ATT GGT GAG AAT CCA AGC TAG CTT GGC GAG ATT TTC AGG 
AGC TAA GGA AGC TAA AAT GGA GAA AAA AAT CAC TGG ATA TAC CAC CGT TGA TAT 
ATC CCA ATG GCA TCG TAA AGA ACA TTT TGA GGC ATT TCA GTC AGT TGC TCA ATG 
TAC CTA TAA CCA GAC CGT TCA GCT GGC ACG ACA GGT TTC CCG ACT GGA AAG CGG 
GCA GTG AGC GCA ACG CAA TTA ATG TGA GTT AGC TCA CTC ATT AGG CAC CCC AGG 
CTT TAC ACT TTA TGC TTC CGG CTC GTA TGT TGT GTG GAA TTG TGA GCG GAT AAC 
AAT TTC ACA CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA AGC TTG CAT GCC TGC 
AGT TGA CAA TTA ATC ATC GGC TCG TAT AAT GGA TCC AAT TGT GAG CGG AAT CGA 
TTT TCA CAC AGG AAA CAG ACC ATG AAT CTA GAG ATG TCT GAC TTC CAA TTA GAA 
ATT CTA AAG AAA CTA GAT GAA TTG GAT GAG ATC AAG TCC ACA CTG GCA ACT TTC 
CCT CAG CAC GGC TCT CAA GAT GTT CTT TCC GCT TTG AAC TCT TTG AAA GCC CAC 
AAC AAG TTA GAG TTT TCC AAG GTC GAC ACG GTT ACG TAT GAC TTG ACC AAA GAA 
GGT GCT CAA ATT TTG AAT GAA GGT TCG TAC GAA ATT AAA CTA GTC AAG CTC ATC 
CAA GAG TTG GGT CAA CTT CAA ATC AAA GAT GTG ATG TCC AAA CTA GGC CCT CAA 
GTT GGT AAG GTC GGT CAG GCT AGA GCT TTC AAG AAC GGC TGG ATC GCC AAA AAC 
GCC TCA AAC GAG CTT GAA CTC TCC GCA AAA TTG CAA AAT ACC GAT TTA AAT GAG 
CTT ACT GAT GAA ACG CAA TCT ATT CTA GCG CAA ATC AAG AAC AAC TCG CAT CTG 
GAT AGC ATT GAC GCC AAG ATT TTG AAC GAC TTG AAG AAA AGA AAG TTA ATT GCT 
CAA GGT AAA ATC ACA GAT TTC AGT GTC ACC AAA GGG CCA GAG TTC TCG ACC GAC 
CTC ACC AAA TTG GAA ACC GAT CTT ACC TCC GAC ATG GTC TCC ACC AAT GCA TAC 
AAG GAC TTG AAG TTC AAG CCT TAC AAT TTC AAT TCT CAA GGT GTG CAA ATA TCT 
TCA GGT GCT CTT CAC CCC TTA AAC AAA GTC AGA GAG GAA TTT AGA CAA ATT TTC 
TTT TCC ATG GGA TTC ACA GAG ATG CCC TCG AAC CAA TAC GTC GAG ACA GGT TTC 
TGG AAC TTC GAT GCC CTT TAC GTC CCA CAA CAG CAT CCT GCT CGT GAC CTG CAA 
GAC ACT TTC TAC ATC AAG GAC CCA CTA ACC GCT GAG TTG CCC GAT GAC AAG ACA 
TAC ATG GAC AAT ATC AAA GCC GTT CAC GAA CAG GGG AGA TTC GGG TCC ATC GGT 
TAT CGT TAC AAC TGG AAG CCA GAA GAA TGT CAA AAA TTG GTC TTG AGA ACT CAC 
TCC ACA GCC ATC TCT GCC AGA ATG CTG CAC GAT TTG GCC AAA GAT CCA AAG CCC 
ACC AGA TTG TTT TCT ATC GAC CGT GTT TTC CGT AAC GAA GCA GTT GAC GCC ACC 
CAT TTG GCC GAA TTC CAC CAG GTG GAA GGT GTT CTT GCC GAC TAC AAC ATT ACT 
CTG GGT GAC CTG ATC AAG TTC ATG GAA GAG TTT TTC GAA AGA ATG GGT GTC ACC 
GGT TTG AGA TTC AAG CCT ACC TAC AAT CCT TAC GGC GAG CCA TCA ATG GAA ATC 
TTT TCT TGG CAC GAA GGT TTG CAA AAA TGG GTC GAA ATC GGT AAC TCT GGT ATG 
TTC AGA CCA GAA ATG CTC GAG TCC ATG GGT CTA CCA AAG GAT CTA AGA GTC CTT 
GGT TGG GGG TTA TCC TTG GAA AGA CCT ACC ATG ATC AAA TAT AAG GTT CAA AAC 
ATC AGA GAA CTG TTA GGT CAT AAA GTC TCT TTG GAC TTT ATC GAA ACC AAT CCT 
GCT GCT AGA TTG GAC GAA GAC TTG TAC GAA TAA GGC AGG AAT AGA TTA TGC CTA 
CCG TCT CCG TGA ACA AGC AGC AAT TAT TTG ATC TTC TAG GCA AAG ACT ACA CTT 
CCC AAG AGT TCG ACG AAT TAT GTT TTG AAT TCG GTA TGG AAA TGG ACG AAG ACA 
CCA CAG AAG AGG CCT TGA AAA CCG GGG AGG AGC CGG AAT TGA AGC TTG ATA TCA 
GTG CCA ATC GTT ACG ATT TGC TTT GTA TCG AAG GTA TTT CAC AGT CGC TGA ACG 
AAT ACT TGG AAC GTA AAG AAA GAC CTG ACT ATA AAT TAA GCA AGC CAA CCA CTA 
AGT TGA TCA TCG ACA AAT CAA CGG AGC AAA TTA GAC CTT TTG CTA CCG CTG CTG 
TAT TGA GAA ATA TCA AGC TTA ACG AAA AAT CTT ACG CTT CTT TTA TTG CCT TGC 
AAG ATA AAT TAC ATG CCA ATC TAT GTA GAA ACA GAA GCT TGG TTG CCA TGG GTA 
CTC ACG ATT TAG ATT CAA TTG AAG GTC CAT TCC ATT ACA GAG CTC TAC CAC CAA 
AGG ACA TCA AGT TCG TAC CAT TGA ATC AAA CCC AAG AGT TTA CTG GTG ACA AAT 
TGA TCG AGT TTT ATA AAT CTC CAG AAC AGA AAA ACA ACA TAG GGA GAT ACG TTC 
ACA TTA TTG AGG ATT CTC CAG TCT TCC CAG TTA TTA TGG ACA GCA AAG ATC GTG 
192 
TTT GCT CCC TGC CAC CAT TAA TCA ATA GTG AAC ATT CGA AGA TCT CTG TGA ACA 
CCC GTA ACA TTT TGA TTG ATA TAA CCG CCA CCG ATA AGA CCA AAG CCG AGA TCG 
TTT TGA ACA TAT TAA CTA CAA TGT TCT CAC GTT ATT GTG ACG AAC CAT TCA CGG 
TTG AGC CTG TAG AAA TTG TCT CTG AAC ACA ATG GCC AAT CCC GTT TGG CGC CAA 
ACT TCA ACG ATA GAA TTA TGG ATG TCT CCA TTA AGT ACA TCA ACT CCT GTC TTG 
GCC TAG ATC AAT CCG CTG ATG AAA TTG CTC ATT GTC TAA AAA AGA TGT CGT TGC 
ATG CCG TTC AAT CAA AGG AAG ACA AGG ACA TCT TGC ACG TTG ACA TTC CGG TAA 
CTA GAC CTG ATA TTT TGC ACG CTT GTG ATA TAA TGG AAG ATG CCG CTG TCG GTT 
ATG GTT TCA ATA ATT TGC CAA AGG GTG AGA AAT TAT CCA ATG CCA ACT TCA TTG 
CCA AAC CAT TAC CAA TCA ACA AGG TTT CTG ATA TTT TCA GAG TTG CAT CCT CTC 
AAG CCA CGT GGG TTG AGG TTT TAC CAT TGA CCT TAT GTT CGC ACG ATG AAA ACT 
TTA AAT TTC TAA GAC AAT CCG ACA ATG ATG ATT TAG CTG TCA AAT TGG CCA ACC 
CAA AGA CTT TGG AAT ACC AAG TTG TTA GAA CCA CTT TAT TGC CTG GTA TCT TAA 
AGA CAG TCA AGG AAA ACA GAA AAC ATT CCT TAC CAA TCA AAG TCT TTG AAA CCG 
GTG ACG TTG TAT TTA AAG ACG ACA AAC TAG AAA GGA AGG CGT ACA ATG AAC GTC 
ACT GGG CTG CCA TCT ACG TGG GTA AGA ATT CTG GGT TTG AAA TCA TTC AAG GGT 
TAT TGG GTA AAA TCA TGC AAA CTT TTA GAA CAG AGT GGA TTG CAG ACT ACG GTG 
CTG CTG CTT CTG GCA GAG GTT ACT GGA TTG AAG AAG ACG ATT CTG TGA AAA CCT 
ATT TCC CAG GTA GAG GTG CCA AGG TCA TGT TCA GAT CCA AAG AAG GCG CTG AGC 
CAA AGC AAA TCG GCC ACT TGG GTG TCT TGC ATC CTG AAG TCA TGA TGA ATT TCG 
ACG TTC CAT TCG CTG CAT CCT TTG TAG AGG TTA ATG CCG AAG TCT TCC TAT AAT 
GTA ATG TTC TAA CAA AAA TTT TTA CTG ATT TAT AAA ACT TAT ATA GAT AGA TAG 
ACA TAT ATA TAT GGG TAC CGA GCT CGA ATT CAC TGG CCG TCG TTT TAC AAC GTC 
GTG ACT GGG AAA ACC CTG GCG TTA CCC AAC TTA ATC GCC TTG CAG CAC ATC CCC 
CTT TCG CCA GCT GGA TAT TAC GGC CTT TTT AAA GAC CGT AAA GAA AAA TAA GCA 
CAA GTT TTA TCC GGC CTT TAT TCA CAT TCT TGC CCG CCT GAT GAA TGC TCA TCC 
GGA ATT TCG TAT GGC AAT GAA AGA CGG TGA GCT GGT GAT ATG GGA TAG TGT TCA 
CCC TTG TTA CAC CGT TTT CCA TGA GCA AAC TGA AAC GTT TTC ATC GCT CTG GAG 
TGA ATA CCA CGA CGA TTT CCG GCA GTT TCT ACA CAT ATA TTC GCA AGA TGT GGC 
GTG TTA CGG TGA AAA CCT GGC CTA TTT CCC TAA AGG GTT TAT TGA GAA TAT GTT 
TTT CGT CTC AGC CAA TCC CTG GGT GAG TTT CAC CAG TTT TGA TTT AAA CGT GGC 
CAA TAT GGA CAA CTT CTT CGC CCC CGT TTT CAC CAT GGG CAA ATA TTA TAC GCA 
AGG CGA CAA GGT GCT GAT GCC GCT GGC GAT TCA GGT TCA TCA TGC CGT CTG TGA 
TGG CTT CCA TGT CGG CAG AAT GCT TAA TGA ATT ACA ACA GTA CTG CGA TGA GTG 
GCA GGG CGG GGC GTA ATT TTT TTA AGG CAG TTA TTG GTG CCC TTA AAC GCC TGG 
GGT AAT GAC TCT CTA GCT TGA GGC ATC AAA TAA AAC GAA AGG CTC AGT CGA AAG 
ACT GGG CCT TTC GTT TTA TCT GTT GTT TGT CGG TGA ACG CTC TCC TGA GTA GGA 
CAA ATC CGC CGC TCT AGA GCT GCC TCG CGC GTT TCG GTG ATG ACG GTG AAA ACC 
TCT GAC ACA TGC AGC TCC CGG AGA CGG TCA CAG CTT GTC TGT AAG CGG ATG CCG 
GGA GCA GAC AAG CCC GTC AGG GCG CGT CAG CGG GTG TTG GCG GGT GTC GGG GCG 
CAG CCA TGA CCC AGT CAC GTA GCG ATA GCG GAG TGT ATA CTG GCT TAA CTA TGC 
GGC ATC AGA GCA GAT TGT ACT GAG AGT GCA CCA TAT GCG GTG TGA AAT ACC GCA 
CAG ATG CGT AAG GAG AAA ATA CCG CAT CAG GCG CTC TTC CGC TTC CTC GCT CAC 
TGA CTC GCT GCG CTC GGT CTG TCG GCT GCG GCG AGC GGT ATC AGC TCA CTC AAA 
GGC GGT AAT ACG GTT ATC CAC AGA ATC AGG GGA TAA CGC AGG AAA GAA CAT GTG 
AGC AAA AGG CCA GCA AAA GGC CAG GAA CCG TAA AAA GGC CGC GTT GCT GGC GTT 
TTT CCA TAG GCT CCG CCC CCC TGA CGA GCA TCA CAA AAA TCG ACG CTC AAG TCA 
GAG GTG GCG AAA CCC GAC AGG ACT ATA AAG ATA CCA GGC GTT TCC CCC TGG AAG 
CTC CCT CGT GCG CTC TCC TGT TCC GAC CCT GCC GCT TAC CGG ATA CCT GTC CGC 
CTT TCT CCC TTC GGG AAG CGT GGC GCT TTC TCA ATG CTC ACG CTG TAG GTA TCT 
CAG TTC GGT GTA GGT CGT TCG CTC CAA GCT GGG CTG TGT GCA CGA ACC CCC CGT 
TCA GCC CGA CCG CTG CGC CTT ATC CGG TAA CTA TCG TCT TGA GTC CAA CCC GGT 
AAG ACA CGA CTT ATC GCC ACT GGC AGC AGC CAC TGG TAA CAG GAT TAG CAG AGC 
GAG GTA TGT AGG CGG TGC TAC AGA GTT CTT GAA GTG GTG GCC TAA CTA CGG CTA 
CAC TAG AAG GAC AGT ATT TGG TAT CTG CGC TCT GCT GAA GCC AGT TAC CTT CGG 
AAA AAG AGT TGG TAG CTC TTG ATC CGG CAA ACA AAC CAC CGC TGG TAG CGG TGG 
TTT TTT TGT TTG CAA GCA GCA GAT TAC GCG CAG AAA AAA AGG ATC TCA AGA AGA 
193 
TCC TTT GAT CTT TTC TAC GGG GTC TGA CGC TCA GTG GAA CGA AAA CTC ACG TTA 
AGG GAT TTT GGT CAT GAG ATT ATC AAA AAG GAT CTT CAC CTA GAT CCT TTT AAA 
TTA AAA ATG AAG TTT TAA ATC AAT CTA AAG TAT ATA TGA GTA AAC TTG GTC TGA 
CAG TTA CCA ATG CTT AAT CAG TGA GGC ACC TAT CTC AGC GAT CTG TCT ATT TCG 
TTC ATC CAT AGC TGC CTG ACT CCC CGT CGT GTA GAT AAC TAC GAT ACG GGA GGG 
CTT ACC ATC TGG CCC CAG TGC TGC AAT GAT ACC GCG AGA CCC ACG CTC ACC GGC 
TCC AGA TTT ATC AGC AAT AAA CCA GCC AGC CGG AAG GGC CGA GCG CAG AAG TGG 
TCC TGC AAC TTT ATC CGC CTC CAT CCA GTC TAT TAA TTG TTG CCG GGA AGC TAG 
AGT AAG TAG TTC GCC AGT TAA TAG TTT GCG CAA CGT TGT TGC CAT TGC TAC AGG 
CAT CGT GGT GTC ACG CTC GTC GTT TGG TAT GGC TTC ATT CAG CTC CGG TTC CCA 
ACG ATC AAG GCG AGT TAC ATG ATC CCC CAT GTT GTG CAA AAA AGC GGT TAG CTC 
CTT CGG TCC TCC GAT CGT TGT CAG AAG TAA GTT GGC CGC AGT GTT ATC ACT CAT 
GGT TAT GGC AGC ACT GCA TAA TTC TCT TAC TGT CAT GCC ATC CGT AAG ATG CTT 
TTC TGT GAC TGG TGA GTA CTC AAC CAA GTC ATT CTG AGA ATA GTG TAT GCG GCG 
ACC GAG TTG CTC TTG CCC GGC GTC AAT ACG GGA TAA TAC CGC GCC ACA TAG CAG 
AAC TTT AAA AGT GCT CAT CAT TGG AAA ACG TTC TTC GGG GCG AAA ACT CTC AAG 
GAT CTT ACC GCT GTT GAG ATC CAG TTC GAT GTA ACC CAC TCG TGC ACC CAA CTG 
ATC TTC AGC ATC TTT TAC TTT CAC CAG CGT TTC TGG GTG AGC AAA AAC AGG AAG 
GCA AAA TGC CGC AAA AAA GGG AAT AAG GGC GAC ACG GAA ATG TTG AAT ACT CAT 
ACT CTT CCT TTT TCA ATA TTA TTG AAG CAT TTA TCA GGG TTA TTG TCT CAT GAG 
CGG ATA CAT ATT TGA ATG TAT TTA GAA AAA TAA ACA AAT AGG GGT TCC GCG CAC 
ATT TCC CCG AAA AGT GCC ACC TGA CGT CTA AGA AAC CAT TAT TAT CAT GAC ATT 
AAC CTA TAA AAA TAG GCG TAT CAC GAG GCC CTT TCG TCT TCA C 
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2. pQE9_GFP6_lacI_yPheRS_naph (8,294 bp) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T5 promoter and lac operon 7   - 87 bp 
 
His_GFP6   115  -  921 bp 
 
yPheRS_alpha subunit 1449  -  2972 bp 
 
yPheRS_beta subunit  2987  -  4774 bp 
 
ColE1 origin   6501 -  6526 bp 
 
beta-lactamase  8089  -  7229 bp 
 
 
Full sequence     
 
CTC GAG AAA TCA TAA AAA ATT TAT TTG CTT TGT GAG CGG ATA ACA ATT ATA ATA 
GAT TCA ATT GTG AGC GGA TAA CAA TTT CAC ACA GAA TTC ATT AAA GAG GAG AAA 
TTA ACT ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC GTC GAC CTG CAG 
CCC CGG GTA CCG GTA GAA AAA ATG AGT AAA GGA GAA GAA CTT TTT ACT GGA GTT 
GTC CCA ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC 
AGT GGA GAG GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT 
TGC ACT ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT TTT ACC 
TAT GGT GTT CAA TGC TTT TCC CGT TAT CCG GAT CAT ATG AAA CGG CAT GAC TTT 
TTT AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA CGC ACT ATA TTT TTT AAA 
GAT GAC GGG AAC TAC AAG ACG CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT 
GTT AAT CGT ATC GAG TTA AAA GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTC 
GGA CAC AAA CTC GAG TAC AAC TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC 
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AAA CAA AAG AAT GGA ATC AAA GCT AAC TTT AAA ATT CGC CAC AAC ATT GAA GAT 
GGA TCC GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC 
CCT GTC CTT TTA CCA GAC AAC CAT TAC CTG TCG ACA CAA TCT GCC CTT TCG AAA 
GAT CCC AAC GAA AAG CGT GAC CAC ATG GTC CTT CTT GAG TTT GTA ACT GCT GCT 
GGG ATT ACA CAT GGC ATG GAT GAG CTC TAC AAA CTG CAG CCA AGC TTA ATT AGC 
TGA AGC TTG GAC TCC TGT TGA TAG ATC CAG TAA TGA CCT CAG AAC TCC ATC TGG 
ATT TGT TCA GAA CGC TCG GTT GCC GCC GGG CGT TTT TTA TTG GTG AGA ATC CAA 
GCT AGC TTG GCG AGA TTT TCA GGA GCT AAG GAA GCT AAA ATG GAG AAA AAA ATC 
ACT GGA TAT ACC ACC GTT GAT ATA TCC CAA TGG CAT CGT AAA GAA CAT TTT GAG 
GCA TTT CAG TCA GTT GCT CAA TGT ACC TAT AAC CAG ACC GTT CAG CTG GCA CGA 
CAG GTT TCC CGA CTG GAA AGC GGG CAG TGA GCG CAA CGC AAT TAA TGT GAG TTA 
GCT CAC TCA TTA GGC ACC CCA GGC TTT ACA CTT TAT GCT TCC GGC TCG TAT GTT 
GTG TGG AAT TGT GAG CGG ATA ACA ATT TCA CAC AGG AAA CAG CTA TGA CCA TGA 
TTA CGC CAA GCT TGC ATG CCT GCA GTT GAC AAT TAA TCA TCG GCT CGT ATA ATG 
GAT CCA ATT GTG AGC GGA ATC GAT TTT CAC ACA GGA AAC AGA CCA TGA ATC TAG 
AGA TGT CTG ACT TCC AAT TAG AAA TTC TAA AGA AAC TAG ATG AAT TGG ATG AGA 
TCA AGT CCA CAC TGG CAA CTT TCC CTC AGC ACG GCT CTC AAG ATG TTC TTT CCG 
CTT TGA ACT CTT TGA AAG CCC ACA ACA AGT TAG AGT TTT CCA AGG TCG ACA CGG 
TTA CGT ATG ACT TGA CCA AAG AAG GTG CTC AAA TTT TGA ATG AAG GTT CGT ACG 
AAA TTA AAC TAG TCA AGC TCA TCC AAG AGT TGG GTC AAC TTC AAA TCA AAG ATG 
TGA TGT CCA AAC TAG GCC CTC AAG TTG GTA AGG TCG GTC AGG CTA GAG CTT TCA 
AGA ACG GCT GGA TCG CCA AAA ACG CCT CAA ACG AGC TTG AAC TCT CCG CAA AAT 
TGC AAA ATA CCG ATT TAA ATG AGC TTA CTG ATG AAA CGC AAT CTA TTC TAG CGC 
AAA TCA AGA ACA ACT CGC ATC TGG ATA GCA TTG ACG CCA AGA TTT TGA ACG ACT 
TGA AGA AAA GAA AGT TAA TTG CTC AAG GTA AAA TCA CAG ATT TCA GTG TCA CCA 
AAG GGC CAG AGT TCT CGA CCG ACC TCA CCA AAT TGG AAA CCG ATC TTA CCT CCG 
ACA TGG TCT CCA CCA ATG CAT ACA AGG ACT TGA AGT TCA AGC CTT ACA ATT TCA 
ATT CTC AAG GTG TGC AAA TAT CTT CAG GTG CTC TTC ACC CCT TAA ACA AAG TCA 
GAG AGG AAT TTA GAC AAA TTT TCT TTT CCA TGG GAT TCA CAG AGA TGC CCT CGA 
ACC AAT ACG TCG AGA CAG GTT TCT GGA ACT TCG ATG CCC TTT ACG TCC CAC AAC 
AGC ATC CTG CTC GTG ACC TGC AAG ACA CTT TCT ACA TCA AGG ACC CAC TAA CCG 
CTG AGT TGC CCG ATG ACA AGA CAT ACA TGG ACA ATA TCA AAG CCG TTC ACG AAC 
AGG GGA GAT TCG GGT CCA TCG GTT ATC GTT ACA ACT GGA AGC CAG AAG AAT GTC 
AAA AAT TGG TCT TGA GAA CTC ACT CCA CAG CCA TCT CTG CCA GAA TGC TGC ACG 
ATT TGG CCA AAG ATC CAA AGC CCA CCA GAT TGT TTT CTA TCG ACC GTG TTT TCC 
GTA ACG AAG CAG TTG ACG CCA CCC ATT TGG CCG AAT TCC ACC AGG TGG AAG GTG 
TTC TTG CCG ACT ACA ACA TTA CTC TGG GTG ACC TGA TCA AGT TCA TGG AAG AGT 
TTT TCG AAA GAA TGG GTG TCA CCG GTT TGA GAT TCA AGC CTA CCT ACG GGC CTT 
ACG GGG AGC CAT CTA TGG AAA TCT TTT CTT GGC ACG AAG GTT TGC AAA AAT GGG 
TCG AAA TCG GTA ACT TTG GTA TGT TCA GAC CAG AAA TGC TCG AGT CCA TGG GTC 
TAC CAA AGG ATC TAA GAG TCC TTG GTT GGG GGT TAT CCT TGG AAA GAC CTA CCA 
TGA TCA AAT ATA AGG TTC AAA ACA TCA GAG AAC TGT TAG GTC ATA AAG TCT CTT 
TGG ACT TTA TCG AAA CCA ATC CTG CTG CTA GAT TGG ACG AAG ACT TGT ACG AAT 
AAG GCA GGA ATA GAT TAT GCC TAC CGT CTC CGT GAA CAA GCA GCA ATT ATT TGA 
TCT TCT AGG CAA AGA CTA CAC TTC CCA AGA GTT CGA CGA ATT ATG TTT TGA ATT 
CGG TAT GGA AAT GGA CGA AGA CAC CAC AGA AGA GGC CTT GAA AAC CGG GGA GGA 
GCC GGA ATT GAA GCT TGA TAT CAG TGC CAA TCG TTA CGA TTT GCT TTG TAT CGA 
AGG TAT TTC ACA GTC GCT GAA CGA ATA CTT GGA ACG TAA AGA AAG ACC TGA CTA 
TAA ATT AAG CAA GCC AAC CAC TAA GTT GAT CAT CGA CAA ATC AAC GGA GCA AAT 
TAG ACC TTT TGC TAC CGC TGC TGT ATT GAG AAA TAT CAA GCT TAA CGA AAA ATC 
TTA CGC TTC TTT TAT TGC CTT GCA AGA TAA ATT ACA TGC CAA TCT ATG TAG AAA 
CAG AAG CTT GGT TGC CAT GGG TAC TCA CGA TTT AGA TTC AAT TGA AGG TCC ATT 
CCA TTA CAG AGC TCT ACC ACC AAA GGA CAT CAA GTT CGT ACC ATT GAA TCA AAC 
CCA AGA GTT TAC TGG TGA CAA ATT GAT CGA GTT TTA TAA ATC TCC AGA ACA GAA 
AAA CAA CAT AGG GAG ATA CGT TCA CAT TAT TGA GGA TTC TCC AGT CTT CCC AGT 
TAT TAT GGA CAG CAA AGA TCG TGT TTG CTC CCT GCC ACC ATT AAT CAA TAG TGA 
ACA TTC GAA GAT CTC TGT GAA CAC CCG TAA CAT TTT GAT TGA TAT AAC CGC CAC 
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CGA TAA GAC CAA AGC CGA GAT CGT TTT GAA CAT ATT AAC TAC AAT GTT CTC ACG 
TTA TTG TGA CGA ACC ATT CAC GGT TGA GCC TGT AGA AAT TGT CTC TGA ACA CAA 
TGG CCA ATC CCG TTT GGC GCC AAA CTT CAA CGA TAG AAT TAT GGA TGT CTC CAT 
TAA GTA CAT CAA CTC CTG TCT TGG CCT AGA TCA ATC CGC TGA TGA AAT TGC TCA 
TTG TCT AAA AAA GAT GTC GTT GCA TGC CGT TCA ATC AAA GGA AGA CAA GGA CAT 
CTT GCA CGT TGA CAT TCC GGT AAC TAG ACC TGA TAT TTT GCA CGC TTG TGA TAT 
AAT GGA AGA TGC CGC TGT CGG TTA TGG TTT CAA TAA TTT GCC AAA GGG TGA GAA 
ATT ATC CAA TGC CAA CTT CAT TGC CAA ACC ATT ACC AAT CAA CAA GGT TTC TGA 
TAT TTT CAG AGT TGC ATC CTC TCA AGC CAC GTG GGT TGA GGT TTT ACC ATT GAC 
CTT ATG TTC GCA CGA TGA AAA CTT TAA ATT TCT AAG ACA ATC CGA CAA TGA TGA 
TTT AGC TGT CAA ATT GGC CAA CCC AAA GAC TTT GGA ATA CCA AGT TGT TAG AAC 
CAC TTT ATT GCC TGG TAT CTT AAA GAC AGT CAA GGA AAA CAG AAA ACA TTC CTT 
ACC AAT CAA AGT CTT TGA AAC CGG TGA CGT TGT ATT TAA AGA CGA CAA ACT AGA 
AAG GAA GGC GTA CAA TGA ACG TCA CTG GGC TGC CAT CTA CGT GGG TAA GAA TTC 
TGG GTT TGA AAT CAT TCA AGG GTT ATT GGG TAA AAT CAT GCA AAC TTT TAG AAC 
AGA GTG GAT TGC AGA CTA CGG TGC TGC TGC TTC TGG CAG AGG TTA CTG GAT TGA 
AGA AGA CGA TTC TGT GAA AAC CTA TTT CCC AGG TAG AGG TGC CAA GGT CAT GTT 
CAG ATC CAA AGA AGG CGC TGA GCC AAA GCA AAT CGG CCA CTT GGG TGT CTT GCA 
TCC TGA AGT CAT GAT GAA TTT CGA CGT TCC ATT CGC TGC ATC CTT TGT AGA GGT 
TAA TGC CGA AGT CTT CCT ATA ATG TAA TGT TCT AAC AAA AAT TTT TAC TGA TTT 
ATA AAA CTT ATA TAG ATA GAT AGA CAT ATA TAT ATA TCT ATA TAT AGA AAC ACA 
ACT AAA GTT TAC CAT GTT TTA TAT AGG GTA CCG AGC TCG AAT TCA CTG GCC GTC 
GTT TTA CAA CGT CGT GAC TGG GAA AAC CGC GGT TAC GTG CAG TCG ATG ATA AGC 
TGT CAA ACA TGA GAA TTG TGC CTA ATG AGT GAG CTA ACT TAC ATT AAT TGC GTT 
GCG CTC ACT GCC CGC TTT CCA GTC GGG AAA CCT GTC GTG CCA GCT GCA TTA ATG 
AAT CGG CCA ACG CGC GGG GAG AGG CGG TTT GCG TAT TGG GCG CCA GGG TGG TTT 
TTC TTT TCA CCA GTG AGA CGG GCA ACA GCT GAT TGC CCT TCA CCG CCT GGC CCT 
GAG AGA GTT GCA GCA AGC GGT CCA CGC TGG TTT GCC CCA GCA GGC GAA AAT CCT 
GTT TGA TGG TGG TTA ACG GCG GGA TAT AAC ATG AGC TGT CTT CGG TAT CGT CGT 
ATC CCA CTA CCG AGA TAT CCG CAC CAA CGC GCA GCC CGG ACT CGG TAA TGG CGC 
GCA TTG CGC CCA GCG CCA TCT GAT CGT TGG CAA CCA GCA TCG CAG TGG GAA CGA 
TGC CCT CAT TCA GCA TTT GCA TGG TTT GTT GAA AAC CGG ACA TGG CAC TCC AGT 
CGC CTT CCC GTT CCG CTA TCG GCT GAA TTT GAT TGC GAG TGA GAT ATT TAT GCC 
AGC CAG CCA GAC GCA GAC GCG CCG AGA CAG AAC TTA ATG GGC CCG CTA ACA GCG 
CGA TTT GCT GGT GAC CCA ATG CGA CCA GAT GCT CCA CGC CCA GTC GCG TAC CGT 
CTT CAT GGG AGA AAA TAA TAC TGT TGA TGG GTG TCT GGT CAG AGA CAT CAA GAA 
ATA ACG CCG GAA CAT TAG TGC AGG CAG CTT CCA CAG CAA TGG CAT CCT GGT CAT 
CCA GCG GAT AGT TAA TGA TCA GCC CAC TGA CGC GTT GCG CGA GAA GAT TGT GCA 
CCG CCG CTT TAC AGG CTT CGA CGC CGC TTC GTT CTA CCA TCG ACA CCA CCA CGC 
TGG CAC CCA GTT GAT CGG CGC GAG ATT TAA TCG CCG CGA CAA TTT GCG ACG GCG 
CGT GCA GGG CCA GAC TGG AGG TGG CAA CGC CAA TCA GCA ACG ACT GTT TGC CCG 
CCA GTT GTT GTG CCA CGC GGT TGG GAA TGT AAT TCA GCT CCG CCA TCG CCG CTT 
CCA CTT TTT CCC GCG TTT TCG CAG AAA CGT GGC TGG CCT GGT TCA CCA CGC GGG 
AAA CGG TCT GAT AAG AGA CAC CGG CAT ACT CTG CGA CAT CGT ATA ACG TTA CTG 
GTT TCA CAT TCA CCA CCC TGA ATT GAC TCT CTT CCG GGC GCT ATC ATG CCA TAC 
CGC GAA AGG TTT TGC ACC ATT CGA TGG TGT CGG AAT TTC GGG CAG CGT TGG GTC 
CTG GCC ACG GGT GCG CAT GAC TTA AGC GGT GTG AAA TAC CGC ACA GAT GCG TAA 
GGA GAA AAT ACC GCA TCA GGC GCT CTT CCG CTT CCT CGC TCA CTG ACT CGC TGC 
GCT CGG TCT GTC GGC TGC GGC GAG CGG TAT CAG CTC ACT CAA AGG CGG TAA TAC 
GGT TAT CCA CAG AAT CAG GGG ATA ACG CAG GAA AGA ACA TGT GAG CAA AAG GCC 
AGC AAA AGG CCA GGA ACC GTA AAA AGG CCG CGT TGC TGG CGT TTT TCC ATA GGC 
TCC GCC CCC CTG ACG AGC ATC ACA AAA ATC GAC GCT CAA GTC AGA GGT GGC GAA 
ACC CGA CAG GAC TAT AAA GAT ACC AGG CGT TTC CCC CTG GAA GCT CCC TCG TGC 
GCT CTC CTG TTC CGA CCC TGC CGC TTA CCG GAT ACC TGT CCG CCT TTC TCC CTT 
CGG GAA GCG TGG CGC TTT CTC AAT GCT CAC GCT GTA GGT ATC TCA GTT CGG TGT 
AGG TCG TTC GCT CCA AGC TGG GCT GTG TGC ACG AAC CCC CCG TTC AGC CCG ACC 
GCT GCG CCT TAT CCG GTA ACT ATC GTC TTG AGT CCA ACC CGG TAA GAC ACG ACT 
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TAT CGC CAC TGG CAG CAG CCA CTG GTA ACA GGA TTA GCA GAG CGA GGT ATG TAG 
GCG GTG CTA CAG AGT TCT TGA AGT GGT GGC CTA ACT ACG GCT ACA CTA GAA GGA 
CAG TAT TTG GTA TCT GCG CTC TGC TGA AGC CAG TTA CCT TCG GAA AAA GAG TTG 
GTA GCT CTT GAT CCG GCA AAC AAA CCA CCG CTG GTA GCG GTG GTT TTT TTG TTT 
GCA AGC AGC AGA TTA CGC GCA GAA AAA AAG GAT CTC AAG AAG ATC CTT TGA TCT 
TTT CTA CGG GGT CTG ACG CTC AGT GGA ACG AAA ACT CAC GTT AAG GGA TTT TGG 
TCA TGA GAT TAT CAA AAA GGA TCT TCA CCT AGA TCC TTT TAA ATT AAA AAT GAA 
GTT TTA AAT CAA TCT AAA GTA TAT ATG AGT AAA CTT GGT CTG ACA GTT ACC AAT 
GCT TAA TCA GTG AGG CAC CTA TCT CAG CGA TCT GTC TAT TTC GTT CAT CCA TAG 
CTG CCT GAC TCC CCG TCG TGT AGA TAA CTA CGA TAC GGG AGG GCT TAC CAT CTG 
GCC CCA GTG CTG CAA TGA TAC CGC GAG ACC CAC GCT CAC CGG CTC CAG ATT TAT 
CAG CAA TAA ACC AGC CAG CCG GAA GGG CCG AGC GCA GAA GTG GTC CTG CAA CTT 
TAT CCG CCT CCA TCC AGT CTA TTA ATT GTT GCC GGG AAG CTA GAG TAA GTA GTT 
CGC CAG TTA ATA GTT TGC GCA ACG TTG TTG CCA TTG CTA CAG GCA TCG TGG TGT 
CAC GCT CGT CGT TTG GTA TGG CTT CAT TCA GCT CCG GTT CCC AAC GAT CAA GGC 
GAG TTA CAT GAT CCC CCA TGT TGT GCA AAA AAG CGG TTA GCT CCT TCG GTC CTC 
CGA TCG TTG TCA GAA GTA AGT TGG CCG CAG TGT TAT CAC TCA TGG TTA TGG CAG 
CAC TGC ATA ATT CTC TTA CTG TCA TGC CAT CCG TAA GAT GCT TTT CTG TGA CTG 
GTG AGT ACT CAA CCA AGT CAT TCT GAG AAT AGT GTA TGC GGC GAC CGA GTT GCT 
CTT GCC CGG CGT CAA TAC GGG ATA ATA CCG CGC CAC ATA GCA GAA CTT TAA AAG 
TGC TCA TCA TTG GAA AAC GTT CTT CGG GGC GAA AAC TCT CAA GGA TCT TAC CGC 
TGT TGA GAT CCA GTT CGA TGT AAC CCA CTC GTG CAC CCA ACT GAT CTT CAG CAT 
CTT TTA CTT TCA CCA GCG TTT CTG GGT GAG CAA AAA CAG GAA GGC AAA ATG CCG 
CAA AAA AGG GAA TAA GGG CGA CAC GGA AAT GTT GAA TAC TCA TAC TCT TCC TTT 
TTC AAT ATT ATT GAA GCA TTT ATC AGG GTT ATT GTC TCA TGA GCG GAT ACA TAT 
TTG AAT GTA TTT AGA AAA ATA AAC AAA TAG GGG TTC CGC GCA CAT TTC CCC GAA 
AAG TGC CAC CTG ACG TCT AAG AAA CCA TTA TTA TCA TGA CAT TAA CCT ATA AAA 
ATA GGC GTA TCA CGA GGC CCT TTC GTC TTC AC 
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3. pQE16_mDHFR_lacI_yPheRS_naph (8109 bp) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T5 promoter and lac operon 7   - 87 bp 
 
mDHFR_His   115  -  660 bp 
 
yPheRS_alpha subunit 1264  -  2787 bp 
 
yPheRS_beta subunit  2802  -  4589 bp 
 
lacIq    5926   -  4842 bp  
 
ColE1 origin   6501  -   6526 bp 
 
beta-lactamase  7904  -  7044 bp 
 
 
Full sequence 
 
CTC GAG AAA TCA TAA AAA ATT TAT TTG CTT TGT GAG CGG ATA ACA ATT ATA ATA 
GAT TCA ATT GTG AGC GGA TAA CAA TTT CAC ACA GAA TTC ATT AAA GAG GAG AAA 
TTA ACT ATG AGA GGA TCC GGC ATC ATG GTT CGA CCA TTG AAC TCG ATC GTC GCC 
GTG TCC CAA AAT ATG GGG ATT GGC AAG AAC GGA GAC CTA CCC TGG CCT CCG CTC 
AGG AAC GAG TTC AAG TAC TTC CAA AGA ATG ACC ACA ACC TCT TCA GTG GAA GGT 
AAA CAG AAT CTG GTG ATT ATG GGT AGG AAA ACC TGG TTC TCC ATT CCT GAG AAG 
AAT CGA CCT TTA AAG GAC AGA ATT AAT ATA GTT CTC AGT AGA GAA CTC AAA GAA 
199 
CCA CCA CGA GGA GCT CAT TTT CTT GCC AAA AGT TTG GAT GAT GCC TTA AGA CTT 
ATT GAA CAA CCG GAA TTG GCA AGT AAA GTA GAC ATG GTT TGG ATA GTC GGA GGC 
AGT TCT GTT TAC CAG GAA GCC ATG AAT CAA CCA GGC CAC CTT AGA CTC TTT GTG 
ACA AGG ATC ATG CAG GAA TTT GAA AGT GAC ACG TTT TTC CCA GAA ATT GAT TTG 
GGG AAA TAT AAA CTT CTC CCA GAA TAC CCA GGC GTC CTC TCT GAG GTC CAG GAG 
GAA AAA GGC ATC AAG TAT AAG TTT GAA GTC TAC GAG AAG AAA GGT TCC AGA TCT 
CAT CAC CAT CAC CAT CAC TAA GCT TAA TTA GCT GAG CTT GGA CTC CTG TTG ATA 
GAT CCA GTA ATG ACC TCA GAA CTC CAT CTG GAT TTG TTC AGA ACG CTC GGT TGC 
CGC CGG GCG TTT TTT ATT GGT GAG AAT CCA AGC TAG CTT GGC GAG ATT TTC AGG 
AGC TAA GGA AGC TAA AAT GGA GAA AAA AAT CAC TGG ATA TAC CAC CGT TGA TAT 
ATC CCA ATG GCA TCG TAA AGA ACA TTT TGA GGC ATT TCA GTC AGT TGC TCA ATG 
TAC CTA TAA CCA GAC CGT TCA GCT GGC ACG ACA GGT TTC CCG ACT GGA AAG CGG 
GCA GTG AGC GCA ACG CAA TTA ATG TGA GTT AGC TCA CTC ATT AGG CAC CCC AGG 
CTT TAC ACT TTA TGC TTC CGG CTC GTA TGT TGT GTG GAA TTG TGA GCG GAT AAC 
AAT TTC ACA CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA AGC TTG CAT GCC TGC 
AGT TGA CAA TTA ATC ATC GGC TCG TAT AAT GGA TCC AAT TGT GAG CGG AAT CGA 
TTT TCA CAC AGG AAA CAG ACC ATG AAT CTA GAG ATG TCT GAC TTC CAA TTA GAA 
ATT CTA AAG AAA CTA GAT GAA TTG GAT GAG ATC AAG TCC ACA CTG GCA ACT TTC 
CCT CAG CAC GGC TCT CAA GAT GTT CTT TCC GCT TTG AAC TCT TTG AAA GCC CAC 
AAC AAG TTA GAG TTT TCC AAG GTC GAC ACG GTT ACG TAT GAC TTG ACC AAA GAA 
GGT GCT CAA ATT TTG AAT GAA GGT TCG TAC GAA ATT AAA CTA GTC AAG CTC ATC 
CAA GAG TTG GGT CAA CTT CAA ATC AAA GAT GTG ATG TCC AAA CTA GGC CCT CAA 
GTT GGT AAG GTC GGT CAG GCT AGA GCT TTC AAG AAC GGC TGG ATC GCC AAA AAC 
GCC TCA AAC GAG CTT GAA CTC TCC GCA AAA TTG CAA AAT ACC GAT TTA AAT GAG 
CTT ACT GAT GAA ACG CAA TCT ATT CTA GCG CAA ATC AAG AAC AAC TCG CAT CTG 
GAT AGC ATT GAC GCC AAG ATT TTG AAC GAC TTG AAG AAA AGA AAG TTA ATT GCT 
CAA GGT AAA ATC ACA GAT TTC AGT GTC ACC AAA GGG CCA GAG TTC TCG ACC GAC 
CTC ACC AAA TTG GAA ACC GAT CTT ACC TCC GAC ATG GTC TCC ACC AAT GCA TAC 
AAG GAC TTG AAG TTC AAG CCT TAC AAT TTC AAT TCT CAA GGT GTG CAA ATA TCT 
TCA GGT GCT CTT CAC CCC TTA AAC AAA GTC AGA GAG GAA TTT AGA CAA ATT TTC 
TTT TCC ATG GGA TTC ACA GAG ATG CCC TCG AAC CAA TAC GTC GAG ACA GGT TTC 
TGG AAC TTC GAT GCC CTT TAC GTC CCA CAA CAG CAT CCT GCT CGT GAC CTG CAA 
GAC ACT TTC TAC ATC AAG GAC CCA CTA ACC GCT GAG TTG CCC GAT GAC AAG ACA 
TAC ATG GAC AAT ATC AAA GCC GTT CAC GAA CAG GGG AGA TTC GGG TCC ATC GGT 
TAT CGT TAC AAC TGG AAG CCA GAA GAA TGT CAA AAA TTG GTC TTG AGA ACT CAC 
TCC ACA GCC ATC TCT GCC AGA ATG CTG CAC GAT TTG GCC AAA GAT CCA AAG CCC 
ACC AGA TTG TTT TCT ATC GAC CGT GTT TTC CGT AAC GAA GCA GTT GAC GCC ACC 
CAT TTG GCC GAA TTC CAC CAG GTG GAA GGT GTT CTT GCC GAC TAC AAC ATT ACT 
CTG GGT GAC CTG ATC AAG TTC ATG GAA GAG TTT TTC GAA AGA ATG GGT GTC ACC 
GGT TTG AGA TTC AAG CCT ACC TAC GGG CCT TAC GGG GAG CCA TCT ATG GAA ATC 
TTT TCT TGG CAC GAA GGT TTG CAA AAA TGG GTC GAA ATC GGT AAC TTT GGT ATG 
TTC AGA CCA GAA ATG CTC GAG TCC ATG GGT CTA CCA AAG GAT CTA AGA GTC CTT 
GGT TGG GGG TTA TCC TTG GAA AGA CCT ACC ATG ATC AAA TAT AAG GTT CAA AAC 
ATC AGA GAA CTG TTA GGT CAT AAA GTC TCT TTG GAC TTT ATC GAA ACC AAT CCT 
GCT GCT AGA TTG GAC GAA GAC TTG TAC GAA TAA GGC AGG AAT AGA TTA TGC CTA 
CCG TCT CCG TGA ACA AGC AGC AAT TAT TTG ATC TTC TAG GCA AAG ACT ACA CTT 
CCC AAG AGT TCG ACG AAT TAT GTT TTG AAT TCG GTA TGG AAA TGG ACG AAG ACA 
CCA CAG AAG AGG CCT TGA AAA CCG GGG AGG AGC CGG AAT TGA AGC TTG ATA TCA 
GTG CCA ATC GTT ACG ATT TGC TTT GTA TCG AAG GTA TTT CAC AGT CGC TGA ACG 
AAT ACT TGG AAC GTA AAG AAA GAC CTG ACT ATA AAT TAA GCA AGC CAA CCA CTA 
AGT TGA TCA TCG ACA AAT CAA CGG AGC AAA TTA GAC CTT TTG CTA CCG CTG CTG 
TAT TGA GAA ATA TCA AGC TTA ACG AAA AAT CTT ACG CTT CTT TTA TTG CCT TGC 
AAG ATA AAT TAC ATG CCA ATC TAT GTA GAA ACA GAA GCT TGG TTG CCA TGG GTA 
CTC ACG ATT TAG ATT CAA TTG AAG GTC CAT TCC ATT ACA GAG CTC TAC CAC CAA 
AGG ACA TCA AGT TCG TAC CAT TGA ATC AAA CCC AAG AGT TTA CTG GTG ACA AAT 
TGA TCG AGT TTT ATA AAT CTC CAG AAC AGA AAA ACA ACA TAG GGA GAT ACG TTC 
ACA TTA TTG AGG ATT CTC CAG TCT TCC CAG TTA TTA TGG ACA GCA AAG ATC GTG 
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TTT GCT CCC TGC CAC CAT TAA TCA ATA GTG AAC ATT CGA AGA TCT CTG TGA ACA 
CCC GTA ACA TTT TGA TTG ATA TAA CCG CCA CCG ATA AGA CCA AAG CCG AGA TCG 
TTT TGA ACA TAT TAA CTA CAA TGT TCT CAC GTT ATT GTG ACG AAC CAT TCA CGG 
TTG AGC CTG TAG AAA TTG TCT CTG AAC ACA ATG GCC AAT CCC GTT TGG CGC CAA 
ACT TCA ACG ATA GAA TTA TGG ATG TCT CCA TTA AGT ACA TCA ACT CCT GTC TTG 
GCC TAG ATC AAT CCG CTG ATG AAA TTG CTC ATT GTC TAA AAA AGA TGT CGT TGC 
ATG CCG TTC AAT CAA AGG AAG ACA AGG ACA TCT TGC ACG TTG ACA TTC CGG TAA 
CTA GAC CTG ATA TTT TGC ACG CTT GTG ATA TAA TGG AAG ATG CCG CTG TCG GTT 
ATG GTT TCA ATA ATT TGC CAA AGG GTG AGA AAT TAT CCA ATG CCA ACT TCA TTG 
CCA AAC CAT TAC CAA TCA ACA AGG TTT CTG ATA TTT TCA GAG TTG CAT CCT CTC 
AAG CCA CGT GGG TTG AGG TTT TAC CAT TGA CCT TAT GTT CGC ACG ATG AAA ACT 
TTA AAT TTC TAA GAC AAT CCG ACA ATG ATG ATT TAG CTG TCA AAT TGG CCA ACC 
CAA AGA CTT TGG AAT ACC AAG TTG TTA GAA CCA CTT TAT TGC CTG GTA TCT TAA 
AGA CAG TCA AGG AAA ACA GAA AAC ATT CCT TAC CAA TCA AAG TCT TTG AAA CCG 
GTG ACG TTG TAT TTA AAG ACG ACA AAC TAG AAA GGA AGG CGT ACA ATG AAC GTC 
ACT GGG CTG CCA TCT ACG TGG GTA AGA ATT CTG GGT TTG AAA TCA TTC AAG GGT 
TAT TGG GTA AAA TCA TGC AAA CTT TTA GAA CAG AGT GGA TTG CAG ACT ACG GTG 
CTG CTG CTT CTG GCA GAG GTT ACT GGA TTG AAG AAG ACG ATT CTG TGA AAA CCT 
ATT TCC CAG GTA GAG GTG CCA AGG TCA TGT TCA GAT CCA AAG AAG GCG CTG AGC 
CAA AGC AAA TCG GCC ACT TGG GTG TCT TGC ATC CTG AAG TCA TGA TGA ATT TCG 
ACG TTC CAT TCG CTG CAT CCT TTG TAG AGG TTA ATG CCG AAG TCT TCC TAT AAT 
GTA ATG TTC TAA CAA AAA TTT TTA CTG ATT TAT AAA ACT TAT ATA GAT AGA TAG 
ACA TAT ATA TAT ATC TAT ATA TAG AAA CAC AAC TAA AGT TTA CCA TGT TTT ATA 
TAG GGT ACC GAG CTC GAA TTC ACT GGC CGT CGT TTT ACA ACG TCG TGA CTG GGA 
AAA CCG CGG TTA CGT GCA GTC GAT GAT AAG CTG TCA AAC ATG AGA ATT GTG CCT 
AAT GAG TGA GCT AAC TTA CAT TAA TTG CGT TGC GCT CAC TGC CCG CTT TCC AGT 
CGG GAA ACC TGT CGT GCC AGC TGC ATT AAT GAA TCG GCC AAC GCG CGG GGA GAG 
GCG GTT TGC GTA TTG GGC GCC AGG GTG GTT TTT CTT TTC ACC AGT GAG ACG GGC 
AAC AGC TGA TTG CCC TTC ACC GCC TGG CCC TGA GAG AGT TGC AGC AAG CGG TCC 
ACG CTG GTT TGC CCC AGC AGG CGA AAA TCC TGT TTG ATG GTG GTT AAC GGC GGG 
ATA TAA CAT GAG CTG TCT TCG GTA TCG TCG TAT CCC ACT ACC GAG ATA TCC GCA 
CCA ACG CGC AGC CCG GAC TCG GTA ATG GCG CGC ATT GCG CCC AGC GCC ATC TGA 
TCG TTG GCA ACC AGC ATC GCA GTG GGA ACG ATG CCC TCA TTC AGC ATT TGC ATG 
GTT TGT TGA AAA CCG GAC ATG GCA CTC CAG TCG CCT TCC CGT TCC GCT ATC GGC 
TGA ATT TGA TTG CGA GTG AGA TAT TTA TGC CAG CCA GCC AGA CGC AGA CGC GCC 
GAG ACA GAA CTT AAT GGG CCC GCT AAC AGC GCG ATT TGC TGG TGA CCC AAT GCG 
ACC AGA TGC TCC ACG CCC AGT CGC GTA CCG TCT TCA TGG GAG AAA ATA ATA CTG 
TTG ATG GGT GTC TGG TCA GAG ACA TCA AGA AAT AAC GCC GGA ACA TTA GTG CAG 
GCA GCT TCC ACA GCA ATG GCA TCC TGG TCA TCC AGC GGA TAG TTA ATG ATC AGC 
CCA CTG ACG CGT TGC GCG AGA AGA TTG TGC ACC GCC GCT TTA CAG GCT TCG ACG 
CCG CTT CGT TCT ACC ATC GAC ACC ACC ACG CTG GCA CCC AGT TGA TCG GCG CGA 
GAT TTA ATC GCC GCG ACA ATT TGC GAC GGC GCG TGC AGG GCC AGA CTG GAG GTG 
GCA ACG CCA ATC AGC AAC GAC TGT TTG CCC GCC AGT TGT TGT GCC ACG CGG TTG 
GGA ATG TAA TTC AGC TCC GCC ATC GCC GCT TCC ACT TTT TCC CGC GTT TTC GCA 
GAA ACG TGG CTG GCC TGG TTC ACC ACG CGG GAA ACG GTC TGA TAA GAG ACA CCG 
GCA TAC TCT GCG ACA TCG TAT AAC GTT ACT GGT TTC ACA TTC ACC ACC CTG AAT 
TGA CTC TCT TCC GGG CGC TAT CAT GCC ATA CCG CGA AAG GTT TTG CAC CAT TCG 
ATG GTG TCG GAA TTT CGG GCA GCG TTG GGT CCT GGC CAC GGG TGC GCA TGA CTT 
AAG CGG TGT GAA ATA CCG CAC AGA TGC GTA AGG AGA AAA TAC CGC ATC AGG CGC 
TCT TCC GCT TCC TCG CTC ACT GAC TCG CTG CGC TCG GTC TGT CGG CTG CGG CGA 
GCG GTA TCA GCT CAC TCA AAG GCG GTA ATA CGG TTA TCC ACA GAA TCA GGG GAT 
AAC GCA GGA AAG AAC ATG TGA GCA AAA GGC CAG CAA AAG GCC AGG AAC CGT AAA 
AAG GCC GCG TTG CTG GCG TTT TTC CAT AGG CTC CGC CCC CCT GAC GAG CAT CAC 
AAA AAT CGA CGC TCA AGT CAG AGG TGG CGA AAC CCG ACA GGA CTA TAA AGA TAC 
CAG GCG TTT CCC CCT GGA AGC TCC CTC GTG CGC TCT CCT GTT CCG ACC CTG CCG 
CTT ACC GGA TAC CTG TCC GCC TTT CTC CCT TCG GGA AGC GTG GCG CTT TCT CAA 
TGC TCA CGC TGT AGG TAT CTC AGT TCG GTG TAG GTC GTT CGC TCC AAG CTG GGC 
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TGT GTG CAC GAA CCC CCC GTT CAG CCC GAC CGC TGC GCC TTA TCC GGT AAC TAT 
CGT CTT GAG TCC AAC CCG GTA AGA CAC GAC TTA TCG CCA CTG GCA GCA GCC ACT 
GGT AAC AGG ATT AGC AGA GCG AGG TAT GTA GGC GGT GCT ACA GAG TTC TTG AAG 
TGG TGG CCT AAC TAC GGC TAC ACT AGA AGG ACA GTA TTT GGT ATC TGC GCT CTG 
CTG AAG CCA GTT ACC TTC GGA AAA AGA GTT GGT AGC TCT TGA TCC GGC AAA CAA 
ACC ACC GCT GGT AGC GGT GGT TTT TTT GTT TGC AAG CAG CAG ATT ACG CGC AGA 
AAA AAA GGA TCT CAA GAA GAT CCT TTG ATC TTT TCT ACG GGG TCT GAC GCT CAG 
TGG AAC GAA AAC TCA CGT TAA GGG ATT TTG GTC ATG AGA TTA TCA AAA AGG ATC 
TTC ACC TAG ATC CTT TTA AAT TAA AAA TGA AGT TTT AAA TCA ATC TAA AGT ATA 
TAT GAG TAA ACT TGG TCT GAC AGT TAC CAA TGC TTA ATC AGT GAG GCA CCT ATC 
TCA GCG ATC TGT CTA TTT CGT TCA TCC ATA GCT GCC TGA CTC CCC GTC GTG TAG 
ATA ACT ACG ATA CGG GAG GGC TTA CCA TCT GGC CCC AGT GCT GCA ATG ATA CCG 
CGA GAC CCA CGC TCA CCG GCT CCA GAT TTA TCA GCA ATA AAC CAG CCA GCC GGA 
AGG GCC GAG CGC AGA AGT GGT CCT GCA ACT TTA TCC GCC TCC ATC CAG TCT ATT 
AAT TGT TGC CGG GAA GCT AGA GTA AGT AGT TCG CCA GTT AAT AGT TTG CGC AAC 
GTT GTT GCC ATT GCT ACA GGC ATC GTG GTG TCA CGC TCG TCG TTT GGT ATG GCT 
TCA TTC AGC TCC GGT TCC CAA CGA TCA AGG CGA GTT ACA TGA TCC CCC ATG TTG 
TGC AAA AAA GCG GTT AGC TCC TTC GGT CCT CCG ATC GTT GTC AGA AGT AAG TTG 
GCC GCA GTG TTA TCA CTC ATG GTT ATG GCA GCA CTG CAT AAT TCT CTT ACT GTC 
ATG CCA TCC GTA AGA TGC TTT TCT GTG ACT GGT GAG TAC TCA ACC AAG TCA TTC 
TGA GAA TAG TGT ATG CGG CGA CCG AGT TGC TCT TGC CCG GCG TCA ATA CGG GAT 
AAT ACC GCG CCA CAT AGC AGA ACT TTA AAA GTG CTC ATC ATT GGA AAA CGT TCT 
TCG GGG CGA AAA CTC TCA AGG ATC TTA CCG CTG TTG AGA TCC AGT TCG ATG TAA 
CCC ACT CGT GCA CCC AAC TGA TCT TCA GCA TCT TTT ACT TTC ACC AGC GTT TCT 
GGG TGA GCA AAA ACA GGA AGG CAA AAT GCC GCA AAA AAG GGA ATA AGG GCG ACA 
CGG AAA TGT TGA ATA CTC ATA CTC TTC CTT TTT CAA TAT TAT TGA AGC ATT TAT 
CAG GGT TAT TGT CTC ATG AGC GGA TAC ATA TTT GAA TGT ATT TAG AAA AAT AAA 
CAA ATA GGG GTT CCG CGC ACA TTT CCC CGA AAA GTG CCA CCT GAC GTC TAA GAA 
ACC ATT ATT ATC ATG ACA TTA ACC TAT AAA AAT AGG CGT ATC ACG AGG CCC TTT 
CGT CTT CAC
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4. pQE32_yPheRS (T415G) (6,895 bp) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T5 promoter and lac operon 7   - 87 bp 
 
yPheRS_alpha subunit 115  -  1680 bp 
 
yPheRS_beta subunit  1695  -  3482 bp 
 
ColE1 origin   5103 -  5127 bp 
 
beta-lactamase  6690  -  5830 bp 
 
 
Full sequence     
 
CTC GAG AAA TCA TAA AAA ATT TAT TTG CTT TGT GAG CGG ATA ACA ATT ATA ATA 
GAT TCA ATT GTG AGC GGA TAA CAA TTT CAC ACA GAA TTC ATT AAA GAG GAG AAA 
TTA ACT ATG AGA GGA TCT CAC CAT CAC CAT CAC CAT GGG ATC CAG ACC ATG AAT 
CTA GAG ATG TCT GAC TTC CAA TTA GAA ATT CTA AAG AAA CTA GAT GAA TTG GAT 
GAG ATC AAG TCC ACA CTG GCA ACT TTC CCT CAG CAC GGC TCT CAA GAT GTT CTT 
TCC GCT TTG AAC TCT TTG AAA GCC CAC AAC AAG TTA GAG TTT TCC AAG GTC GAC 
ACG GTT ACG TAT GAC TTG ACC AAA GAA GGT GCT CAA ATT TTG AAT GAA GGT TCG 
TAC GAA ATT AAA CTA GTC AAG CTC ATC CAA GAG TTG GGT CAA CTT CAA ATC AAA 
GAT GTG ATG TCC AAA CTA GGC CCT CAA GTT GGT AAG GTC GGT CAG GCT AGA GCT 
TTC AAG AAC GGC TGG ATC GCC AAA AAC GCC TCA AAC GAG CTT GAA CTC TCC GCA 
AAA TTG CAA AAT ACC GAT TTA AAT GAG CTT ACT GAT GAA ACG CAA TCT ATT CTA 
GCG CAA ATC AAG AAC AAC TCG CAT CTG GAT AGC ATT GAC GCC AAG ATT TTG AAC 
GAC TTG AAG AAA AGA AAG TTA ATT GCT CAA GGT AAA ATC ACA GAT TTC AGT GTC 
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ACC AAA GGG CCA GAG TTC TCG ACC GAC CTC ACC AAA TTG GAA ACC GAT CTT ACC 
TCC GAC ATG GTC TCC ACC AAT GCA TAC AAG GAC TTG AAG TTC AAG CCT TAC AAT 
TTC AAT TCT CAA GGT GTG CAA ATA TCT TCA GGT GCT CTT CAC CCC TTA AAC AAA 
GTC AGA GAG GAA TTT AGA CAA ATT TTC TTT TCC ATG GGA TTC ACA GAG ATG CCC 
TCG AAC CAA TAC GTC GAG ACA GGT TTC TGG AAC TTC GAT GCC CTT TAC GTC CCA 
CAA CAG CAT CCT GCT CGT GAC CTG CAA GAC ACT TTC TAC ATC AAG GAC CCA CTA 
ACC GCT GAG TTG CCC GAT GAC AAG ACA TAC ATG GAC AAT ATC AAA GCC GTT CAC 
GAA CAG GGG AGA TTC GGG TCC ATC GGT TAT CGT TAC AAC TGG AAG CCA GAA GAA 
TGT CAA AAA TTG GTC TTG AGA ACT CAC TCC ACA GCC ATC TCT GCC AGA ATG CTG 
CAC GAT TTG GCC AAA GAT CCA AAG CCC ACC AGA TTG TTT TCT ATC GAC CGT GTT 
TTC CGT AAC GAA GCA GTT GAC GCC ACC CAT TTG GCC GAA TTC CAC CAG GTG GAA 
GGT GTT CTT GCC GAC TAC AAC ATT ACT CTG GGT GAC CTG ATC AAG TTC ATG GAA 
GAG TTT TTC GAA AGA ATG GGT GTC ACC GGT TTG AGA TTC AAG CCT ACC TAC AAT 
CCT TAC GGC GAG CCA TCA ATG GAA ATC TTT TCT TGG CAC GAA GGT TTG CAA AAA 
TGG GTC GAA ATC GGT AAC TCT GGT ATG TTC AGA CCA GAA ATG CTC GAG TCC ATG 
GGT CTA CCA AAG GAT CTA AGA GTC CTT GGT TGG GGG TTA TCC TTG GAA AGA CCT 
ACC ATG ATC AAA TAT AAG GTT CAA AAC ATC AGA GAA CTG TTA GGT CAT AAA GTC 
TCT TTG GAC TTT ATC GAA ACC AAT CCT GCT GCT AGA TTG GAC GAA GAC TTG TAC 
GAA TAA GGC AGG AAT AGA TTA TGC CTA CCG TCT CCG TGA ACA AGC AGC AAT TAT 
TTG ATC TTC TAG GCA AAG ACT ACA CTT CCC AAG AGT TCG ACG AAT TAT GTT TTG 
AAT TCG GTA TGG AAA TGG ACG AAG ACA CCA CAG AAG AGG CCT TGA AAA CCG GGG 
AGG AGC CGG AAT TGA AGC TTG ATA TCA GTG CCA ATC GTT ACG ATT TGC TTT GTA 
TCG AAG GTA TTT CAC AGT CGC TGA ACG AAT ACT TGG AAC GTA AAG AAA GAC CTG 
ACT ATA AAT TAA GCA AGC CAA CCA CTA AGT TGA TCA TCG ACA AAT CAA CGG AGC 
AAA TTA GAC CTT TTG CTA CCG CTG CTG TAT TGA GAA ATA TCA AGC TTA ACG AAA 
AAT CTT ACG CTT CTT TTA TTG CCT TGC AAG ATA AAT TAC ATG CCA ATC TAT GTA 
GAA ACA GAA GCT TGG TTG CCA TGG GTA CTC ACG ATT TAG ATT CAA TTG AAG GTC 
CAT TCC ATT ACA GAG CTC TAC CAC CAA AGG ACA TCA AGT TCG TAC CAT TGA ATC 
AAA CCC AAG AGT TTA CTG GTG ACA AAT TGA TCG AGT TTT ATA AAT CTC CAG AAC 
AGA AAA ACA ACA TAG GGA GAT ACG TTC ACA TTA TTG AGG ATT CTC CAG TCT TCC 
CAG TTA TTA TGG ACA GCA AAG ATC GTG TTT GCT CCC TGC CAC CAT TAA TCA ATA 
GTG AAC ATT CGA AGA TCT CTG TGA ACA CCC GTA ACA TTT TGA TTG ATA TAA CCG 
CCA CCG ATA AGA CCA AAG CCG AGA TCG TTT TGA ACA TAT TAA CTA CAA TGT TCT 
CAC GTT ATT GTG ACG AAC CAT TCA CGG TTG AGC CTG TAG AAA TTG TCT CTG AAC 
ACA ATG GCC AAT CCC GTT TGG CGC CAA ACT TCA ACG ATA GAA TTA TGG ATG TCT 
CCA TTA AGT ACA TCA ACT CCT GTC TTG GCC TAG ATC AAT CCG CTG ATG AAA TTG 
CTC ATT GTC TAA AAA AGA TGT CGT TGC ATG CCG TTC AAT CAA AGG AAG ACA AGG 
ACA TCT TGC ACG TTG ACA TTC CGG TAA CTA GAC CTG ATA TTT TGC ACG CTT GTG 
ATA TAA TGG AAG ATG CCG CTG TCG GTT ATG GTT TCA ATA ATT TGC CAA AGG GTG 
AGA AAT TAT CCA ATG CCA ACT TCA TTG CCA AAC CAT TAC CAA TCA ACA AGG TTT 
CTG ATA TTT TCA GAG TTG CAT CCT CTC AAG CCA CGT GGG TTG AGG TTT TAC CAT 
TGA CCT TAT GTT CGC ACG ATG AAA ACT TTA AAT TTC TAA GAC AAT CCG ACA ATG 
ATG ATT TAG CTG TCA AAT TGG CCA ACC CAA AGA CTT TGG AAT ACC AAG TTG TTA 
GAA CCA CTT TAT TGC CTG GTA TCT TAA AGA CAG TCA AGG AAA ACA GAA AAC ATT 
CCT TAC CAA TCA AAG TCT TTG AAA CCG GTG ACG TTG TAT TTA AAG ACG ACA AAC 
TAG AAA GGA AGG CGT ACA ATG AAC GTC ACT GGG CTG CCA TCT ACG TGG GTA AGA 
ATT CTG GGT TTG AAA TCA TTC AAG GGT TAT TGG GTA AAA TCA TGC AAA CTT TTA 
GAA CAG AGT GGA TTG CAG ACT ACG GTG CTG CTG CTT CTG GCA GAG GTT ACT GGA 
TTG AAG AAG ACG ATT CTG TGA AAA CCT ATT TCC CAG GTA GAG GTG CCA AGG TCA 
TGT TCA GAT CCA AAG AAG GCG CTG AGC CAA AGC AAA TCG GCC ACT TGG GTG TCT 
TGC ATC CTG AAG TCA TGA TGA ATT TCG ACG TTC CAT TCG CTG CAT CCT TTG TAG 
AGG TTA ATG CCG AAG TCT TCC TAT AAT GTA ATG TTC TAA CAA AAA TTT TTA CTG 
ATT TAT AAA ACT TAT ATA GAT AGA TAG ACA CAT AAA TGT ATC TAT ATA TAG AAA 
CAC AAC TAA AGT TTA CCA TCT TAA AGG TAA TGG GTA CCC CGG GTC GAC CTG CAG 
CCA AGC TTA ATT AGC TGA GCT TGG ACT CCT GTT GAT AGA TCC AGT AAT GAC CTC 
AGA ACT CCA TCT GGA TTT GTT CAG AAC GCT CGG TTG CCG CCG GGC GTT TTT TAT 
TGG TGA GAA TCC AAG CTA GCT TGG CGA GAT TTT CAG GAG CTA AGG AAG CTA AAA 
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TGG AGA AAA AAA TCA CTG GAT ATA CCA CCG TTG ATA TAT CCC AAT GGC ATC GTA 
AAG AAC ATT TTG AGG CAT TTC AGT CAG TTG CTC AAT GTA CCT ATA ACC AGA CCG 
TTC AGC TGG ATA TTA CGG CCT TTT TAA AGA CCG TAA AGA AAA ATA AGC ACA AGT 
TTT ATC CGG CCT TTA TTC ACA TTC TTG CCC GCC TGA TGA ATG CTC ATC CGG AAT 
TTC GTA TGG CAA TGA AAG ACG GTG AGC TGG TGA TAT GGG ATA GTG TTC ACC CTT 
GTT ACA CCG TTT TCC ATG AGC AAA CTG AAA CGT TTT CAT CGC TCT GGA GTG AAT 
ACC ACG ACG ATT TCC GGC AGT TTC TAC ACA TAT ATT CGC AAG ATG TGG CGT GTT 
ACG GTG AAA ACC TGG CCT ATT TCC CTA AAG GGT TTA TTG AGA ATA TGT TTT TCG 
TCT CAG CCA ATC CCT GGG TGA GTT TCA CCA GTT TTG ATT TAA ACG TGG CCA ATA 
TGG ACA ACT TCT TCG CCC CCG TTT TCA CCA TGG GCA AAT ATT ATA CGC AAG GCG 
ACA AGG TGC TGA TGC CGC TGG CGA TTC AGG TTC ATC ATG CCG TTT GTG ATG GCT 
TCC ATG TCG GCA GAA TGC TTA ATG AAT TAC AAC AGT ACT GCG ATG AGT GGC AGG 
GCG GGG CGT AAT TTT TTT AAG GCA GTT ATT GGT GCC CTT AAA CGC CTG GGG TAA 
TGA CTC TCT AGC TTG AGG CAT CAA ATA AAA CGA AAG GCT CAG TCG AAA GAC TGG 
GCC TTT CGT TTT ATC TGT TGT TTG TCG GTG AAC GCT CTC CTG AGT AGG ACA AAT 
CCG CCC TCT AGA GCT GCC TCG CGC GTT TCG GTG ATG ACG GTG AAA ACC TCT GAC 
ACA TGC AGC TCC CGG AGA CGG TCA CAG CTT GTC TGT AAG CGG ATG CCG GGA GCA 
GAC AAG CCC GTC AGG GCG CGT CAG CGG GTG TTG GCG GGT GTC GGG GCG CAG CCA 
TGA CCC AGT CAC GTA GCG ATA GCG GAG TGT ATA CTG GCT TAA CTA TGC GGC ATC 
AGA GCA GAT TGT ACT GAG AGT GCA CCA TAT GCG GTG TGA AAT ACC GCA CAG ATG 
CGT AAG GAG AAA ATA CCG CAT CAG GCG CTC TTC CGC TTC CTC GCT CAC TGA CTC 
GCT GCG CTC GGT CGT TCG GCT GCG GCG AGC GGT ATC AGC TCA CTC AAA GGC GGT 
AAT ACG GTT ATC CAC AGA ATC AGG GGA TAA CGC AGG AAA GAA CAT GTG AGC AAA 
AGG CCA GCA AAA GGC CAG GAA CCG TAA AAA GGC CGC GTT GCT GGC GTT TTT CCA 
TAG GCT CCG CCC CCC TGA CGA GCA TCA CAA AAA TCG ACG CTC AAG TCA GAG GTG 
GCG AAA CCC GAC AGG ACT ATA AAG ATA CCA GGC GTT TCC CCC TGG AAG CTC CCT 
CGT GCG CTC TCC TGT TCC GAC CCT GCC GCT TAC CGG ATA CCT GTC CGC CTT TCT 
CCC TTC GGG AAG CGT GGC GCT TTC TCA TAG CTC ACG CTG TAG GTA TCT CAG TTC 
GGT GTA GGT CGT TCG CTC CAA GCT GGG CTG TGT GCA CGA ACC CCC CGT TCA GCC 
CGA CCG CTG CGC CTT ATC CGG TAA CTA TCG TCT TGA GTC CAA CCC GGT AAG ACA 
CGA CTT ATC GCC ACT GGC AGC AGC CAC TGG TAA CAG GAT TAG CAG AGC GAG GTA 
TGT AGG CGG TGC TAC AGA GTT CTT GAA GTG GTG GCC TAA CTA CGG CTA CAC TAG 
AAG GAC AGT ATT TGG TAT CTG CGC TCT GCT GAA GCC AGT TAC CTT CGG AAA AAG 
AGT TGG TAG CTC TTG ATC CGG CAA ACA AAC CAC CGC TGG TAG CGG TGG TTT TTT 
TGT TTG CAA GCA GCA GAT TAC GCG CAG AAA AAA AGG ATC TCA AGA AGA TCC TTT 
GAT CTT TTC TAC GGG GTC TGA CGC TCA GTG GAA CGA AAA CTC ACG TTA AGG GAT 
TTT GGT CAT GAG ATT ATC AAA AAG GAT CTT CAC CTA GAT CCT TTT AAA TTA AAA 
ATG AAG TTT TAA ATC AAT CTA AAG TAT ATA TGA GTA AAC TTG GTC TGA CAG TTA 
CCA ATG CTT AAT CAG TGA GGC ACC TAT CTC AGC GAT CTG TCT ATT TCG TTC ATC 
CAT AGT TGC CTG ACT CCC CGT CGT GTA GAT AAC TAC GAT ACG GGA GGG CTT ACC 
ATC TGG CCC CAG TGC TGC AAT GAT ACC GCG AGA CCC ACG CTC ACC GGC TCC AGA 
TTT ATC AGC AAT AAA CCA GCC AGC CGG AAG GGC CGA GCG CAG AAG TGG TCC TGC 
AAC TTT ATC CGC CTC CAT CCA GTC TAT TAA TTG TTG CCG GGA AGC TAG AGT AAG 
TAG TTC GCC AGT TAA TAG TTT GCG CAA CGT TGT TGC CAT TGC TAC AGG CAT CGT 
GGT GTC ACG CTC GTC GTT TGG TAT GGC TTC ATT CAG CTC CGG TTC CCA ACG ATC 
AAG GCG AGT TAC ATG ATC CCC CAT GTT GTG CAA AAA AGC GGT TAG CTC CTT CGG 
TCC TCC GAT CGT TGT CAG AAG TAA GTT GGC CGC AGT GTT ATC ACT CAT GGT TAT 
GGC AGC ACT GCA TAA TTC TCT TAC TGT CAT GCC ATC CGT AAG ATG CTT TTC TGT 
GAC TGG TGA GTA CTC AAC CAA GTC ATT CTG AGA ATA GTG TAT GCG GCG ACC GAG 
TTG CTC TTG CCC GGC GTC AAT ACG GGA TAA TAC CGC GCC ACA TAG CAG AAC TTT 
AAA AGT GCT CAT CAT TGG AAA ACG TTC TTC GGG GCG AAA ACT CTC AAG GAT CTT 
ACC GCT GTT GAG ATC CAG TTC GAT GTA ACC CAC TCG TGC ACC CAA CTG ATC TTC 
AGC ATC TTT TAC TTT CAC CAG CGT TTC TGG GTG AGC AAA AAC AGG AAG GCA AAA 
TGC CGC AAA AAA GGG AAT AAG GGC GAC ACG GAA ATG TTG AAT ACT CAT ACT CTT 
CCT TTT TCA ATA TTA TTG AAG CAT TTA TCA GGG TTA TTG TCT CAT GAG CGG ATA 
CAT ATT TGA ATG TAT TTA GAA AAA TAA ACA AAT AGG GGT TCC GCG CAC ATT TCC 
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CCG AAA AGT GCC ACC TGA CGT CTA AGA AAC CAT TAT TAT CAT GAC ATT AAC CTA 
TAA AAA TAG GCG TAT CAC GAG GCC CTT TCG TCT TCA C 
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5. pREP4_ytRNAPhe_AAA (4084 bp) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vector size          4084  bp 
agpt promoter        259-260  bp 
RBS         336-344  bp 
Aminoglycosie phosphotransferase     357-1151 bp 
 
lacI promoter        2638-2639 bp 
lacI repressor         1529-2611 bp 
 
lpp promoter        3029-3083 bp 
ytRNA         2945-3020 bp  
transcriptional terminator(rrnC)     2938-2909 bp 
 
p15A origin of replication      3408-3411 bp 
 
 
Full sequence       
 
AAG CTT CAC GCT GCC GCA AGC ACT CAG GGC GCA AGG GCT GCT AAA GGA AGC GGA 
ACA CGT AGA AAG CCA GTC CGC AGA AAC GGT GCT GAC CCC GGA TGA ATG TCA GCT 
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ACT GGG CTA TCT GGA CAA GGG AAA ACG CAA GCG CAA AGA GAA AGC AGG TAG CTT 
GCA GTG GGC TTA CAT GGC GAT AGC TAG ACT GGG CGG TTT TAT GGA CAG CAA GCG 
AAC CGG AAT TGC CAG CTG GGG CGC CCT CTG GTA AGG TTG GGA AGC CCT GCA AAG 
TAA ACT GGA TGG CTT TCT TGC CGC CAA GGA TCT GAT GGC GCA GGG GAT CAA GAT 
CTG ATC AAG AGA CAG GAT GAC GGT CGT TTC GCA TGC TTG AAC AAG ATG GAT TGC 
ACG CAG GTT CTC CGG CCG CTT GGG TGG AGA GGC TAT TCG GCT ATG ACT GGG CAC 
AAC AGA CAA TCG GCT GCT CTG ATG CCG CCG TGT TCC GGC TGT CAG CGC AGG GGC 
GCC CGG TTC TTT TTG TCA AGA CCG ACC TGT CCG GTG CCC TGA ATG AAC TGC AGG 
ACG AGG CAG CGC GGC TAT CGT GGC TGG CCA CGA CGG GCG TTC CTT GCG CAG CTG 
TGC TCG ACG TTG TCA CTG AAG CGG GAA GGG ACT GGC TGC TAT TGG GCG AAG TGC 
CGG GGC AGG ATC TCC TGT CAT CTC ACC TTG CTC CTG CCG AGA AAG TAT CCA TCA 
TGG CTG ATG CAA TGC GGC GGC TGC ATA CGC TTG ATC CGG CTA CCT GCC CAT TCG 
ACC ACC AAG CGA AAC ATC GCA TCG AGC GAG CAC GTA CTC GGA TGG AAG CCG GTC 
TTG TCG ATC AGG ATG ATC TGG ACG AAG AGC ATC AGG GGC TCG CGC CAG CCG AAC 
TGT TCG CCA GGC TCA AGG CGC GCA TGC CCG ACG GCG AGG ATC TCG TCG TGA CCC 
ATG GCG ATG CCT GCT TGC CGA ATA TCA TGG TGG AAA ATG GCC GCT TTT CTG GAT 
TCA TCG ACT GTG GCC GGC TGG GTG TGG CGG ACC GCT ATC AGG ACA TAG CGT TGG 
CTA CCC GTG ATA TTG CTG AAG AGC TTG GCG GCG AAT GGG CTG ACC GCT TCC TCG 
TGC TTT ACG GTA TCG CCG CTC CCG ATT CGC AGC GCA TCG CCT TCT ATC GCC TTC 
TTG ACG AGT TCT TCT GAG CGG GAC TCT GGG GTT CGA AAT GAC CGA CCA AGC GAC 
GCC CAA CCT GCC ATC ACG AGA TTT CGA TTC CAC CGC CGC CTT CTA TGA AAG GTT 
GGG CTT CGG AAT CGT TTT CCG GGA CGC CGG CTG GAT GAT CCT CCA GCG CGG GGA 
TCT CAT GCT GGA GTT CTT CGC CCA CCC CGG GCT CGA TCC CCT CGC GAG TTG GTT 
CAG CTG CTG CCT GAG GCT GGA CGA CCT CGC GGA GTT CTA CCG GCA GTG CAA ATC 
CGT CGG CAT CCA GGA AAC CAG CAG CGG CTA TCC GCG CAT CCA TGC CCC CGA ACT 
GCA GGA GTG GGG AGG CAC GAT GGC CGC TTT GGT CGA CAA TTC GCG CTA ACT TAC 
ATT AAT TGC GTT GCG CTC ACT GCC CGC TTT CCA GTC GGG AAA CCT GTC GTG CCA 
GCT GCA TTA ATG AAT CGG CCA ACG CGC GGG GAG AGG CGG TTT GCG TAT TGG GCG 
CCA GGG TGG TTT TTC TTT TCA CCA GTG AGA CGG GCA ACA GCT GAT TGC CCT TCA 
CCG CCT GGC CCT GAG AGA GTT GCA GCA AGC GGT CCA CGC TGG TTT GCC CCA GCA 
GGC GAA AAT CCT GTT TGA TGG TGG TTA ACG GCG GGA TAT AAC ATG AGC TGT CTT 
CGG TAT CGT CGT ATC CCA CTA CCG AGA TAT CCG CAC CAA CGC GCA GCC CGG ACT 
CGG TAA TGG CGC GCA TTG CGC CCA GCG CCA TCT GAT CGT TGG CAA CCA GCA TCG 
CAG TGG GAA CGA TGC CCT CAT TCA GCA TTT GCA TGG TTT GTT GAA AAC CGG ACA 
TGG CAC TCC AGT CGC CTT CCC GTT CCG CTA TCG GCT GAA TTT GAT TGC GAG TGA 
GAT ATT TAT GCC AGC CAG CCA GAC GCA GAC GCG CCG AGA CAG AAC TTA ATG GGC 
CCG CTA ACA GCG CGA TTT GCT GGT GAC CCA ATG CGA CCA GAT GCT CCA CGC CCA 
GTC GCG TAC CGT CTT CAT GGG AGA AAA TAA TAC TGT TGA TGG GTG TCT GGT CAG 
AGA CAT CAA GAA ATA ACG CCG GAA CAT TAG TGC AGG CAG CTT CCA CAG CAA TGG 
CAT CCT GGT CAT CCA GCG GAT AGT TAA TGA TCA GCC CAC TGA CGC GTT GCG CGA 
GAA GAT TGT GCA CCG CCG CTT TAC AGG CTT CGA CGC CGC TTC GTT CTA CCA TCG 
ACA CCA CCA CGC TGG CAC CCA GTT GAT CGG CGC GAG ATT TAA TCG CCG CGA CAA 
TTT GCG ACG GCG CGT GCA GGG CCA GAC TGG AGG TGG CAA CGC CAA TCA GCA ACG 
ACT GTT TGC CCG CCA GTT GTT GTG CCA CGC GGT TGG GAA TGT AAT TCA GCT CCG 
CCA TCG CCG CTT CCA CTT TTT CCC GCG TTT TCG CAG AAA CGT GGC TGG CCT GGT 
TCA CCA CGC GGG AAA CGG TCT GAT AAG AGA CAC CGG CAT ACT CTG CGA CAT CGT 
ATA ACG TTA CTG GTT TCA CAT TCA CCA CCC TGA ATT GAC TCT CTT CCG GGC GCT 
ATC ATG CCA TAC CGC GAA AGG TTT TGC GCC ATT CGA TGG TGT CAA CGT AAA TGC 
ATG CCG CTT CGC CTT CGC GCG CGA ATT GTC GAC CCT GTC CCT CCT GTT CAG CTA 
CTG ACG GGG TGG TGC GTA ACG GCA AAA GCA CCG CCG GAC ATC AGC GCT AGC GGA 
GTG TAC TGG CGA AAG GGG GAG GTG CTG CAA GGC GAT TAA GTT GGG TAA CGC CAG 
GGT TTT CCC AGT CAC GAC GTT GTA AAA CGA CGG CCA GTG CCA AGC TTA AAA AAA 
ATC CTT AGC TTT CGC TAA GGA TCT GCA GTG GTG CGA ACT CTG TGG ATC GAA CAC 
AGG ACC TCC AGA TTT TTA GTC TGG CGC TCT CCC AAC TGA GCT AAG TCC GCG AAT 
TCA GCG TTA CAA GTA TTA CAC AAA GTT TTT TAT GTT GAG AAT ATT TTT TTG ATG 
GGG CGC CAC TTA TTT TTG ATC GTT CGC TCA AAG AAG CGG CGC CAG GGT GGT TTT 
TCT TTT CAC CAG TGA GAC GGG CAA CAG CTG GCT TAC TAT GTT GGC ACT GAT GAG 
GGT GTC AGT GAA GTG CTT CAT GTG GCA GGA GAA AAA AGG CTG CAC CGG TGC GTC 
AGC AGA ATA TGT GAT ACA GGA TAT ATT CCG CTT CCT CGC TCA CTG ACT CGC TAC 
GCT CGG TCG TTC GAC TGC GGC GAG CGG AAA TGG CTT ACG AAC GGG GCG GAG ATT 
TCC TGG AAG ATG CCA GGA AGA TAC TTA ACA GGG AAG TGA GAG GGC CGC GGC AAA 
GCC GTT TTT CCA TAG GCT CCG CCC CCC TGA CAA GCA TCA CGA AAT CTG ACG CTC 
AAA TCA GTG GTG GCG AAA CCC GAC AGG ACT ATA AAG ATA CCA GGC GTT TCC CCT 
GGC GGC TCC CTC GTG CGC TCT CCT GTT CCT GCC TTT CGG TTT ACC GGT GTC ATT 
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CCG CTG TTA TGG CCG CGT TTG TCT CAT TCC ACG CCT GAC ACT CAG TTC CGG GTA 
GGC AGT TCG CTC CAA GCT GGA CTG TAT GCA CGA ACC CCC CGT TCA GTC CGA CCG 
CTG CGC CTT ATC CGG TAA CTA TCG TCT TGA GTC CAA CCC GGA AAG ACA TGC AAA 
AGC ACC ACT GGC AGC AGC CAC TGG TAA TTG ATT TAG AGG AGT TAG TCT TGA AGT 
CAT GCG CCG GTT AAG GCT AAA CTG AAA GGA CAA GTT TTG GTG ACT GCG CTC CTC 
CAA GCC AGT TAC CTC GGT TCA AAG AGT TGG TAG CTC AGA GAA CCT TCG AAA AAC 
CGC CCT GCA AGG CGG TTT TTT CGT TTT CAG AGC AAG AGA TTA CGC GCA GAC CAA 
AAC GAT CTC AAG AAG ATC ATC TTA TTA ATC AGA TAA AAT ATT TCT AGA TTT CAG 
TGC AAT TTA TCT CTT CAA ATG TAG CAC CTG AAG TCA GCC CCA TAC GAT ATA AGT 
TGT TAA TTC TCA TGT TTG ACA GCT TAT CAT CGA T 
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Appendix B   
Marker Protein Information 
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1. GFPUV  (Clontech)  (without a N-terminal hexa-histidine tag) 
 
DNA sequence 
 
ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA ATT CTT GTT GAA TTA 
GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA GAG GGT GAA GGT GAT 
GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT ACT GGA AAA CTA CCT 
GTT CCA TGG CCA ACA CTT GTC ACT ACT TTC TCT TAT GGT GTT CAA TGC TTT TCC 
CGT TAT CCG GAT CAT ATG AAA CGG CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA 
GGT TAT GTA CAG GAA CGC ACT ATA TCT TTC AAA GAT GAC GGG AAC TAC AAG ACG 
CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT GTT AAT CGT ATC GAG TTA AAA 
GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTC GGA CAC AAA CTC GAG TAC AAC 
TAT AAC TCA CAC AAT GTA TAC ATC ACG GCA GAC AAA CAA AAG AAT GGA ATC AAA 
GCT AAC TTC AAA ATT CGC CAC AAC ATT GAA GAT GGA TCC GTT CAA CTA GCA GAC 
CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC CTT TTA CCA GAC AAC 
CAT TAC CTG TCG ACA CAA TCT GCC CTT TCG AAA GAT CCC AAC GAA AAG CGT GAC 
CAC ATG GTC CTT CTT GAG TTT GTA ACT GCT GCT GGG ATT ACA CAT GGC ATG GAT 
GAG CTC TAC AAA CTG CAG CCA AGC TTA ATT AGC TGA 
 
Amino acid sequence 
 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFSYGVQCF
SRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLE
YNYNSHNVYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNE
KRDHMVLLEFVTAAGITHGMDELYKLQPSLIS 
 
 
2. GFPUV 
 
DNA sequence 
 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC GTC GAC CTG CAG CCC CGG 
GTA CCG GTA GAA AAA ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA 
ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA 
GAG GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT 
ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT TTC TCT TAT GGT 
GTT CAA TGC TTT TCC CGT TAT CCG GAT CAT ATG AAA CGG CAT GAC TTT TTC AAG 
AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA CGC ACT ATA TCT TTC AAA GAT GAC 
GGG AAC TAC AAG ACG CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT GTT AAT 
CGT ATC GAG TTA AAA GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTC GGA CAC 
AAA CTC GAG TAC AAC TAT AAC TCA CAC AAT GTA TAC ATC ACG GCA GAC AAA CAA 
AAG AAT GGA ATC AAA GCT AAC TTC AAA ATT ATG AGA GGA TCG CAT CAC CAT CAC 
CAT CAC GGA TCC GTC GAC CTG CAG CCC CGG GTA CCG GTA GAA AAA ATG AGT AAA 
GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA ATT CTT GTT GAA TTA GAT GGT GAT 
GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA GAG GGT GAA GGT GAT GCA ACA TAC 
GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT ACT GGA AAA CTA CCT GTT CCA TGG 
CCA ACA CTT GTC ACT ACT TTC TCT TAT GGT GTT CAA TGC TTT TCC CGT TAT CCG 
GAT CAT ATG AAA CGG CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA 
CAG GAA CGC ACT ATA TCT TTC AAA GAT GAC GGG AAC TAC AAG ACG CGT GCT GAA 
GTC AAG TTT GAA GGT GAT ACC CTT GTT AAT CGT ATC GAG TTA AAA GGT ATT GAT 
TTT AAA GAA GAT GGA AAC ATT CTC GGA CAC AAA CTC GAG TAC AAC TAT AAC TCA 
CAC AAT GTA TAC ATC ACG GCA GAC AAA CAA AAG AAT GGA ATC AAA GCT AAC TTC 
AAA ATT CGC CAC AAC ATT GAA GAT GGA TCC GTT CAA CTA GCA GAC CAT TAT CAA 
CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC CTT TTA CCA GAC AAC CAT TAC CTG 
211 
TCG ACA CAA TCT GCC CTT TCG AAA GAT CCC AAC GAA AAG CGT GAC CAC ATG GTC 
CTT CTT GAG TTT GTA ACT GCT GCT GGG ATT ACA CAT GGC ATG GAT GAG CTC TAC 
AAA CTG CAG CCA AGC TTA ATT AGC TGA 
 
Amino acid sequence 
 
MRGSHHHHHHGSVDLQPRVPVEKMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFIC
TTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYKTRAEVKFEGDTL
VNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGD
GPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYKLQPSLIS 
 
 
3. GFP3 
 
F64L, S65T, S99F, and T153M mutations in GFPUV  
 
DNA sequence 
 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC GTC GAC CTG CAG CCC CGG 
GTA CCG GTA GAA AAA ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA 
ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA 
GAG GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT 
ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT CTG ACC TAT GGT 
GTT CAA TGC TTC TCC CGT TAT CCG GAT CAT ATG AAA CGG CAT GAC TTT TTC AAG 
AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA CGC ACT ATA TTC TTC AAA GAT GAC 
GGG AAC TAC AAG ACG CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT GTT AAT 
CGT ATC GAG TTA AAA GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTC GGA CAC 
AAA CTC GAG TAC AAC TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA 
AAG AAT GGA ATC AAA GCT AAC TTC AAA ATT CGC CAC AAC ATT GAA GAT GGA TCC 
GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC 
CTT TTA CCA GAC AAC CAT TAC CTG TCG ACA CAA TCT GCC CTT TCG AAA GAT CCC 
AAC GAA AAG CGT GAC CAC ATG GTC CTT CTT GAG TTT GTA ACT GCT GCT GGG ATT 
ACA CAT GGC ATG GAT GAG CTC TAC AAA CTG CAG CCA AGC TTA ATT AGC TGA 
 
Amino acid sequence 
 
MRGSHHHHHHGSVDLQPRVPVEKMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFIC
TTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL
VNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGD
GPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYKLQPSLIS 
 
 
4. GFP6 
 
L64F mutation and all Phe codons are changed to UUU in GFP3  
 
DNA sequence 
 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC GTC GAC CTG CAG CCC CGG 
GTA CCG GTA GAA AAA ATG AGT AAA GGA GAA GAA CTT TTT ACT GGA GTT GTC CCA 
ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA 
GAG GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT 
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ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT TTT ACC TAT GGT 
GTT CAA TGC TTT TCC CGT TAT CCG GAT CAT ATG AAA CGG CAT GAC TTT TTT AAG 
AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA CGC ACT ATA TTT TTT AAA GAT GAC 
GGG AAC TAC AAG ACG CGT GCT GAA GTC AAG TTT GAA GGT GAT ACC CTT GTT AAT 
CGT ATC GAG TTA AAA GGT ATT GAT TTT AAA GAA GAT GGA AAC ATT CTC GGA CAC 
AAA CTC GAG TAC AAC TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA 
AAG AAT GGA ATC AAA GCT AAC TTT AAA ATT CGC CAC AAC ATT GAA GAT GGA TCC 
GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC 
CTT TTA CCA GAC AAC CAT TAC CTG TCG ACA CAA TCT GCC CTT TCG AAA GAT CCC 
AAC GAA AAG CGT GAC CAC ATG GTC CTT CTT GAG TTT GTA ACT GCT GCT GGG ATT 
ACA CAT GGC ATG GAT GAG CTC TAC AAA CTG CAG CCA AGC TTA ATT AGC TGA 
 
Amino acid sequence 
MRGSHHHHHHGSVDLQPRVPVEKMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFIC
TTGKLPVPWPTLVTTFTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL
VNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGD
GPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYKLQPSLIS 
 
 
5. GFP_WC 
 
All Phe codons are changed to UUC in GFP3  
 
DNA sequence 
 
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA TCC GTC GAC CTG CAG CCC CGG 
GTA CCG GTA GAA AAA ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA 
ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTC TCT GTC AGT GGA 
GAG GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTC ATT TGC ACT 
ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT CTG ACC TAT GGT 
GTT CAA TGC TTC TCC CGT TAT CCG GAT CAT ATG AAA CGG CAT GAC TTC TTC AAG 
AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA CGC ACT ATA TTC TTC AAA GAT GAC 
GGG AAC TAC AAG ACG CGT GCT GAA GTC AAG TTC GAA GGT GAT ACC CTT GTT AAT 
CGT ATC GAG TTA AAA GGT ATT GAT TTC AAA GAA GAT GGA AAC ATT CTC GGA CAC 
AAA CTC GAG TAC AAC TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA 
AAG AAT GGA ATC AAA GCT AAC TTC AAA ATT CGC CAC AAC ATT GAA GAT GGA TCC 
GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC 
CTT TTA CCA GAC AAC CAT TAC CTG TCG ACA CAA TCT GCC CTT TCG AAA GAT CCC 
AAC GAA AAG CGT GAC CAC ATG GTC CTT CTT GAG TTC GTA ACT GCT GCT GGG ATT 
ACA CAT GGC ATG GAT GAG CTC TAC AAA CTG CAG CCA AGC TTA ATT AGC TGA 
 
Amino acid sequence 
 
MRGSHHHHHHGSVDLQPRVPVEKMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFIC
TTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL
VNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGD
GPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYKLQPSLIS 
 
 
6. GFP6 (2UUU) 
 
AGA (Arg) to UUU (Phe) mutation in position 2 of GFP6 
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7. GFP6 (2UUC) 
 
AGA (Arg) to UUU (Phe) mutation in position 2 of GFP6 
 
 
8. GFP6 (158Am) 
 
AAA (Lys) to UAG (an amber codon) mutation in position 158 of GFP6 
 
 
9. GFP3C 
 
GFP3 with a C-terminal hexa-histidine tag 
 
DNA sequence 
 
ATG CGA GGA TCC CTG CAG CCC CGG GTA CCG GTA GAA AAA ATG AGT AAA GGA GAA 
GAA CTT TTC ACT GGA GTT GTC CCA ATT CTT GTT GAA TTA GAT GGT GAT GTT AAT 
GGG CAC AAA TTT TCT GTC AGT GGA GAG GGT GAA GGT GAT GCA ACA TAC GGA AAA 
CTT ACC CTT AAA TTT ATT TGC ACT ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA 
CTT GTC ACT ACT CTG ACC TAT GGT GTT CAA TGC TTC TCC CGT TAT CCG GAT CAT 
ATG AAA CGG CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA 
CGC ACT ATA TTC TTC AAA GAT GAC GGG AAC TAC AAG ACG CGT GCT GAA GTC AAG 
TTT GAA GGT GAT ACC CTT GTT AAT CGT ATC GAG TTA AAA GGT ATT GAT TTT AAA 
GAA GAT GGA AAC ATT CTC GGA CAC AAA CTC GAG TAC AAC TAT AAC TCA CAC AAT 
GTA TAC ATC ATG GCA GAC AAA CAA AAG AAT GGA ATC AAA GCT AAC TTC AAA ATT 
CGC CAC AAC ATT GAA GAT GGA TCC GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT 
ACT CCA ATT GGC GAT GGC CCT GTC CTT TTA CCA GAC AAC CAT TAC CTG TCG ACA 
CAA TCT GCC CTT TCG AAA GAT CCC AAC GAA AAG CGT GAC CAC ATG GTC CTT CTT 
GAG TTT GTA ACT GCT GCT GGG ATT ACA CAT GGC ATG GAT GAG CTC TAC AAA CTG 
CAG CAT CAC CAT CAC CAT CAC TAA 
 
Amino acid sequence 
 
MRGSLQPRVPVEKMSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWP
TLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGID
FKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHY
LSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYKLQHHHHHH 
 
 
10. GFP3C (158UUG) 
 
AAA (Lys) to UUG (Leu) mutation in position 158 of GFP3C 
 
 
11. mDHFR (Qiagen)  
 
C-terminal hexa-histidine tag 
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DNA sequence 
 
ATG AGA GGA TCC GGC ATC ATG GTT CGA CCA TTG AAC TCG ATC GTC GCC GTG TCC 
CAA AAT ATG GGG ATT GGC AAG AAC GGA GAC CTA CCC TGG CCT CCG CTC AGG AAC 
GAG TTC AAG TAC TTC CAA AGA ATG ACC ACA ACC TCT TCA GTG GAA GGT AAA CAG 
AAT CTG GTG ATT ATG GGT AGG AAA ACC TGG TTC TCC ATT CCT GAG AAG AAT CGA 
CCT TTA AAG GAC AGA ATT AAT ATA GTT CTC AGT AGA GAA CTC AAA GAA CCA CCA 
CGA GGA GCT CAT TTT CTT GCC AAA AGT TTG GAT GAT GCC TTA AGA CTT ATT GAA 
CAA CCG GAA TTG GCA AGT AAA GTA GAC ATG GTT TGG ATA GTC GGA GGC AGT TCT 
GTT TAC CAG GAA GCC ATG AAT CAA CCA GGC CAC CTT AGA CTC TTT GTG ACA AGG 
ATC ATG CAG GAA TTT GAA AGT GAC ACG TTT TTC CCA GAA ATT GAT TTG GGG AAA 
TAT AAA CTT CTC CCA GAA TAC CCA GGC GTC CTC TCT GAG GTC CAG GAG GAA AAA 
GGC ATC 
 
Amino acid sequence 
 
MRGSGIMVRPLNSIVAVSQNMGIGKNGDLPWPPLRNEFKYFQRMTTTSSVEGKQNLVIMGRKTWFSIPEKN
RPLKDRINIVLSRELKEPPRGAHFLAKSLDDALRLIEQPELASKVDMVWIVGGSSVYQEAMNQPGHLRLFV
TRIMQEFESDTFFPEIDLGKYKLLPEYPGVLSEVQEEKGI 
 
 
12. mDHFR2 
 
UUC (Phe) in position 38 and UUU (Phe) in position 95 to UUG (Leu) mutations in 
mDHFR 
 
DNA sequence 
 
ATG AGA GGA TCC GGC ATC ATG GTT CGA CCA TTG AAC TCG ATC GTC GCC GTG TCC 
CAA AAT ATG GGG ATT GGC AAG AAC GGA GAC CTA CCC TGG CCT CCG CTC AGG AAC 
GAG TTG AAG TAC TTC CAA AGA ATG ACC ACA ACC TCT TCA GTG GAA GGT AAA CAG 
AAT CTG GTG ATT ATG GGT AGG AAA ACC TGG TTC TCC ATT CCT GAG AAG AAT CGA 
CCT TTA AAG GAC AGA ATT AAT ATA GTT CTC AGT AGA GAA CTC AAA GAA CCA CCA 
CGA GGA GCT CAT TTG CTT GCC AAA AGT TTG GAT GAT GCC TTA AGA CTT ATT GAA 
CAA CCG GAA TTG GCA AGT AAA GTA GAC ATG GTT TGG ATA GTC GGA GGC AGT TCT 
GTT TAC CAG GAA GCC ATG AAT CAA CCA GGC CAC CTC AGA CTC TTT GTG ACA AGG 
ATC ATG CAG GAA TTT GAA AGT GAC ACG TTT TTC CCA GAA ATT GAT TTG GGG AAA 
TAT AAA CTT CTC CCA GAA TAC CCA GGC GTC CTC TCT GAG GTC CAG GAG GAA AAA 
GGC ATC AAG TAT AAG TTT GAA GTC TAC GAG AAG AAA GGT TCC AGA TCT CAT CAC 
CAT CAC CAT CAC 
 
Amino acid sequence 
 
MRGSGIMVRPLNSIVAVSQNMGIGKNGDLPWPPLRNELKYFQRMTTTSSVEGKQNLVIMGRKTWFSIPEKN
RPLKDRINIVLSRELKEPPRGAHLLAKSLDDALRLIEQPELASKVDMVWIVGGSSVYQEAMNQPGHLRLFV
TRIMQEFESDTFFPEIDLGKYKLLPEYPGVLSEVQEEKGIKYKFEVYEKKGSRSHHHHHH 
 
 
13. mDHFR2 (100UUA) 
 
UUG to UUA mutation in position 100 of mDHFR2 
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Appendix C   
Names and Sequences of PCR Primers 
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Primer name Primer sequence 
GFP1 5’- AC CTGCAG CCC CGG GTA CCG GTA GAA - 3’ 
GFP2 5’- AC CTGCAG TTT GTA GAG CTC ATC CAT - 3’ 
F64LS65T_f 5’- CTT GTC ACT ACT CTG ACC TAT GGT GTT CAA TGC TTC TCC CGT - 3’ 
F64LS65T_r 5’- ACG GGA GAA GCA TTG AAC ACC ATA GGT CAG AGT AGT GAC AAG - 3’ 
S99F_f 5’- GTA CAG GAA CGC ACT ATA TTC TTC AAA GAT GAC GGG AAC - 3’ 
S99F_r 5’- GTT CCC GTC ATC TTT GAA GAA TAT AGT GCG TTC CTG TAC - 3’ 
T153M_f 5’- CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA AAG AAT GGA - 3’ 
T153M_r 5’- TCC ATT CTT TTG TTT GTC TGC CAT GAT GTA TAC ATT GTG - 3’ 
Primer 1 5’- GTG CCA CCT GAC GTC TAA GAA ACC ATT ATT ATC ATG ACA TTA ACC - 3’ 
Primer 2 5' - GAG TAA AGG AGA AGA ACT TTT TAC TGG AGT TGT CCC AAT TC - 3' 
Primer 3 5’- GAA TTG GGA CAA CTC CAG TAA AAA GTT CTT CTC CTT TAC TC - 3’ 
Primer 4 5’- GGC CAA CAC TTG TCA CTA CTT TTA CCT ATG GTG TTC AAT GCT T - 3’ 
Primer 5 5’- AAG CAT TGA ACA CCA TAG GTA AAA GTA GTG ACA AGT GTT GGC C - 3’ 
Primer 6 5’- CAT ATG AAA CGG CAT GAC TTT TTT AAG AGT GCC ATG CCC GAA G - 3’ 
Primer 7 5’- CTT CGG GCA TGG CAC TCT TAA AAA AGT CAT GCC GTT TCA TAT G - 3’ 
Primer 8 5’- GTT ATG TAC AGG AAC GCA CTA TAT TTT TCA AAG ATG ACG GGA ACT ACA A - 3’ 
Primer 9 5’- TTG TAG TTC CCG TCA TCT TTG AAA AAT ATA GTG CGT TCC TGT ACA TAA C - 3’ 
Primer 10 5’- ACA AAA GAA TGG AAT CAA AGC TAA CTT TAA AAT TCG CCA CAA CAT TGA AGA TG - 3’ 
Primer 11 5’- CAT CTT CAA TGT TGT GGC GAA TTT TAA AGT TAG CTT TGA TTC CAT TCT TTT GT - 3’ 
Primer 12 5’- CGC CAA GCT AGC TTG GAT TCT CAC CAA TAA AAA ACG CCC - 3’ 
Primer 13 5’- TAC CTA TGG TGT TCA ATG CTT TTC CCG TTA TCC GGA TCA TAT G - 3’ 
Primer 14 5’- CAT ATG ATC CGG ATA ACG GGA AAA GCA TTG AAC ACC ATA GGT A - 3’ 
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Primer 15 5’- GTT ATG TAC AGG AAC GCA CTA TAT TTT TTA AAG ATG ACG GGA ACT ACA AG - 3’ 
Primer 16 5’- CTT GTA GTT CCC GTC ATC TTT AAA AAA TAT AGT GCG TTC CTG TAC ATA AC - 3’ 
Primer 17 5’- GT GAT GTT AAT GGG CAC AAA TTC TCT GTC AGT GGA GAG GGT- 3’ 
Primer 18 5’- ACC CTC TCC ACT GAC AGA GAA TTT GTG CCC ATT AAC ATC AC- 3’ 
Primer 19 5’- CA TAC GGA AAA CTT ACC CTT AAA TTC ATT TGC ACT ACT GGA AAA CTA CC- 3’ 
Primer 20 5’- GGT AGT TTT CCA GTA GTG CAA ATG AAT TTA AGG GTA AGT TTT CCG TAT G- 3’ 
Primer 21 5’- AT CAT ATG AAA CGG CAT GAC TTC TTC AAG AGT GCC ATG CCC- 3’ 
Primer 22 5’- GGG CAT GGC ACT CTT GAA GAA GTC ATG CCG TTT CAT ATG AT- 3’ 
Primer 23 5’- CG CGT GCT GAA GTC AAG TTC GAA GGT GAT ACC CTT GT- 3’ 
Primer 24 5’- AC AAG GGT ATC ACC TTC GAA CTT GAC TTC AGC ACG CG- 3’ 
Primer 25 5’- CGT ATC GAG TTA AAA GGT ATT GAT TTC AAA GAA GAT GGA AAC ATT CTC GGA- 3’ 
Primer 26 5’- TCC GAG AAT GTT TCC ATC TTC TTT GAA ATC AAT ACC TTT TAA CTC GAT ACG - 3’ 
lacI_AflII_f 5’- CAT ATT CTT AAG TCA TGC GCA CCC GTG GCC AGG ACC C - 3’ 
lacI_SacII_r 5’- CAA CTC CCG CGG TTA CGT GCA GAT GAT AAG CTG TCA AAC - 3’ 
pQE_AflII_f 5’-CAA GTA CTT AAG CGG TGT GAA ATA CCG CAC AGA TGC GTA AGG -3’ 
pQE_SacII_r 5’- GAT CAT CCG CGG TTT TCC CAG TCA CGA CGT TGT AAA ACG - 3’ 
437_f 5’ - GTC GAA ATC GGT AAC NNK GGT ATG TTC AGA CCA GAA ATG CTC G -3’ 
437_r 5’ - CGA GCA TTT CTG GTC TGA ACA TAC CMN NGT TAC CGA TTT CGA C - 3’ 
412_415_418_f 5’ - C AAG CCT ACC TAC NNK CCT TAC NNK GAG CCA NNK ATG GAA ATC TTT T - 3’ 
412_415_418_r 5’- A AAA GAT TTC CAT MNN TGG CTC MNN GTA AGG MN N GTA GG T AGG CTT G - 3’ 
2F_UUU_f 5’ - C ATT AAA GAG GAG AAA TTA ACT ATG TTT GGA TCG CAT CAC - 3’ 
2F_UUU_r 5’ - GTG ATG CGA TCC AAA CAT AGT TAA TTT CTC CTC TTT AAT G - 3’ 
2F_UUC_f 5’ - C ATT AAA GAG GAG AAA TTA ACT ATG TTC GGA TCG CAT CAC - 3’ 
218 
2F_UUC_r 5’ - GTG ATG CGA TCC GAA CAT AGT TAA TTT CTC CTC TTT AAT G - 3’ 
R_lacP_f GCA CCC CAG TCT TTA CAC TAT GCC TAC CGT CTC CGT GAA C 
R_lacP_r GTT CAC GGA GAC GGT AGG CAT AGT GTA AAG ACT GGG GTG C 
Ins_SD_A_Del_lacO_f CGT ATA ATG GAT CC C GAT TTT CAC ATA AGG AGC AGA CC ATG 
Ins_SD_A_Del_lacO_r CAT GGT CTG CTC CTT ATG TGA AAA TCG GGA TCC ATT ATA CG 
ytRNA-GAA_f 5’ - CAC AGG ACC TCC AGA TTT TCA GTC TGG CGC TCT CC - 3’ 
ytRNA-GAA_r 5’ - GGA GAG CGC CAG ACT GAA AAT CTG GAG GTC CTG TG - 3’ 
ytRNA-CAA_f 5’ - CAC AGG ACC TCC AGA TTT TGA GTC TGG CGC TCT CC - 3’ 
ytRNA-CAA_r 5’ - GGA GAG CGC CAG ACT CAA AAT CTG GAG GTC CTG TG - 3’ 
L100_UUA_f 5’ - CTT GCC AAA AGT TTA GAT GAT GCC TTA AGA C - 3’ 
L100_UUA_r 5’ - GTC TTA AGG CAT CAT CTA AAC TTT TGG CAA G - 3’ 
PstI_70_f 5’ - GCA TGC GAG GAT CCC TGC AGC ATC ACC ATC ACC - 3’ 
PstI_70_r 5’- GGT GAT GGT GAT GCT GCA GGG ATC CTC GCA TGC - 3’ 
K158_UUG_f 5’ - ATG GCA GAC AAA CAA TTG AAC GGA ATC AAA GCT AAC TTC -3’   
K158_UUG_r 5’ - GAA GTT AGC TTT GAT TCC GTT CAA TTG TTT GTC TGC CAT - 3’  
K158_UAG_f 5’ - CAT CAT GGC AGA CAA ACA ATA GAA TGG AAT CAA AGC TAA C - 3’ 
K158_UAG_r 5’ - GTT AGC TTT GAT TCC ATT CTA TTG TTT GTC TGC CAT GAT G- 3’ 
 
 
 
 
 
   
 
